

Novartis Research and Development

LOU064/remibrutinib


Clinical Trial Protocol CLOU064A2301 / NCT05030311

**A multicenter, randomized, double-blind,  
placebo-controlled Phase 3 study of remibrutinib (LOU064)  
to investigate the efficacy, safety and tolerability for 52  
weeks in adult chronic spontaneous urticaria patients  
inadequately controlled by H1-antihistamines**

Document type: Global Amended Protocol Version  
EUDRACT number: 2021-000471-37  
Version number: 01 (Clean)  
Clinical Trial Phase: III  
Release date: 23-May-2022 (content final)

Property of Novartis  
Confidential

May not be used, divulged, published, or otherwise disclosed  
without the consent of Novartis  
Clinical Trial Protocol Template Version 4.0 dated 15-Feb-2021




## Table of contents

|  |    |
|--|----|
| Table of contents .....  | 2  |
| List of tables .....   | 5  |
| List of figures .....  | 6  |
| List of abbreviations .....  | 7  |
| Glossary of terms .....  | 11 |
| Protocol summary .....   | 17 |
| 1 Introduction .....   | 23 |
| 1.1 Background .....   | 23 |
| 1.2 Purpose .....  | 24 |
| 2 Objectives, endpoints and estimands .....  | 24 |
| 2.1 Primary estimands .....  | 29 |
| 2.2 Secondary estimands .....  | 30 |
| 3 Study design .....   | 31 |
| 4 Rationale .....  | 32 |
| 4.1 Rationale for study design .....   | 32 |
| 4.1.1 Rationale for choice of background therapy .....                                       | 34 |
| 4.2 Rationale for dose/regimen and duration of treatment .....                               | 34 |
| 4.3 Rationale for choice of control drugs (comparator/placebo) or combination<br>drugs ..... | 37 |
| 4.4 Purpose and timing of interim analyses/design adaptations .....                          | 38 |
| 4.5 Risks and benefits .....   | 39 |
| 4.6 Rationale for Public Health Emergency mitigation procedures .....                        | 43 |
| 5 Study Population .....   | 43 |
| 5.1 Inclusion criteria .....   | 44 |
| 5.2 Exclusion criteria .....   | 44 |
| 6 Treatment .....  | 47 |
| 6.1 Study treatment .....  | 47 |
| 6.1.1 Investigational and control drugs .....  | 48 |
| 6.1.2 Additional study treatments .....  | 48 |
| 6.1.3 Treatment arms/group .....   | 48 |
| 6.1.4 Treatment duration .....   | 48 |
| 6.2 Other treatment(s) .....   | 48 |
| 6.2.1 Concomitant therapy .....  | 48 |
| 6.2.2 Permitted concomitant therapy requiring caution and/or action .....                    | 49 |
| 6.2.3 Prohibited medication .....  | 49 |
| 6.2.4 Rescue medication .....  | 52 |

|       |  |    |
|-------|--|----|
| 6.3   | Preparation and dispensation .....                               | 53 |
| 6.3.1 | Handling of study treatment and other treatment.....             | 53 |
| 6.3.2 | Instruction for prescribing and taking study treatment .....     | 54 |
| 6.4   | Participant numbering, treatment assignment, randomization ..... | 54 |
| 6.4.1 | Participant numbering .....                                      | 54 |
| 6.4.2 | Treatment assignment, randomization .....                        | 55 |
| 6.5   | Treatment blinding.....  | 55 |
| 6.6   | Dose escalation and dose modification.....                       | 56 |
| 6.6.1 | Follow-up for toxicities.....                                    | 56 |
| 6.7   | Additional treatment guidance.....                               | 56 |
| 6.7.1 | Treatment compliance .....                                       | 56 |
| 6.7.2 | Emergency breaking of assigned treatment code.....               | 57 |
| 6.7.3 | Treatment of overdose.....                                       | 57 |
| 7     | Informed consent procedures .....                                | 58 |
| 8     | Visit schedule and assessments .....                             | 59 |
| 8.1   | Screening .....  | 66 |
| 8.1.1 | Information to be collected on screening failures .....          | 66 |
| 8.2   | Participant demographics/other baseline characteristics .....    | 66 |
| 8.3   | Efficacy.....  | 67 |
| 8.3.1 | eDiary assessments.....  | 67 |
| 8.3.2 | Other Patient Reported Outcomes (PRO) assessments.....           | 70 |
| 8.3.3 | Appropriateness of efficacy assessments .....                    | 72 |
| 8.3.4 | Other assessments: evidence of urticaria .....                   | 72 |
|       | █ █  | 73 |
| 8.4   | Safety .....   | 73 |
| 8.4.1 | Laboratory evaluations.....                                      | 75 |
| 8.4.2 | Electrocardiogram (ECG) .....                                    | 76 |
| 8.4.3 | Pregnancy and assessments of fertility .....                     | 77 |
| 8.4.4 | Appropriateness of safety measurements.....                      | 78 |
| 8.5   | Additional assessments.....                                      | 78 |
| 8.5.1 | Clinical Outcome Assessments (COAs) .....                        | 78 |
|       | █ █  | 78 |
|       | █ █  | 79 |
| 9     | Discontinuation and completion.....                              | 80 |
| 9.1   | Discontinuation from study treatment and from study .....        | 80 |
| 9.1.1 | Discontinuation from study treatment.....                        | 80 |




|        |  |     |
|--------|--|-----|
| 9.1.2  | Discontinuation from study.....  | 82  |
| 9.1.3  | Lost to follow-up.....   | 82  |
| 9.2    | Withdrawal of informed consent/Opposition to use data/biological samples ..... | 82  |
| 9.3    | Study completion and post-study treatment .....                                | 83  |
| 9.4    | Early study termination by the sponsor .....                                   | 83  |
| 10     | Safety monitoring, reporting and committees .....                              | 84  |
| 10.1   | Definition of adverse events and reporting requirements.....                   | 84  |
| 10.1.1 | Adverse events .....   | 84  |
| 10.1.2 | Serious adverse events .....   | 85  |
| 10.1.3 | SAE reporting.....   | 86  |
| 10.1.4 | Pregnancy reporting .....  | 87  |
| 10.1.5 | Reporting of study treatment errors including misuse/abuse.....                | 88  |
| 10.2   | Additional Safety Monitoring.....  | 88  |
| 10.2.1 | Liver safety monitoring.....   | 88  |
| 10.2.2 | Renal safety monitoring .....  | 89  |
| 10.3   | Committees.....  | 89  |
| 10.3.1 | Data Monitoring Committee .....  | 89  |
| 10.3.2 | Steering Committee.....  | 90  |
| 11     | Data Collection and Database management.....                                   | 90  |
| 11.1   | Data collection.....   | 90  |
| 11.2   | Database management and quality control .....                                  | 90  |
| 11.3   | Site monitoring .....  | 91  |
| 12     | Data analysis and statistical methods .....                                    | 91  |
| 12.1   | Analysis sets .....  | 92  |
| 12.2   | Participant demographics and other baseline characteristics.....               | 92  |
| 12.3   | Treatments .....   | 92  |
| 12.4   | Analysis supporting primary objectives .....                                   | 93  |
| 12.4.1 | Definition of primary endpoint(s).....   | 93  |
| 12.4.2 | Statistical model, hypothesis, and method of analysis.....                     | 93  |
| 12.4.3 | Handling of intercurrent events of primary estimand .....                      | 94  |
| 12.4.4 | Handling of missing values not related to intercurrent event .....             | 95  |
| 12.4.5 | Sensitivity analyses .....   | 96  |
| 12.4.6 | Supplementary analysis.....  | 96  |
| 12.5   | Analysis supporting secondary objectives.....                                  | 97  |
| 12.5.1 | Efficacy and/or Pharmacodynamic endpoint(s).....                               | 97  |
| 12.5.2 | Safety endpoints .....   | 101 |







|        |   |     |
|--------|---|-----|
|        |   | 102 |
|        |   | 102 |
|        |   | 103 |
|        |   | 103 |
|        |   | 103 |
|        |   | 104 |
| 12.7   | Interim analyses .....  | 105 |
| 12.8   | Sample size calculation.....  | 105 |
| 12.8.1 | Primary endpoint(s).....  | 105 |
| 12.8.2 | Secondary endpoint(s).....  | 106 |
| 13     | Ethical considerations and administrative procedures .....                                | 107 |
| 13.1   | Regulatory and ethical compliance.....  | 107 |
| 13.2   | Responsibilities of the investigator and IRB/IEC.....                                     | 107 |
| 13.3   | Publication of study protocol and results.....  | 107 |
| 13.4   | Quality Control and Quality Assurance.....  | 107 |
| 13.5   | Participant Engagement .....  | 108 |
| 14     | Protocol adherence .....  | 108 |
| 14.1   | Protocol amendments.....  | 108 |
| 15     | References .....  | 109 |
| 16     | Appendices .....  | 113 |
| 16.1   | Appendix 1: Clinically notable laboratory values and vital signs .....                    | 113 |
| 16.2   | Appendix 2: Liver event and laboratory trigger definitions & follow-up requirements ..... | 114 |
| 16.3   | Appendix 3: Specific Renal Alert Criteria and Actions and Event Follow-up....             | 118 |
| 16.4   | Appendix 4: PRO Tools.....  | 120 |



**List of tables**

|           |  |    |
|-----------|--|----|
| Table 2-1 | Objectives and related endpoints – Scenario with UAS7 as the primary efficacy endpoint .....             | 25 |
| Table 2-2 | Objectives and related endpoints - Scenario with ISS7 and HSS7 as the co-primary efficacy endpoints..... | 28 |
| Table 6-1 | Investigational and control drug.....  | 48 |
| Table 6-2 | Permitted concomitant therapy requiring caution and/or action .....                                      | 49 |
| Table 6-3 | Prohibited medication .....  | 49 |
| Table 8-1 | Assessment Schedule .....  | 61 |
| Table 8-2 | UPDD .....   | 67 |
| Table 8-3 | Hives Severity Score.....  | 68 |



|   |  |     |
|---|--|-----|
| Table 8-4   | Itch Severity Score .....  | 68  |
|  |        | 69  |
|  |        | 69  |
| Table 8-7   | DLQI score bands and impact on patient's life .....                                      | 70  |
| Table 8-8   | Physical assessments .....   | 74  |
| Table 8-9   | Laboratory assessments .....   | 75  |
| Table 10-1  | Guidance for capturing the study treatment errors including misuse/abuse .....           | 88  |
| Table 16-1  | Liver event and laboratory trigger definitions .....                                     | 114 |
| Table 16-2  | Follow up requirements for liver laboratory triggers: ALT, AST and TBL .....             | 114 |
| Table 16-3  | Follow up requirements for liver laboratory triggers - Isolated Hyperbilirubinemia ..... | 116 |
| Table 16-4  | Specific renal alert criteria and actions .....  | 118 |
| Table 16-5  | Renal event follow-up .....  | 119 |

**List of figures**

|   |  |     |
|---|--|-----|
| Figure 3-1  | Study Design .....   | 32  |
| Figure 4-1  | UAS7 score change from baseline over time estimated with a mixed-effect repeated measurement analysis, by treatment group (FAS)..... | 36  |
| Figure 4-2  | UAS7 = 0 and UAS7 ≤ 6 response rate over time by treatment group (as observed) (FAS) .....   | 36  |
|  |    | 73  |
| Figure 12-1   | Testing strategy with UAS7 as the primary endpoint .....   | 99  |
| Figure 12-2   | Testing strategy with ISS7/HSS7 as the co-primary endpoints .....  | 101 |



### List of abbreviations

|          |   |
|----------|---|
| AAS      | Angioedema Activity Score                     |
| AD       | Atopic Dermatitis                             |
| AE       | Adverse Event                                 |
| ALP      | Alkaline Phosphatase                          |
| ALT      | Alanine Aminotransferase                      |
| APTT     | Activated Partial Thromboplastin Time         |
| AST      | Aspartate Aminotransferase                    |
| ATC      | Anatomical Therapeutic Chemical               |
| b.i.d.   | bis in die/twice a day                        |
| BCR      | B cell receptor                               |
| BCRP     | Breast Cancer Resistance Protein              |
| BP       | Blood Pressure                                |
| BTK      | Bruton's Tyrosine Kinase                      |
| BTKi     | Bruton's Tyrosine Kinase inhibitor            |
| BUN      | Blood Urea Nitrogen                           |
| CINDU    | Chronic Inducible Urticaria                   |
| CIU      | Chronic Idiopathic Urticaria                  |
| CK       | Creatine Kinase                               |
| CMO&PS   | Chief Medical Office and Patient Safety       |
| COA      | Clinical Outcome Assessment                   |
| COVID-19 | Coronavirus disease 2019                      |
| CRA      | Clinical Research Associate                   |
| CRF      | Case Report/Record Form (paper or electronic) |
| CRO      | Contract Research Organization                |
| CSR      | Clinical Study Report                         |
| CSU      | Chronic Spontaneous Urticaria                 |
| CU       | Chronic Urticaria                             |
| CV       | Coefficient of Variation                      |
| CYP      | Cytochrome P                                  |
| DBP      | Diastolic Blood Pressure                      |
| DIN      | Drug Inducted Nephrotoxicity                  |
| DLQI     | Dermatology Life Quality Index                |
| DMC      | Data Monitoring Committee                     |
| DNA      | Deoxyribonucleic Acid                         |
| ECG      | Electrocardiogram                             |
| EDC      | Electronic Data Capture                       |
| eDiary   | Electronic Diary                              |
| eGFR     | Estimated Glomerular Filtration Rate          |
| ████████ | ████████████████████                          |
| eSAE     | Electronic Serious Adverse Event              |
| eSource  | Electronic Source                             |



|       |   |
|-------|---|
| FAS   | Full Analysis Set   |
| FcγR  | Fc gamma receptor   |
| FcεR  | Fc epsilon Receptor   |
| FSH   | Follicle-stimulating Hormone  |
| GCP   | Good Clinical Practice  |
| GCS   | Global Clinical Supply  |
| GGT   | Gamma-glutamyl transferase  |
| GLDH  | Glutamate dehydrogenase   |
| h     | Hour  |
| HBc   | Hepatitis B core  |
| HBcAb | Antibodies against hepatitis B core antigen (anti-HBcAg antibodies)                                 |
| HBsAb | Antibodies against hepatitis B surface antigen (anti-HBsAg antibodies)                              |
| HBsAg | Hepatitis B virus surface antigen   |
| HBV   | Hepatitis B Virus   |
| HCP   | Healthcare Professional   |
| HCV   | Hepatitis C Virus   |
| HCVAb | Hepatitis C Virus Antibody  |
| HDL   | High-Density Lipoprotein  |
| hERG  | Human ether-a-go-go related gene  |
| HIV   | Human immunodeficiency virus  |
| HRQoL | Health-Related Quality of Life  |
| HSS   | Hives Severity Score  |
| HSS7  | Weekly Hives Severity Score   |
| i.v.  | Intravenous   |
| IA    | Intra-articular   |
| IB    | Investigator's Brochure   |
| ICF   | Informed Consent Form   |
| ICH   | International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use |
| IEC   | Independent Ethics Committee  |
| Ig    | Immunoglobulin  |
| IMP   | Investigational Medicinal Product   |
| IN    | Investigator Notification   |
| INR   | International Normalized Ratio  |
| IRB   | Institutional Review Board  |
| IRT   | Interactive Response Technology   |
| ISS   | Itch Severity Score   |
| ISS7  | Weekly Itch Severity Score  |
| ■     | ■   |
| ■     | ■   |
| J2R   | Jump to Reference   |
| KDIGO | Kidney Disease Improving Global Outcome   |





|          |   |
|----------|---|
| LC-MS/MS | Liquid Chromatography–Mass Spectrometry       |
| LDH      | Lactate Dehydrogenase                         |
| LDL      | Low-Density Lipoprotein                       |
| LFT      | Liver Function Test                           |
| LLOQ     | Lower Limit of Quantification                 |
| LTRA     | Leukotriene Receptor Antagonists              |
| MAR      | Missing At Random                             |
| MCH      | Mean Corpuscular Hemoglobin                   |
| MCHC     | Mean Corpuscular Hemoglobin Concentration     |
| MCV      | Mean Corpuscular Volume                       |
| MedDRA   | Medical dictionary for regulatory activities  |
| mg       | Milligram(s)                                  |
| MI       | Multiple Imputation                           |
| ml       | Milliliter(s)                                 |
| MMRM     | Mixed effect Model for Repeated Measurements  |
| NOAC     | Novel Oral Anti Coagulant                     |
| NSAID    | Nonsteroidal Anti-Inflammatory Drug           |
| PA       | Primary analysis                              |
| Pbo      | Placebo                                       |
| PCR      | Protein-creatinine ratio                      |
| PD       | Pharmacodynamic(s)                            |
| PE       | Primary endpoint                              |
| █        | █   |
| █        | █   |
| PK       | Pharmacokinetic(s)                            |
| PRO      | Patient Reported Outcomes                     |
| PT       | Prothrombin Time                              |
| q.d.     | Once a Day                                    |
| QMS      | Quality Management System                     |
| QTcF     | QT interval corrected by Fridericia's formula |
| RAS      | Randomized Set                                |
| RDO      | Retrieved Drop Out                            |
| RNA      | Ribonucleic Acid                              |
| s.c.     | Subcutaneous                                  |
| SAE      | Serious Adverse Event                         |
| SAF      | Safety Set                                    |
| SBP      | Systolic Blood Pressure                       |
| SD       | Standard Deviation                            |
| SjS      | Sjoegren's Syndrome                           |
| SMQ      | Standardized MedDRA Query                     |
| SUSAR    | Suspected Unexpected Serious Adverse Reaction |



|       |                                  |
|-------|----------------------------------|
| TBL   | Total Bilirubin                  |
| █     | █                                |
| UAS   | Urticaria Activity Score         |
| UAS7  | Weekly Urticaria Activity Score  |
| █     | █                                |
| ULN   | Upper Limit of Normal            |
| UPDD  | Urticaria Patient Daily Diary    |
| UV    | Ultraviolet                      |
| WHO   | World Health Organization        |
| WoCBP | Women of Child-Bearing Potential |
| █     | █                                |



## Glossary of terms

|                                      |   |
|--------------------------------------|---|
| Additional treatment                 | Medicinal products that may be used during the clinical trial as described in the protocol, but not as an investigational medicinal product (e.g., any background therapy)  |
| Assessment                           | A procedure used to generate data required by the study   |
| Biologic Samples                     | A biological specimen including, for example, blood (plasma, serum), saliva, tissue, urine, stool, etc. taken from a study participant  |
| Clinical Outcome Assessment (COA)    | A measure that describes or reflects how a participant feels, functions, or survives  |
| Coded Data                           | Personal Data which has been de-identified by the investigative center team by replacing personal identifiers with a code.  |
| Cohort                               | A group of individuals who share a common exposure, experience or characteristic, or a group of individuals followed up or traced over time   |
| Control drug                         | A study drug (active or placebo) used as a comparator to reduce assessment bias, preserve blinding of investigational drug, assess internal study validity, and/or evaluate comparative effects of the investigational drug   |
| Discontinuation from study           | Point/time when the participant permanently stops receiving the study treatment and further protocol required assessments or follow-up, for any reason. No specific request is made to stop the use of their samples or data.   |
| Discontinuation from study treatment | Point/time when the participant permanently stops receiving the study treatment for any reason (prior to the planned completion of study drug administration, if any). Participant agrees to the other protocol required assessments including follow-up. No specific request is made to stop the use of their samples or data.   |
| Dosage                               | Dose of the study treatment given to the participant in a time unit (e.g., 100 mg once a day, 75 mg twice a day)  |
| Electronic Data Capture (EDC)        | Electronic data capture (EDC) is the electronic acquisition of clinical study data using data collection systems, such as Web-based applications, interactive voice response systems and clinical laboratory interfaces. EDC includes the use of Electronic Case Report Forms (eCRFs) which are used to capture data transcribed from source data/documents used at the point of care                                       |
| End of the clinical trial            | The end of the clinical trial is defined as the last visit of the last participant or at a later point in time as defined by the protocol   |
| Enrollment                           | Point/time of participant entry into the study at which informed consent must be obtained. The action of enrolling one or more participants   |
| eSource (DDE)                        | eSource Direct Data Entry (DDE) refers to the capture of clinical study data electronically, at the point of care. eSource Platform/Applications combines source documents and case report forms (eCRFs) into one application, allowing for the real time collection of clinical trial information to sponsors and other oversight authorities, as appropriate  |
| Estimand                             | As defined in the ICH E9(R1) addendum, estimand is a precise description of the treatment effect reflecting the clinical question posed by the trial objective. It summarizes at a population-level what the outcomes would be in the same participants under different treatment conditions being compared. Attributes of an estimand include the population, variable (or endpoint) and treatment of interest, as well as |

|                                  |   |
|----------------------------------|---|
|                                  | the specification of how the remaining intercurrent events are addressed and a population-level summary for the variable.   |
| Healthy volunteer                | A person with no known significant health problems who volunteers to be a study participant   |
| Intercurrent events              | Events occurring after treatment initiation that affect either the interpretation or the existence of the measurements associated with the clinical question of interest.   |
| Investigational drug/ treatment  | The drug whose properties are being tested in the study   |
| Medication number                | A unique identifier on the label of medication kits   |
| Mis-randomized participants      | Mis-randomized participants are those who were not qualified for randomization and who did not take study treatment, but have been inadvertently randomized into the study  |
| Off-site                         | Describes trial activities that are performed at remote location by an off-site healthcare professional, such as procedures performed at the participant's home.  |
| Other treatment                  | Treatment that may be needed/allowed during the conduct of the study (i.e., concomitant or rescue therapy)  |
| Part                             | A sub-division of a study used to evaluate specific objectives or contain different populations. For example, one study could contain a single dose part and a multiple dose part, or a part in participants with established disease and in those with newly diagnosed disease |
| Participant                      | A trial participant (can be a healthy volunteer or a patient). "Participant" terminology is used in the protocol whereas term "Subject" is used in data collection  |
| Participant number               | A unique number assigned to each participant upon signing the informed consent. This number is the definitive, unique identifier for the participant and should be used to identify the participant throughout the study for all data collected, sample labels, etc.            |
| Patient-Reported Outcome (PRO)   | A measurement based on a report that comes directly from the patient about the status of a participant's health condition without amendment or interpretation of the patient's report by a clinician or anyone else   |
| Period                           | The subdivisions of the trial design (e.g., Screening, Treatment, Follow-up) which are described in the Protocol. Periods define the study phases and will be used in clinical trial database setup and eventually in analysis  |
| Personal data                    | Participant information collected by the Investigator that is coded and transferred to Novartis for the purpose of the clinical trial. This data includes participant identifier information, study information and biological samples.   |
| Premature participant withdrawal | Point/time when the participant exits from the study prior to the planned completion of all study drug administration and/or assessments; at this time all study drug administration is discontinued and no further assessments are planned                                     |
| Randomization                    | The process of assigning trial participants to investigational drug or control/comparator drug using an element of chance to determine the assignments in order to reduce bias.   |
| Randomization number             | A unique identifier assigned to each randomized participant   |

|   |   |
|---|---|
| Re-screening  | If a participant fails the initial screening and is considered as a Screen Failure, he/she can be invited once for a new Screening visit after medical judgment and as specified by the protocol  |
| Remote  | Describes any trial activities performed at a location that is not the investigative site where the investigator will conduct the trial, but is for example a home or another appropriate location  |
| Screen Failure  | A participant who did not meet one or more criteria that were required for participation in the study   |
| Source Data/Document  | Source data refers to the initial record, document, or primary location from where data comes. The data source can be a database, a dataset, a spreadsheet or even hard-coded data, such as paper or eSource  |
| Start of the clinical trial   | The start of the clinical trial is defined as the signature of the informed consent by the first participant  |
| Study treatment   | Any drug or combination of drugs or intervention administered to the study participants as part of the required study procedures; includes investigational drug(s), control(s) or background therapy  |
| Study treatment discontinuation   | When the participant permanently stops taking any of the study drug(s) prior to the defined study treatment completion date (if any) for any reason; may or may not also be the point/time of study discontinuation   |
| Tele-visit  | Procedures or communications conducted using technology such as telephone or video-conference, whereby the participant is not at the investigative site where the investigator will conduct the trial.  |
| Treatment arm/group   | A treatment arm/group defines the dose and regimen or the combination, and may consist of 1 or more cohorts.  |
| Treatment of interest   | The treatment of interest and, as appropriate, the alternative treatment to which comparison will be made. These might be individual interventions, combinations of interventions administered concurrently, e.g., as add-on to standard of care, or might consist of an overall regimen involving a complex sequence of interventions. This is the treatment of interest used in describing the related clinical question of interest, which might or might not be the same as the study treatment.  |
| Variable (or endpoint)  | The variable (or endpoint) to be obtained for each participant that is required to address the clinical question. The specification of the variable might include whether the participant experiences an intercurrent event.  |
| Withdrawal of study consent (WoC) / Opposition to use of data /biological samples | Withdrawal of consent from the study occurs when the participant explicitly requests to stop use of their data and biological samples (opposition to use data and biological samples) AND no longer wishes to receive study treatment, AND does not agree to further protocol required assessments. This request should be in writing (depending on local regulations) and recorded in the source documentation.<br><br>Opposition to use data/biological samples occurs in the countries where collection and processing of personal data is justified by a different legal reason than consent. |

## Amendment 1 (23-May-2022)

### Amendment rationale

Amendment 1 implements recommendations from the US FDA regarding statistical analysis for covering intercurrent event handling for COVID-19 related reasons for treatment discontinuation and the use of the same covariates in both primary and secondary endpoints. In addition, feedback received from Health Authorities and Institutional Review Boards (IRBs)/Independent Ethics Committees (IECs) for both pivotal Phase 3 trials (CLOU064A2301 and CLOU064A2302) was considered to ensure consistency across the program and the protocol amended as indicated below.

Furthermore, clarifications and corrections were made, and [Section 4.5](#) Risks and benefits has been amended to include updates from the LOU064 Investigator Brochure Edition 9 (03-May-2022) as indicated below.

At the time of this amendment (V01) release, enrollment is ongoing with 205 patients screened and 114 patients randomized.

### Changes to the protocol

Changes to specific sections of the protocol are shown in the track changes version of the protocol using strike through red font for deletions and red underline for insertions.

- [Section 2.1](#): Methods for handling of intercurrent events have been updated considering US FDA feedback.
- [Section 2.2](#): Methods for handling of intercurrent events have been updated considering US FDA feedback.
- [Section 4.5](#): Risks and benefits has been amended to include updates from the LOU064 Investigator Brochure Edition 9. No change to risk-benefit assessment of the study.
- [Section 5.2](#): Exclusion criteria 13 and 18 updated to reflect the feedback received from Health Authorities, exclusion criteria 19 updated to clarify maximum dose of clopidogrel.
- [Section 6.2.3](#): Clarification that immunomodulating biologics are considered prohibited medication under immunosuppressive medications; prohibition period for live attenuated vaccines updated to reflect feedback from Health Authorities; maximum dose for long-term clopidogrel use added. Clarification that live attenuated vaccines are prohibited 6 weeks prior to randomization until at least 4 weeks after last dose of study treatment as consistent with exclusion criteria and Investigator Brochure. Remibrutinib updated with study treatment for clarification.
- [Section 6.6](#): Clarification that interruptions are permitted related to study treatment.
- [Section 6.7.3](#): New section added regarding treatment of overdose, to align with the updated Novartis protocol template merged with the TransCelerate Common Protocol Template developed with input from industry, regulators, sites, CROs and IRBs

- [Section 8](#): Order of assessments clarified.
- [Table 8-1](#): Dispense participants' eDiary and Subject's eDiary review removed for Week 56/Safety FU/Study completion visit considering eDiary completion ends at Week 52/Study discontinuation; Weight added at Randomization/Baseline and Week 24 to allow for eGFR calculation; Rescue medication dispensation and usage removed from Week 56/Safety FU/Study completion visit considering eDiary completion ends at Week 52/Study discontinuation; Footnotes 1, 3, and 7 updated for additional clarity; Footnote 4 updated to reflect feedback from Health Authorities; Footnotes 17 and 18 added for clarity.
- [Section 8.3.1](#): Duration of eDiary completion clarified.
- [REDACTED]
- [Table 8-8](#): Body temperature added to Physical Examination assessments to reflect feedback from Health Authorities.
- [Table 8-9](#): Hepatitis screening and Hepatitis re-activation monitoring amended as aligned with central laboratory testing procedures.
- [Section 9.1.1](#): Clarified that participant can request discontinuation from study treatment in writing or verbally, definition of severe/serious infections removed to reflect feedback from Health Authorities.
- [Section 9.1.2](#): Clarified that participant can request discontinuation from study in writing or verbally to reflect feedback from Health Authorities.
- [Section 9.2](#): Clarified that participant can request withdrawal of consent in writing or verbally to reflect feedback from Health Authorities.
- [Section 10.1.1](#): "Dose Reduced/increased" removed as dose modifications not permitted
- [Section 10.1.3](#): Reporting timelines and follow-up for SAEs clarified to reflect feedback from Health Authorities.
- [Section 12.4.3](#): Handling of intercurrent events amended considering US FDA feedback.
- [Section 12.4.5](#): Tipping point analysis removed from sensitivity analysis methods considering US FDA feedback.
- [Section 12.4.6](#): Handling of intercurrent events amended considering US FDA feedback.
- [Section 12.5.1](#): Analysis method for absolute change from baseline in ISS7 and HSS7 at Week 12 amended considering US FDA feedback.
- [REDACTED]
- [Section 15](#): Additional references added and two references removed to align with updated Investigator Brochure and [Section 4.5](#).
- [Section 16.1](#): QTcF increase  $\geq 60$  msec from baseline added to the definition of a notable QTc value for ECGs for clarification.



Additional minor changes (e.g., correction of typographical errors) have been incorporated directly in the protocol with track changes, even if not listed specifically in this section.

### **IRBs/IECs**

A copy of this amended protocol will be sent to the Institutional Review Board (IRBs)/Independent Ethics Committee (IECs) and Health Authorities.

The changes described in this amended protocol require IRB/IEC approval prior to implementation.

The changes herein affect the Informed Consent. Sites are required to update and submit for approval a revised Informed Consent that takes into account the changes described in this protocol amendment.





## Protocol summary

|                                   |  |
|-----------------------------------|--|
| <b>Protocol number</b>            | CLOU064A2301   |
| <b>Full Title</b>                 | A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urticaria patients inadequately controlled by H1-antihistamines  |
| <b>Brief title</b>                | A Phase 3 study of efficacy and safety of remibrutinib in the treatment of chronic spontaneous urticaria in adults inadequately controlled by H1-antihistamines  |
| <b>Sponsor and Clinical Phase</b> | Novartis<br>Phase 3  |
| <b>Investigation type</b>         | Drug   |
| <b>Study type</b>                 | Interventional   |
| <b>Purpose</b>                    | The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) 25 mg b.i.d. in adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in comparison to placebo.   |
| <b>Primary Objective(s)</b>       | <p>The primary objective of this study is to demonstrate that remibrutinib (25 mg b.i.d.) is superior to placebo in CSU with respect to change from baseline in Weekly Urticaria Activity Score (UAS7) in Weekly Itch Severity Score (ISS7) and Weekly Hive Severity Score (HSS7) for the second primary endpoint scenario) at Week 12.</p> <p>The primary clinical question of interest is: What is the effect of remibrutinib treatment versus placebo on the change from baseline in UAS7 score (in HSS7 and ISS7 for the second primary endpoint scenario) after 12 weeks of treatment in adult participants with CSU who are inadequately controlled by H1-antihistamine and receiving a stable locally label approved dose of a second generation H1-antihistamine, regardless of discontinuation from study treatment for any reason and regardless of intake of a different second generation H1-antihistamine as rescue medication and considering strongly confounding prohibited medication as an unfavourable outcome?</p> |
| <b>Secondary Objectives</b>       | <p><b>Scenario #1 with UAS7 as the primary endpoint</b></p> <p>To demonstrate that a greater proportion of participants achieve disease activity control (UAS7 <math>\leq</math> 6) at Week 12 when treated with remibrutinib (25 mg b.i.d.) compared to placebo-treated participants.</p> <ul style="list-style-type: none"><li>The secondary clinical question of interest is: What is the effect of remibrutinib treatment versus placebo on the UAS7 <math>\leq</math> 6 response after 12 weeks treatment in adult participants with CSU who are inadequately controlled by H1-antihistamine and receiving a stable locally label approved dose of a second generation H1-antihistamine, regardless of treatment discontinuation for any reason and regardless of intake of a different second generation H1-antihistamine as rescue medication and considering strongly confounding prohibited medication as an unfavourable outcome?</li></ul>  |

|  |  |
|--|--|
|  | <p>To demonstrate that a greater proportion of participants achieve complete absence of hives and itch (UAS7 = 0) at Week 12 when treated with remibrutinib (25 mg b.i.d.) compared to placebo-treated participants</p> <ul style="list-style-type: none"><li>• The secondary clinical question of interest is: What is the effect of remibrutinib treatment versus placebo on the UAS7 = 0 response after 12 weeks treatment in adult participants with CSU who are inadequately controlled by H1-antihistamine and receiving a stable locally label approved dose of a second generation H1-antihistamine, regardless of treatment discontinuation for any reason and regardless of intake of a different second generation H1-antihistamine as rescue medication and considering strongly confounding prohibited medication as an unfavourable outcome?</li></ul> <p>To demonstrate the superiority of remibrutinib (25 mg b.i.d.) versus placebo with respect to a reduction from baseline in the weekly itch severity score (ISS7) at Week 12</p> <p>To demonstrate the superiority of remibrutinib (25 mg b.i.d.) versus placebo with respect to a reduction from baseline in the weekly hive severity score (HSS7) at Week 12</p> <p>To demonstrate that a greater proportion of participants achieve UAS7 ≤ 6 at Week 2 when treated with remibrutinib (25 mg b.i.d.) compared to placebo-treated participants</p> <p>To demonstrate that a greater proportion of participants who are treated with remibrutinib (25 mg b.i.d.) achieve dermatology life quality index (DLQI) = 0-1 at Week 12 compared to placebo-treated participants</p> <p>To demonstrate that remibrutinib (25 mg b.i.d.) treated participants maintain disease activity control (defined as UAS7 ≤ 6) for more weeks compared to placebo treated participants over a total of 12 weeks</p> <p>To demonstrate that remibrutinib (25 mg b.i.d.) treated participants have more angioedema occurrence-free weeks over a total of 12 weeks compared with placebo-treated participants</p> <p>To demonstrate the safety and tolerability of remibrutinib (25 mg b.i.d.)</p> <p><b>Scenario #2 with ISS7 and HSS7 as the co-primary endpoints</b></p> <p>To demonstrate that remibrutinib (25 mg b.i.d.) is superior to placebo in CSU with respect to change from baseline in UAS7 at Week 12</p> <p>To demonstrate that a greater proportion of participants achieve disease activity control (UAS7 ≤ 6) at Week 12 who are treated with remibrutinib (25 mg b.i.d.) compared to placebo-treated participants</p> <ul style="list-style-type: none"><li>• The secondary clinical question of interest is: What is the effect of remibrutinib treatment versus placebo on the UAS7 ≤ 6 response after 12 weeks treatment in adult participants with CSU who are inadequately controlled by H1-antihistamine and receiving a stable locally label approved dose of a second generation H1-antihistamine, regardless of treatment discontinuation for any reason and regardless of intake of a different second generation H1-antihistamine as rescue medication and considering strongly confounding prohibited medication as an unfavourable outcome?</li></ul> |
|--|--|




|                            |   |
|----------------------------|---|
|                            | <p>To demonstrate that a greater proportion of participants achieve complete absence of hives and itch (UAS7 = 0) at Week 12 who are treated with remibrutinib (25 mg b.i.d.) compared to placebo-treated participants</p> <ul style="list-style-type: none"> <li>The secondary clinical question of interest is: What is the effect of remibrutinib treatment versus placebo on the UAS7=0 response after 12 weeks treatment in adult participants with CSU who are inadequately controlled by H1-antihistamine and receiving a stable locally label approved dose of a second generation H1-antihistamine, regardless of treatment discontinuation for any reason and regardless of intake of a different second generation H1-antihistamine as rescue medication and considering strongly confounding prohibited medication as an unfavourable outcome?</li> </ul> <p>To demonstrate that a greater proportion of participants achieve UAS7 ≤ 6 at Week 2 who are treated with remibrutinib (25 mg b.i.d.) compared to placebo-treated participants</p> <p>To demonstrate that a greater proportion of participants who are treated with remibrutinib (25 mg b.i.d.) achieve DLQI = 0-1 at Week 12 compared to placebo-treated participants</p> <p>To demonstrate that remibrutinib (25 mg b.i.d.) treated participants maintain disease activity control (defined as UAS7 ≤ 6) for more weeks compared to placebo treated participants over 12 weeks</p> <p>To demonstrate that remibrutinib (25 mg b.i.d.) treated participants have more angioedema occurrence-free weeks over 12 weeks compared with placebo-treated participants</p> <p>To demonstrate the safety and tolerability of remibrutinib (25 mg b.i.d.)</p> |
| <p><b>Study design</b></p> | <p>This is a global Phase 3 multicenter, randomized, double-blind, parallel-group, placebo-controlled study investigating the safety, tolerability, and efficacy of remibrutinib (25 mg b.i.d.) in participants with CSU inadequately controlled by second generation H1-antihistamines. The study consists of four periods, the total study duration is up to 60 weeks: screening period of up to 4 weeks, double-blind placebo controlled treatment period of 24 weeks, open-label treatment with remibrutinib period of 28 weeks, treatment free follow-up period of 4 weeks.</p>  |
| <p><b>Rationale</b></p>    | <p>Signs and symptoms of CSU are a direct consequence of mast cell degranulation with release of inflammatory mediators including histamine. Bruton's tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase which is indispensable for Fc epsilon receptor (FcεR1), Fc gamma receptor (FcγR) as well as B cell receptor (BCR) signaling and a central signaling kinase in mast cell activation. It has been demonstrated that BTK inhibition can effectively inhibit mast cell activation. Remibrutinib (LOU064) is a low molecular weight compound for oral administration that covalently binds and inhibits BTK with high selectivity. In Phase 1, remibrutinib was well tolerated at all doses without any dose-limiting toxicity and showed encouraging blood and skin pharmacodynamics (PD) with a favorable safety profile, fully supporting further development. The Phase 2b clinical trial CLOU064A2201 demonstrated clinical efficacy of remibrutinib 25 mg b.i.d. in the treatment of CSU patients with a fast onset of action and a favorable safety profile. This Phase 3 study is designed to confirm and further evaluate the efficacy and safety of remibrutinib in adult CSU patients at a dose of 25 mg b.i.d. A second, nearly identical Phase 3 study will be conducted in parallel.</p>  |



|                               |  |
|-------------------------------|--|
| <b>Study population</b>       | <p>The study population will consist of approximately 450 randomized female and male adult participants (300 in the active arm and 150 in placebo arm) with CSU inadequately controlled by second generation H1-antihistamines.</p> <p>The screen failure rate is estimated to be 30%, meaning approximately 645 participants are expected to be screened.</p> <p>Participants will be stratified based on prior exposure to anti-immunoglobulin (Ig) E biologics and geographic region. Maximum number of participants with prior exposure to anti-IgE biologics will be limited to approximately 30% of the total study population.</p>  |
| <b>Key Inclusion criteria</b> | <ul style="list-style-type: none"><li>• Signed informed consent must be obtained prior to participation in the study.</li><li>• Male and female adult participants <math>\geq 18</math> years of age at the time of screening.</li><li>• CSU duration for <math>\geq 6</math> months prior to screening (defined as the onset of CSU determined by the investigator based on all available supporting documentation).</li><li>• Diagnosis of CSU inadequately controlled by second generation H1-antihistamines at the time of randomization defined as:<ul style="list-style-type: none"><li>• The presence of itch and hives for <math>\geq 6</math> consecutive weeks prior to screening despite the use of second generation H1-antihistamines during this time period</li><li>• UAS7 score (range 0-42) <math>\geq 16</math>, ISS7 score (range 0-21) <math>\geq 6</math> and HSS7 score (range 0-21) <math>\geq 6</math> during the 7 days prior to randomization (Day 1)</li></ul></li><li>• Documentation of hives within three months before randomization (either at screening and/or at randomization; or documented in the participants medical history).</li><li>• Willing and able to complete an Urticaria Patient Daily Diary (UPDD) for the duration of the study and adhere to the study protocol.</li><li>• Participants must not have had more than one missing UPDD entry (either morning or evening) in the 7 days prior to randomization (Day 1).</li></ul> |
| <b>Key Exclusion criteria</b> | <ul style="list-style-type: none"><li>• Participants having a clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria) including urticaria factitia (symptomatic dermatographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticaria</li><li>• Other diseases with symptoms of urticaria or angioedema, including but not limited to urticaria vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary urticaria, or drug-induced urticaria</li><li>• Any other skin disease associated with chronic itching that might influence in the investigator's opinion the study evaluations and results, e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis</li><li>• Evidence of clinically significant cardiovascular (such as but not limited to myocardial infarction, unstable ischemic heart disease, New York heart association (NYHA) Class III/IV left ventricular failure, arrhythmia and uncontrolled hypertension within 12 months prior to Visit 1), neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study</li></ul>  |

|                                      |   |
|--------------------------------------|---|
|                                      | <p>results or otherwise preclude participation or protocol adherence of the participant</p> <ul style="list-style-type: none"> <li>• Significant bleeding risk or coagulation disorders</li> <li>• History of gastrointestinal bleeding, e.g., in association with use of nonsteroidal anti-inflammatory drugs (NSAID), that was clinically relevant (e.g., where intervention was indicated or requiring hospitalization or blood transfusion)</li> <li>• Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited.</li> <li>• Requirement for anticoagulant medication (for example, warfarin or Novel Oral Anti-Coagulants (NOAC))</li> <li>• History or current hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis or hepatic failure or Aspartate Aminotransferase (AST)/ Alanine Aminotransferase (ALT) levels of more than 1.5 x upper limit of normal (ULN) or International Normalized Ratio (INR) of more than 1.5 at screening</li> </ul> |
| <p><b>Study treatment</b></p>        | <ul style="list-style-type: none"> <li>• LOU064 25mg film-coated tablets (blinded)</li> <li>• LOU064 25mg placebo film-coated tablets (blinded)</li> <li>• LOU064 25mg film-coated tablets (open-label)</li> </ul>  |
| <p><b>Efficacy assessments</b></p>   | <p>All efficacy measures are Patient Reported Outcomes (PROs):</p> <p><b>Electronic Diary (eDiary) assessments</b></p> <ul style="list-style-type: none"> <li>• Urticaria Patients Daily Diary (UPDD), which assesses: <ul style="list-style-type: none"> <li>• Hives Severity Score (HSS)</li> <li>• Itch Severity Score (ISS)</li> <li>• Urticaria Activity Score (UAS)</li> </ul> </li> <li>• [REDACTED]</li> <li>• [REDACTED]</li> <li>• [REDACTED]</li> <li>• angioedema occurrence</li> <li>• number of calls to doctor, nurse or nurse practitioner</li> <li>• Angioedema Activity Score (AAS)</li> </ul>  |
| <p>[REDACTED]</p>                    | <p>[REDACTED]</p>   |
| <p><b>Key safety assessments</b></p> | <p>Adverse event (AE) monitoring</p> <p>Physical examinations</p> <p>Vital signs</p> <p>Monitoring of laboratory markers in blood and urine</p> <p>Central electrocardiogram (ECG) monitoring</p>   |
| <p><b>Other assessments</b></p>      | <p><b>Other PROs assessments</b></p> <ul style="list-style-type: none"> <li>• Dermatology Life Quality Index (DLQI)</li> </ul> <p>[REDACTED]</p>  |



|                      |   |
|----------------------|---|
|                      | <p>[REDACTED]</p>   |
| <b>Data analysis</b> | <p>The main purpose of this study is to demonstrate that remibrutinib (25 mg b.i.d.) is superior to placebo in CSU with respect to change from baseline in UAS7 at Week 12 (for second scenario, in ISS7 and HSS7). A linear mixed model with repeated measures (MMRM) will be used to estimate treatment differences for change from baseline in UAS7 score (ISS7 and HSS7 for second scenario) at Week 12, based on the full analysis set (FAS).</p> <p>For secondary endpoints, a logistic regression model will be used to estimate treatment differences for disease activity control at weeks 2 and 12, complete response and DLQI = 0/1 endpoints at week 12. Negative binomial regression model will be used to estimate treatment differences for the cumulative number of weeks achieving AAS7 = 0 response and UAS7 &lt;= 6 between baseline and Week 12.</p> <p>The primary and secondary endpoints analyses are planned to use the multiple testing strategy to control the family-wise error at <math>\alpha = 0.025</math> (one-sided).</p> <p>Summary tables will be presented by treatment group and visit (as applicable) using descriptive statistics, which include absolute and relative frequencies for categorical variables and arithmetic mean, standard deviation, minimum, maximum, median and 25<sup>th</sup> and 75<sup>th</sup> percentiles for continuous variables.</p> |
| <b>Key words</b>     | BTK inhibitor; Chronic spontaneous urticaria; Urticaria activity score; Hives severity score; Itch severity score   |



## 1 Introduction

### 1.1 Background

Chronic Spontaneous Urticaria (CSU), also known as Chronic Idiopathic Urticaria (CIU), is defined as the spontaneous occurrence of itchy wheals (hives), angioedema or both, lasting for at least 6 weeks (Zuberbier et al 2014, Zuberbier et al 2018). The classic description of urticaria is a wheal and flare with a pale elevated lesion and surrounding erythema, ranging in size from a few millimeters to a few centimeters across, usually occurring in groups and often coalescing to form large confluent lesions. Wheals and angioedema in CSU involve the degranulation of mast cells, which release histamine, proteases and cytokines. These mediators induce vasodilatation, increase vascular permeability, and stimulate sensory nerve endings leading to swelling, redness and itch (Kaplan et al 1978, Saini and Kaplan 2018).

CSU can be debilitating, is associated with intense itching and has a major impact on patient's quality of life, comparable to that of severe coronary artery disease (Greaves 2003, Powell et al 2007). The overall burden of CSU and CSU-associated angioedema for affected patients is substantial: CSU and its symptoms have a negative impact on numerous aspects of their daily life, including mental health, work productivity, sleep, partnership and family life (O'Donnell et al 1997, Maurer et al 2017, Gonçalo et al 2021).

Second generation H1-antihistamines are recommended as first-line treatment for patients with CSU, but less than 40% of patients respond adequately (Guillén-Aguinaga et al 2016). While up-titration of second generation H1-antihistamines up to 4-fold the approved dose is recommended by most CSU treatment guidelines as second-line therapy (Zuberbier et al 2018), the efficacy of up-titrated H1-antihistamines in CSU has not been studied in larger clinical trials, and up-titration is considered off-label. The use of H2-antihistamines and Leukotriene Receptor Antagonists (LTRAs) has in the past been recommended by treatment guidelines for patients who remained symptomatic despite treatment with H1-antihistamines (Zuberbier et al 2009, Bernstein et al 2014), although their use has not been well supported by clinical studies. In the latest version of the treatment guidelines (Zuberbier et al 2018), neither H2-antihistamines nor LTRAs are perceived to have sufficient evidence to maintain them as recommendable in the algorithm. Short courses of systemic corticosteroids are sometimes added to the treatment regimen; however, they are not recommended in treatment guidelines for long-term use, as this would expose patients to the well-known risk of adverse effects associated with chronic systemic corticosteroid use. Omalizumab is an effective third-line therapy for CSU patients. However, less than 50% of patients treated with omalizumab reach complete control of signs and symptoms (Kaplan et al 2016). Therefore, there is a high unmet medical need for new treatment options for CSU patients inadequately controlled by H1-antihistamines.

Bruton's tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase and member of the TEC kinase family. BTK is expressed in selected cells of the adaptive and innate immune system including B cells, macrophages and mast cells/basophils. BTK is indispensable for signaling through the Fc epsilon receptor (FcεR1 for IgE), the activating Fc gamma receptors (FcγR for IgG), as well as the B cell antigen receptor (BCR) and therefore an important signaling node in the activation/degranulation of B cells, macrophages, mast cells or basophils (Rip et al 2018).

BTK inhibitors (BTKi) like ibrutinib have been first approved for the treatment of B cell malignancies (Hendriks et al 2014). Due to the above described role of BTK in adaptive as well as innate immune signaling and associated with that, its role in immune-mediated diseases, targeting BTK is regarded as a promising new approach for the treatment of various immune-mediated conditions.

Mast cells and basophils play a key role in the pathophysiology of CSU, and it has been demonstrated that BTK inhibition leads to blockade of mast cell and basophil activation/degranulation in vitro and to reduced wheal sizes in skin prick tests with patients suffering from IgE-mediated allergies (Smiljkovic et al 2017, Regan et al 2017, Dispenza et al 2017). Thus, BTK inhibition is a promising therapeutic concept for the treatment of CSU.

Remibrutinib (LOU064) is a low molecular weight compound for oral administration that covalently binds and inhibits BTK with high selectivity (Angst et al 2020, Gabizon and London 2020). In Phase 1, remibrutinib was well-tolerated at all doses without any dose-limiting toxicity and showed encouraging blood and skin pharmacodynamics with a favorable safety profile, fully supporting further development for diseases driven by mast cells, basophils, and B cells, such as chronic spontaneous urticaria (Kaul et al 2021). The Phase 2b clinical trial CLOU064A2201 primary endpoint analysis demonstrated clinical efficacy and a fast onset of action of remibrutinib in the treatment of CSU patients as well as a favorable safety profile (for detailed information please refer to the Investigator's Brochure (IB)).

Taken together, remibrutinib may offer a novel therapeutic approach for patients with CSU and is advanced to Phase 3 clinical development.

## 1.2 Purpose

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) 25 mg b.i.d. in adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in comparison to placebo.

Inadequate control of CSU by H1-antihistamines is defined as:

- The presence of itch and hives for  $\geq 6$  consecutive weeks prior to screening despite the use of second generation H1-antihistamines during this time period
- UAS7 score (range 0-42)  $\geq 16$ , ISS7 score (range 0-21)  $\geq 6$  and HSS7 score (range 0-21)  $\geq 6$  during the 7 days prior to randomization (Day 1).

## 2 Objectives, endpoints and estimands



There are two primary objective scenarios based on regional regulatory precedent and Health Authorities' feedback. These two primary objective scenarios will be tested in two distinct testing strategies (Table 2-1 and Table 2-2). Distinctions in the secondary objectives reflect the corresponding scenario: the primary objective in one scenario is presented as secondary objective(-s) in another. The other secondary objectives are identical in both scenarios.




**Table 2-1 Objectives and related endpoints – Scenario with UAS7 as the primary efficacy endpoint**

| <b>Objective(s)</b>   | <b>Endpoint(s)</b>   |
|---|--|
| <b>Primary objective(s)</b>   | <b>Endpoint(s) for primary objective(s)</b>  |
| <ul style="list-style-type: none"> <li>To demonstrate that remibrutinib (25 mg b.i.d.) is superior to placebo in CSU with respect to change from baseline in UAS7 at Week 12</li> </ul>   | <ul style="list-style-type: none"> <li>Absolute change from baseline in UAS7 at Week 12</li> </ul>   |
| <b>Secondary objective(s)</b>   | <b>Endpoint(s) for secondary objective(s)</b>  |
| <ul style="list-style-type: none"> <li>To demonstrate that a greater proportion of participants achieve disease activity control (UAS7 ≤ 6) at Week 12 who are treated with remibrutinib (25 mg b.i.d.) compared to placebo-treated participants</li> <li>To demonstrate that a greater proportion of participants achieve complete absence of hives and itch (UAS7 = 0) at Week 12 who are treated with remibrutinib (25 mg b.i.d.) compared to placebo-treated participants</li> <li>To demonstrate the superiority of remibrutinib (25 mg b.i.d.) treated participants with respect to a reduction from baseline in the weekly itch severity score at Week 12 compared to placebo-treated participants</li> <li>To demonstrate the superiority of remibrutinib (25 mg b.i.d.) treated participants with respect to a reduction from baseline in the weekly hive severity score at Week 12 compared to placebo-treated participants</li> <li>To demonstrate that a greater proportion of participants achieve UAS7 ≤ 6 at Week 2 who are treated with remibrutinib (25 mg b.i.d.) compared to placebo-treated participants</li> <li>To demonstrate that a greater proportion of participants who are treated with remibrutinib (25 mg b.i.d.) achieve DLQI = 0-1 at Week 12 compared to placebo-treated participants</li> <li>To demonstrate that remibrutinib (25 mg b.i.d.) treated participants maintain disease activity control (defined as UAS7 ≤ 6) for more weeks compared to placebo treated participants over 12 weeks</li> </ul> | <ul style="list-style-type: none"> <li>Achievement of UAS7 ≤ 6 (yes/no) at Week 12</li> <li>Achievement of UAS7 = 0 (yes/no) at Week 12</li> <li>Improvement of severity of itch, assessed as absolute change from baseline in ISS7 score at Week 12</li> <li>Improvement of severity of hives, assessed as absolute change from baseline in HSS7 score at Week 12</li> <li>Achieving early onset of disease activity control, as defined as achievement of UAS7 ≤ 6 (yes/no) at Week 2</li> <li>No impact on participants' dermatology-quality of life, as defined by achievement of DLQI = 0-1 (yes/no) at Week 12</li> <li>Achieving sustained disease activity control, assessed as cumulative number of weeks with an UAS7 ≤ 6 response between baseline and Week 12</li> </ul> |
| <ul style="list-style-type: none"> <li>To demonstrate that remibrutinib (25 mg b.i.d.) treated participants have more</li> </ul>  | <ul style="list-style-type: none"> <li>Number of weeks without angioedema, assessed by the cumulative number of weeks</li> </ul>   |

| Objective(s)  | Endpoint(s)   |
|---|---|
| angioedema occurrence-free weeks over 12 weeks compared with placebo-treated participants | with an AAS7 = 0 response between baseline and Week 12  |
| • To demonstrate the safety and tolerability of remibrutinib (25 mg b.i.d.)               | • Occurrence of treatment emergent adverse events and serious adverse events during the study |



---

| Objective(s)  | Endpoint(s) |
|---|-------------|
|  |             |



**Table 2-2 Objectives and related endpoints - Scenario with ISS7 and HSS7 as the co-primary efficacy endpoints**

| <b>Objective(s)</b>   | <b>Endpoint(s)</b>   |
|---|--|
| <b>Primary objective(s)</b>   | <b>Endpoint(s) for primary objective(s)</b>  |
| <ul style="list-style-type: none"> <li>To demonstrate that remibrutinib (25 mg b.i.d.) is superior to placebo in CSU with respect to change from baseline in ISS7 and HSS7 at Week 12</li> </ul>  | <ul style="list-style-type: none"> <li>Absolute change from baseline in ISS7 at Week 12</li> <li>Absolute change from baseline in HSS7 at Week 12</li> </ul>   |
| <b>Secondary objective(s)</b>   | <b>Endpoint(s) for secondary objective(s)</b>  |
| <ul style="list-style-type: none"> <li>To demonstrate that remibrutinib (25 mg b.i.d.) is superior to placebo in CSU with respect to change from baseline in UAS7 at Week 12</li> <li>To demonstrate that a greater proportion of participants achieve disease activity control (UAS7 ≤ 6) at Week 12 who are treated with remibrutinib (25 mg b.i.d.) compared to placebo-treated participants</li> <li>To demonstrate that a greater proportion of participants achieve complete absence of hives and itch (UAS7 = 0) at Week 12 who are treated with remibrutinib (25 mg b.i.d.) compared to placebo-treated participants</li> <li>To demonstrate that a greater proportion of participants achieve UAS7 ≤ 6 at Week 2 who are treated with remibrutinib (25 mg b.i.d.) compared to placebo-treated participants</li> <li>To demonstrate that a greater proportion of participants who are treated with remibrutinib (25 mg b.i.d.) achieve DLQI = 0-1 at Week 12 compared to placebo-treated participants</li> <li>To demonstrate that remibrutinib (25 mg b.i.d.) treated participants maintain disease activity control (defined as UAS7 ≤ 6) for more weeks compared to placebo treated participants over 12 weeks</li> <li>To demonstrate that remibrutinib (25 mg b.i.d.) treated participants have more angioedema occurrence-free weeks over 12 weeks compared with placebo-treated participants</li> <li>To demonstrate the safety and tolerability of remibrutinib (25 mg b.i.d.)</li> </ul> | <ul style="list-style-type: none"> <li>Absolute change from baseline in UAS7 at Week 12</li> <li>Achievement of UAS7 ≤ 6 (yes/no) at Week 12</li> <li>Achievement of UAS7 = 0 (yes/no) at Week 12</li> <li>Achieving early onset of disease activity control, as defined as achievement of UAS7 ≤ 6 (yes/no) at Week 2</li> <li>No impact on participants' dermatology quality of life as defined by achievement of DLQI = 0-1 (yes/no) at Week 12.</li> <li>Achieving sustained disease activity control, assessed as cumulative number of weeks with an UAS7 ≤ 6 response between baseline and Week 12</li> <li>Number of weeks without angioedema, assessed by the cumulative number of weeks with an AAS7 = 0 response between baseline and Week 12</li> <li>Occurrence of treatment emergent adverse events and serious adverse events (SAEs) during the study</li> </ul> |

---

---

**Objective(s)**

**Endpoint(s)**

**2.1 Primary estimands**

The estimand is the precise description of the treatment effect and reflects strategies to address events occurring during trial conduct which could impact the interpretation of the trial results (e.g., premature discontinuation of treatment).

**Primary estimand for scenario with UAS7 as primary efficacy endpoint**

The primary clinical question of interest is: What is the effect of remibrutinib treatment versus placebo on the change from baseline in UAS7 score after 12 weeks treatment in adult participants with CSU who are inadequately controlled by H1-antihistamine and receiving a stable locally label approved dose of a second generation H1-antihistamine, regardless of discontinuation from study treatment for any reason and regardless of intake of a different second generation H1-antihistamine as rescue medication and considering strongly confounding prohibited medication as an unfavourable outcome?

The primary estimand is described by the following attributes:

1. **Population:** participants with inadequately controlled CSU despite treatment with second generation H1-antihistamine who have CSU duration  $\geq 6$  months, a UAS7 score  $\geq 16$ , ISS7  $\geq 6$  and HSS7 score  $\geq 6$  in the last 7 days prior to randomization.
2. **Endpoint:** Change in UAS7 from baseline at Week 12.
3. **Treatment of interest:** the randomized study treatment (remibrutinib 25 mg b.i.d. or placebo) regardless of treatment compliance, with background medication of locally label approved dose second generation H1-antihistamine, and a different second generation H1-antihistamine as rescue medication.
4. **Summary Measurement:** the mean difference between treatment groups.
5. **Handling of intercurrent events:**
  - Discontinuation of study treatment due to any: Treatment policy strategy
  - Intake of strongly confounding prohibited medication (e.g., biologics treatment at any time before Week 12, cyclosporin after Week 8, systemic corticosteroids after Week 8): Composite strategy (irrespective of potential occurrence of other intercurrent events)
  - Intake of rescue medication, switch of background medication, intake of other prohibited medication: Treatment policy strategy

### Primary estimand for scenario with ISS7/HSS7 as co-primary efficacy endpoints

The primary clinical question of interest is: What is the effect of remibrutinib treatment versus placebo on the co-primary endpoints change from baseline in ISS7 score and change from baseline in HSS7 score after treatment in adult participants with CSU who are inadequately controlled by H1-antihistamine and receiving a stable locally label approved dose of a second generation H1-antihistamine, regardless of discontinuation from study treatment for any reason and regardless of intake of a different second generation H1-antihistamine as rescue medication and considering strongly confounding prohibited medication as an unfavourable outcome?

The primary estimand is described by the following attributes:

1. **Population:** participants with inadequately controlled CSU despite treatment with second generation H1-antihistamine who have CSU duration  $\geq 6$  months, a UAS7 score  $\geq 16$ , ISS7  $\geq 6$  and HSS7 score  $\geq 6$  in the last 7 days prior to randomization.
2. **Endpoint (co-primary):** Change in ISS7 from baseline at Week 12 and change in HSS7 from baseline at Week 12.
3. **Treatment of interest:** the randomized study treatment (remibrutinib 25 mg b.i.d. or placebo) regardless of treatment compliance, with background medication of locally label approved dose second generation H1-antihistamine, and a different second generation H1-antihistamine as rescue medication.
4. **Summary Measurement:** the mean difference between treatment groups.
5. **Handling of intercurrent events:**
  - Discontinuation of study treatment due to any reason: Treatment policy strategy
  - Intake of strongly confounding prohibited medication (e.g., biologics treatment at any time before Week 12, cyclosporin after Week 8, systemic corticosteroids after Week 8): Composite strategy (irrespective of potential occurrence of other intercurrent events)
  - Intake of rescue medication, switch of background medication, intake of other prohibited medication: Treatment policy strategy

## 2.2 Secondary estimands

### Secondary estimand on the secondary endpoint UAS7 $\leq 6$ response at week 12

The secondary clinical question of interest is: What is the effect of remibrutinib treatment versus placebo on the UAS7  $\leq 6$  response after 12 weeks treatment in adult participants with CSU who are inadequately controlled by H1-antihistamine and receiving a stable locally label approved dose of a second generation H1-antihistamine, regardless of treatment discontinuation for any reason and regardless of intake of a different second generation H1-antihistamine as rescue medication and considering strongly confounding prohibited medication as an unfavourable outcome?

The secondary estimand is described by the following attributes:

1. **Population:** patients with inadequately controlled CSU despite treatment with second generation H1-antihistamine who have CSU duration  $\geq 6$  months, a UAS7 score  $\geq 16$ , ISS7 score  $\geq 6$  and HSS7 score  $\geq 6$  in the last 7 days prior to randomization.
2. **Endpoint:** UAS7  $\leq 6$  response at Week 12.

3. **Treatment of interest:** the randomized study treatment (remibrutinib 25 mg b.i.d. or placebo) regardless of treatment compliance, with background medication of locally label approved dose second generation H1-antihistamine, and a different second generation H1-antihistamine as rescue medication.
4. **Summary Measurement:** the odds ratio between treatment groups.
5. **Handling of intercurrent events:**
  - Discontinuation of study treatment due to any reason non-compliance (dose interruption): Treatment policy strategy
  - Intake of strongly confounding prohibited medication (e.g., biologics treatment at any time before Week 12, cyclosporin after Week 8, systemic corticosteroids after Week 8): Composite strategy (irrespective of potential occurrence of other intercurrent events)
  - Intake of rescue medication, switch of background medication, intake of other prohibited medication: Treatment policy strategy

#### **Secondary estimand on the secondary endpoint UAS7 = 0 response at week 12**

Similar Estimand approach will be implemented for UAS7= 0 as for UAS7 ≤ 6.

**Other secondary estimand on the other secondary endpoints as defined in Table 2-1 and Table 2-2.**

Similar Estimand approach will be implemented for these endpoints as the primary Estimand or co-primary Estimand.

### **3 Study design**

This is a global, multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase 3 study investigating the safety, tolerability, and efficacy of remibrutinib (25 mg b.i.d.) in adult participants with CSU inadequately controlled by second generation H1-antihistamines. The study consists of four periods, the total study duration is up to 60 weeks (Figure 3-1):


- **Screening period:** up to 4 weeks.
- **Double-blind treatment period:** 24 weeks of double-blind treatment with remibrutinib (25 mg b.i.d.) or placebo.
- **Open-label treatment period:** 28 weeks of open-label treatment with remibrutinib (25 mg b.i.d.).
- **Follow-up period:** 4 weeks of treatment-free follow-up.

The primary analysis may be conducted after all participants have completed Week 24 or discontinued earlier and when a minimum of 150 participants across both Phase 3 pivotal studies (a second, nearly identical Phase 3 study will be conducted in parallel) have completed the treatment period at Week 52 (see Section 4.4). **All participants will be on a stable, locally label approved dose of a second generation H1-antihistamine (“background therapy”) throughout the entire study (starting a minimum of 7 days prior to randomization until the end of the study).** To treat unbearable symptoms of CSU, participants will be allowed to use another second generation H1-antihistamine on an as-needed basis (“rescue therapy”). Eligible participants will be randomly assigned to the treatment arms in a 2:1 ratio. The study

population will consist of approximately 450 female and male adult participants (300 in the active arm and 150 in the placebo arm) with CSU inadequately controlled by second generation H1-antihistamines at least at locally label approved dose. Participants will be stratified based on prior exposure to anti-IgE biologics and geographic region.

An extension study is in development. Eligible participants may roll over at Week 52 (after completing 52 weeks of treatment and all scheduled assessments planned at this visit). The details of the study design and procedures of the extension, if implemented, will be described in a separate protocol.

**Figure 3-1 Study Design**



D-1: Day 1, b.i.d.: bis in die/twice a day, mg: milligram(s), Pbo: placebo, PA: Primary Analysis, PE: Primary Endpoint, Scr: Screening, W: Week

## 4 Rationale

### 4.1 Rationale for study design

The primary analysis of the Phase 2b dose-range finding study CLOU064A2201 demonstrated that treatment with remibrutinib 25 mg b.i.d. substantially improves signs and symptoms of CSU compared to placebo, in participants who have not adequately responded to prior treatment with H1-antihistamines and other CSU therapies including omalizumab. This Phase 3 study is designed to confirm and further evaluate the efficacy and safety of remibrutinib at a dose of 25 mg b.i.d. (as determined by the phase 2b dose-range finding study CLOU064A2201, see also section [Section 4.2](#)) in adult CSU patients. It is a randomized, double-blind, parallel-group, and placebo-controlled study that consists of four periods:

1. **Screening period:** the screening period of up to four weeks will allow the assessment of eligibility of participants and the determination of baseline disease activity.



2. **Double-blind treatment period:** a placebo-controlled, double-blind treatment period until Week 24. The placebo-controlled, double-blind design is mandatory to enable a robust assessment of the efficacy of remibrutinib without bias by the fluctuating nature of CSU (and the resulting significant placebo effect). Furthermore, it is required for a robust assessment of the safety profile of remibrutinib in comparison to placebo over an adequate period of time (for further details please see [Section 4.3](#)). This design is in line with other major Phase 3 trials in the field of CSU, e.g., with ligelizumab (NCT03580369 and NCT03580356), which ensures comparability. In order to limit the number of participants exposed to placebo while maintaining the scientific validity of the study, the randomization ratio will be 2:1 of active vs. placebo treatment. A placebo comparison up to Week 24 (which is beyond the primary endpoint at Week 12) will provide a background incidence in the study population for possible safety findings and will ensure a valid assessment of the durability of the treatment response. It will support a more robust characterization of the safety profile of remibrutinib, i.e., if safety events are observed in both the placebo and remibrutinib arms, it may be inferred that the events are not necessarily related to the study treatment. To limit the duration of placebo treatment, the placebo-controlled treatment period will stop at Week 24, since a period of 24 weeks allows a reliable and valid assessment of efficacy and safety in patients with CSU.
3. **Open-label treatment period:** during this treatment period of 28 weeks, all participants will receive open-label remibrutinib (25 mg b.i.d.). Together with the preceding double-blind, placebo-controlled period, a total of up to 52 weeks of remibrutinib (25 mg b.i.d.) treatment will be studied within this trial. This is in line with current CSU treatment guidelines ([Zuberbier et al 2018](#)) and will provide adequate long-term efficacy and safety data to fully characterize the value of remibrutinib (25 mg b.i.d.) in CSU treatment. Switching placebo treated participants to active treatment with remibrutinib at Week 24 gives all participants the opportunity to receive active treatment with remibrutinib within the course of this study.
4. **Follow-up period:** a treatment-free follow-up period of four weeks at the end of the study will be implemented for all participants who do not enroll into the extension study (currently in planning stage). This allows the assessment of safety of treatment discontinuation as well as the dynamics of potential re-occurrence of CSU signs and symptoms after treatment discontinuation.

The study population consists of participants with CSU (UAS7 score  $\geq 16$ , with HSS7 score  $\geq 6$  and ISS7 score  $\geq 6$ ), who have a duration of CSU of  $\geq 6$  months and who are inadequately controlled despite treatment with second generation H1-antihistamines at least at locally label approved dose. Importantly, patients who have inadequately responded to or did not tolerate anti-IgE biologic treatments are also eligible for this study. Thus, CSU patients with a high unmet medical need are the target population for this study.

Historically, the treatment paradigm for CSU focused primarily on the key symptom itch, as assessed by the weekly Itch Severity Score (ISS7). Over the past several years, the emphasis and target of therapy, as described in the current CSU treatment guidelines ([Zuberbier et al 2018](#)), have evolved to also integrate the second key symptom of CSU, which is hives. Therefore, UAS7, which is a composite of ISS7 and the weekly Hives Severity Score (HSS7), is now recommended, rather than using ISS7 alone. Thus, the primary endpoint of this

study is change in UAS7 from baseline at Week 12 or a co-primary endpoint of change from baseline in ISS7 and HSS7 at Week 12. Two separate statistical analyses will be used to enable the two different primary and consecutive secondary endpoints, in order to fulfill regional health authority requests. They will be assessed in independent testing strategies for all participants. Furthermore, a primary endpoint at Week 12 ensures adequate comparability of the efficacy outcomes with other major Phase 3 trials in the field of CSU, e.g., with omalizumab (Maurer et al 2013) or ligelizumab (NCT03580369 and NCT03580356). UAS7-based responder analyses (UAS7 $\leq$ 6 and UAS7=0), the assessment of the impact of remibrutinib treatment on itch (ISS7) and hives (HSS7), the assessment of the impact of remibrutinib treatment on dermatology-related quality of life (DLQI-response of 0/1), and the assessment of the impact of remibrutinib treatment on the number of weeks without occurrence of angioedema (AAS7=0) have been selected as secondary endpoints to further assess the efficacy of remibrutinib.

Assessing remibrutinib (25 mg b.i.d.) as add-on to background medication consisting of a locally approved second generation H1-antihistamine follows the recommendations of the current treatment guidelines (Zuberbier et al 2018).

Applying a treatment policy strategy for treatment non-compliance, the use of rescue medication (a second generation H1-antihistamine that differs from the background medication), and most other intercurrent events aims to assess remibrutinib as a CSU therapy (as an add-on to background medication) close to a "real-life" situation. Only intercurrent events that are likely to impose a strong bias on the efficacy readout (such as use of highly effective biologics with a long half-life) will be handled using a composite strategy.

Taken together, the study design will allow the investigation of the efficacy and safety of remibrutinib in CSU as per current scientific, medical, ethical and regulatory standards, while limiting the burden for participants as much as possible.

#### **4.1.1 Rationale for choice of background therapy**

Second-generation H1-antihistamines are chosen as background medication. Considering the add-on remibrutinib therapy, this reflects the current treatment guidelines, which recommend to add a second or third-line therapy to H1-antihistamine background therapy in CSU patients who are not adequately controlled by H1-antihistamines (Zuberbier et al 2018). Furthermore, it allows active treatment of participants in the placebo arm, including the use of additional rescue medication. Thus, participants in the placebo arm are not left without CSU treatment.

#### **4.2 Rationale for dose/regimen and duration of treatment**

In this study, remibrutinib will be given in a dosing regimen of 25 mg b.i.d. for a duration of up to 52 weeks. A treatment duration of up to 52 weeks is in line with the current treatment guidelines (Zuberbier et al 2018) and in line with other current major Phase 3 trials in the CSU indication, e.g., with ligelizumab (NCT03580369 and NCT03580356). Therefore, it allows the collection of efficacy and safety data for remibrutinib over a treatment duration, which is applied in real-world clinical practice and which allows comparison to other Phase 3 trials in the same indication. Furthermore, a treatment duration of up to 52 weeks is covered by pre-clinical toxicity data and is used in the Phase 2b extension study CLOU064A2201E1.

The target population of this trial includes difficult-to-treat patients, such as patients with concomitant CINDU, long disease history and patients with prior inadequate response to anti-IgE biologics. In such cases a treatment duration of up to 52 weeks and more can be required. An extension study is under development and eligible participants will have the opportunity to roll over after completing 52 weeks of study treatment in this trial.


Based on the safety data from the completed and ongoing remibrutinib trials, the clinical safety profile of remibrutinib is favorable and supports the selected dose of 25 mg b.i.d. In the primary endpoint analysis of the dose-range finding Phase 2b study CLOU064A2201 (cut-off date at 14-Jan-2021), most adverse events (AEs) were mild in severity, without patterns of clustering or dose-dependency. Ongoing clinical safety review of CLOU064A2201E1, a long-term extension study of CLOU064A2201, with a 52-week treatment period with 100 mg remibrutinib b.i.d. did not reveal any safety signals. In addition, the clinical safety data from the completed Phase 1 studies, which tested doses of remibrutinib up to 600 mg q.d. and 200 mg b.i.d., was favorable and did not raise any concerns. For more detailed information on the safety profile of remibrutinib, please see [Section 4.5](#) and the Investigator's Brochure.

In the dose-range finding study CLOU064A2201, the efficacy of remibrutinib as an add-on to background therapy of second generation H1-antihistamines was assessed versus placebo for the following dose regimens: 10 mg q.d., 35 mg q.d., 100 mg q.d., 10 mg b.i.d., 25 mg b.i.d., 100 mg b.i.d. The treatment duration was 12 weeks and the primary endpoint was change in UAS7 score from baseline at Week 4. The key secondary endpoints were defined as change in UAS7 score from baseline at Week 12, change in UAS7 score from baseline over time, percentage of participants with UAS7 = 0 (complete absence of hives and itch) over time, and percentage of participants with UAS7 ≤ 6 (disease activity control) over time. At the time of the primary endpoint analysis, there were 301 participants (40-47 per arm) among 309 under full analysis set with a UAS7 score at Week 4, and 233 participants (29-37 per arm) with a UAS7 score at Week 12. The treatment groups were overall well balanced in terms of demography and baseline disease characteristics.


The study demonstrated clinical efficacy of remibrutinib in the treatment of CSU, with all tested doses showing superior efficacy over placebo at Week 4. A dose-response relationship was established for the q.d. and b.i.d. remibrutinib dosing regimens compared to placebo with respect to the change from baseline in UAS7 score at Week 4, with the dose-response plateau already achieved at 10 mg for q.d. dosing (=10 mg total daily exposure) and at 25 mg for b.i.d. dosing (=50 mg total daily exposure).



**Figure 4-1 UAS7 score change from baseline over time estimated with a mixed-effect repeated measurement analysis, by treatment group (FAS)**



**Figure 4-2 UAS7 = 0 and UAS7 ≤ 6 response rate over time by treatment group (as observed) (FAS)**



Assessing the higher hurdle  $UAS7 \leq 6$  (disease activity control) and  $UAS7 = 0$  (total absence of itch and hives) response rates enabled further differentiation between the tested doses (Figure 4-1 and Figure 4-2): At Week 4, the remibrutinib 25 mg b.i.d. dosing regimen achieved numerically higher  $UAS7 \leq 6$  response rates than all other tested doses: 55.8% under 25 mg b.i.d. compared to 43.2%, 40.9%, 42.6%, 34.1%, 44.4%, 4.8% under 10 mg q.d., 35 mg q.d.,

100 mg q.d., 10 mg b.i.d., 100 mg b.i.d., placebo (non-responder imputation). In line with that, the 25 mg b.i.d. dosing regimen also achieved considerably higher UAS7=0 response rates than all other tested doses at Week 4: 41.9% under 25 mg b.i.d. compared to 18.2%, 22.7%, 17.0%, 18.2%, 22.2%, 0.0% under 10 mg q.d., 35 mg q.d., 100 mg q.d., 10 mg b.i.d., 100 mg b.i.d., placebo (non-responder imputation). The numerically higher efficacy of the 25 mg b.i.d. dosing regimen compared to all other doses was observed consistently over time, with higher UAS7  $\leq$  6 and UAS7 = 0 response rates from Week 2 throughout Week 12 (Figure 4-2). Furthermore, the 25 mg b.i.d. dosing regimen showed the fastest onset of action, with high response rates already achieved at Week 2 (Figure 4-2).

At Week 12, the UAS7  $\leq$  6 and UAS7 = 0 response rates for placebo treated participants were relatively high (31.3% and 15.7%), reflecting the fluctuating nature of CSU (Figure 4-2). While still showing numerical superiority, the q.d. dosing regimens (10 mg q.d., 35 mg q.d., 100 mg q.d.) showed a tendency towards weaker differentiation vs placebo in UAS7  $\leq$  6 and UAS7 = 0 response at Week 12 (UAS7  $\leq$  6: 43.2%, 40.9%, 42.6%; UAS7 = 0: 29.4%, 29.4%, 32.4%) (as observed), whereas the 25 mg b.i.d. regimen was able to maintain a notable difference (UAS7  $\leq$  6: 63.6%, UAS7 = 0: 48.5%). B.i.d. dosing is also supported from a pharmacokinetics, pharmacodynamics and mode-of-action perspective, in order to ensure sustained BTK inhibition over 24 hours, considering the relatively fast turn-over of the covalent BTK-remibrutinib complex in tissue (see Investigator's Brochure for details).

Taken together, all tested remibrutinib dosing regimens demonstrated superior efficacy in treating signs and symptoms of CSU compared to placebo, when assessing the mean change from baseline in UAS7. However, when analyzing higher hurdle efficacy endpoints with higher discriminatory power (UAS7  $\leq$  6 or UAS7 = 0) and later time points with higher placebo response rates, the 25 mg b.i.d. treatment regimen showed notably higher efficacy than the other tested regimens, especially than the q.d. regimens.

A lower b.i.d. dose (10 mg b.i.d.) or once daily dosing (35 mg q.d.), does not enable participants to achieve the maximum efficacy, which can be achieved with 25 mg b.i.d. dosing, especially when considering the UAS7  $\leq$  6 and UAS7 = 0 response rates. At the same time, higher dosing regimens, such as 100 mg b.i.d., are not required to reach maximum efficacy.

As the safety data also support the 25 mg b.i.d. dosing regimen (see Section 4.5 and the Investigator's Brochure) with a favorable safety profile and no dose-dependent safety signals, remibrutinib 25 mg b.i.d. was selected as the optimal dose for this Phase 3 study.

### 4.3 Rationale for choice of control drugs (comparator/placebo) or combination drugs

Placebo was chosen as a comparator for this trial to adjust for the fluctuating nature of CSU, which can result in a pronounced placebo effect. Therefore, comparison to placebo allows a robust and scientifically valid efficacy assessment. Furthermore, comparison to placebo allows a meaningful safety assessment. The use of placebo in this study population is considered to be appropriate since participants will additionally receive background therapy of H1-antihistamines (see Section 6.1.2) and will have access to additional rescue medication (see Section 6.2.4). Although it is an inclusion criterion of the study to be inadequately controlled by H1-antihistamines, this does not mean that participants do not benefit from



H1-antihistamines at all. The allowed H1-antihistamine background treatment still alleviates participants' symptoms to a certain degree. Thus, participants in the placebo arm are not left without treatment during the placebo-controlled period. Furthermore, participants in the placebo arm will be switched to active treatment with remibrutinib at Week 24, giving all participants the opportunity to receive treatment with remibrutinib during the course of the trial.

As the target patient population is hard-to-treat CSU patients with a prior inadequate response to second generation H1-antihistamines, the only potential active comparator according to the current treatment guidelines would be omalizumab (Zuberbier et al 2018). CSU patients, who have already been treated with, and potentially failed to respond to, omalizumab, have a high unmet medical need, since they are currently left without approved treatment options. Adding omalizumab as an active comparator to the study would significantly restrict the study population, as these omalizumab (or any other anti-IgE biologics) pretreated patients would need to be excluded from the study in order to prevent a potential prior treatment bias and allow a fair comparison, thus preventing the collection of efficacy and safety data for this population. Additionally, the burden for enrolled participants would increase as the administration routes of remibrutinib (oral) and omalizumab (subcutaneous (s.c.)) would mandate a double-dummy design with placebo injections for participants in the remibrutinib arm and 4-weekly visits throughout the entire study duration (instead of extended periods between visits after Week 24 as per the current study design). Furthermore, the long half-life of omalizumab (approximately 4 weeks vs a half-life of approximately 1 hour for remibrutinib) would mandate a significantly longer treatment-free follow-up period after the end of the treatment period. Due to differences in the route of administration (s.c. vs. oral), different PK-PD profiles and speed of onset kinetics, omalizumab is not considered an ideal comparator for remibrutinib. Lastly, historical comparisons of the data from the confirmatory omalizumab trials to the current remibrutinib trial will be possible, given their similarities with regard to patient population, background medication, endpoints and the use of placebo as the control arm in the omalizumab studies.

Taken together, a placebo comparison over 24 weeks is appropriate and justified for this trial, allowing a robust and scientifically valid assessment of the safety and efficacy of remibrutinib. The additional comparative information which could be gained by adding the active comparator omalizumab does not outweigh the restrictions in study population and the additional participant burden this would entail.

#### **4.4 Purpose and timing of interim analyses/design adaptations**

A primary analysis may be conducted when all participants have completed their Week 24 visit or discontinued early and when a minimum of 150 participants across both Phase 3 pivotal studies have completed the treatment period (a second, nearly identical Phase 3 study will be conducted in parallel). The minimum of 150 participants reaching week 52 should enable analysis on a minimum of 100 participants exposed to remibrutinib for 52 weeks considering the initial randomization to either the remibrutinib or the placebo arm (2:1). The results of the primary analysis will further inform decision making for the remibrutinib development program.

After the primary analysis and/or after all participants have entered the open label treatment period, additional optional interim analyses may be conducted to support potential Health

Authority interactions and requests (these interim analyses are not expected to have any impact on the conduct or scientific integrity of the study).

#### 4.5 Risks and benefits

Signs and symptoms of CSU are a direct consequence of mast cell degranulation with release of inflammatory mediators including histamine (Ferrer 2015, Saini and Kaplan 2018). Bruton's tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase that is indispensable for FcεR1 signaling and a central signaling kinase in mast cell activation. It has been demonstrated that BTK inhibition can effectively inhibit mast cell activation and reduce wheal sizes in skin prick tests (Regan et al 2017; Dispenza et al 2018; Kaul et al 2019). In Phase 1, remibrutinib was well-tolerated at all doses without any dose-limiting toxicity and showed encouraging blood and skin pharmacodynamics with a favorable safety profile, fully supporting further development for diseases driven by mast cells, basophils, or B cells, such as CSU. Furthermore, remibrutinib has been shown to effectively reduce wheal size in skin prick tests (Kaul et al 2021). The Phase 2b clinical trial CLOU064A2201 (primary endpoint analysis) demonstrated clinical efficacy of remibrutinib in the treatment of CSU patients with a fast onset of action and a favorable safety profile.

Based on this data, 25 mg b.i.d. has been selected as the optimal dosing regimen for the treatment of CSU patients. Treatment with remibrutinib 25 mg b.i.d. resulted in a substantial reduction of the UAS7 score, which measures frequency/intensity of hives and itch, the two key symptoms defining the burden of CSU for affected participants. The benefit for CSU patients treated with remibrutinib 25 mg b.i.d. was also reflected by substantial improvements in health-related quality of life (HRQoL), as measured by the DLQI score (see Investigator's Brochure for details).

BTK inhibition is a new therapeutic principle for the treatment of CSU that significantly differs from currently available treatment options in terms of its mode of action and route of administration. Remibrutinib may therefore offer a treatment option for patients with contraindications against or inadequate response to approved treatment options for CSU including anti-IgE directed biologics. These patients, for whom a high unmet need for new treatments exists, are part of the eligible patient population of this study. In the above-mentioned Phase 2b trial CLOU064A2201, remibrutinib showed a rapid onset of action already after the first week of treatment, which is of significant benefit for CSU patients, who often have a high current symptom burden. Furthermore, the oral route of administration of remibrutinib offers additional convenience compared to injectable biologics.

Taken together, the benefit for study participants is that treatment with remibrutinib could substantially improve their CSU signs and symptoms and lead to a better quality of life.

The available clinical safety experience has documented favorable safety and tolerability of remibrutinib. As of 10-Mar-2022, approximately 903 participants (healthy volunteers (HVs) and patients suffering from CSU, asthma, Sjogren's Syndrome (SjS), atopic dermatitis (AD), and relapsing multiple sclerosis (RMS)) have been exposed to remibrutinib at doses ranging from 0.5 mg to 600 mg, placebo or comparator. A maximum tolerated dose has not been identified.

In the final analysis of the Phase 2b trial CLOU064A2201 in patients with CSU, 309 participants (safety set (SAF)) received remibrutinib at doses/regimens up to 100 mg b.i.d. for up to 12 weeks. Most adverse events (AEs) were mild in severity, without clustering of specific AEs and no apparent dose related pattern was identified. The most frequent adverse events were reported in the following System Organ Classes (SOC): Infections and infestations (24.0% any remibrutinib dose vs 21.4% in placebo arm), Skin and subcutaneous tissue disorders (16.9% vs 4.8%), Nervous system disorders (13.1% vs 16.7%), and Gastrointestinal disorders (11.2% vs 11.9%). The most frequent AEs (defined by MedDRA Preferred Term (PT), occurring in  $\geq 5\%$  of participants in either Any remibrutinib or placebo arm) were:

- Headache: 9.7% in any remibrutinib arm vs. 14.3% in placebo arm
- Nasopharyngitis: 8.6% in any remibrutinib arm vs. 7.1% in placebo arm
- Chronic spontaneous urticaria: 6.0% in any remibrutinib arm vs. 2.4% in placebo arm (the events of chronic spontaneous urticaria were flares primarily reported by participants during the treatment-free follow-up period)

In interim analysis 2 (IA2; cut-off May-2021) of the Phase 2b long-term open-label extension trial CLOU064A2201E1, data from 183 CSU participants enrolled with a median exposure to remibrutinib 100 mg b.i.d. of 35.14 weeks showed a similar safety profile to that in the core CLOU064A2201 study. Most AEs were non-serious, mild in severity, and did not lead to treatment discontinuation. The most common SOCs ( $\geq 10\%$  of subjects) were Infections and infestations (23%), Skin and subcutaneous tissue disorders (17.5%), Gastrointestinal disorders (14.2%) and Nervous systems disorders (10.4%). The 3 most commonly reported PTs were headache (6.6%), COVID-19 (4.9%), and diarrhea (4.9%). Based on the mode of action of remibrutinib, pre-clinical safety information, drug-drug-interaction studies, and the review of currently available literature as well as safety information of approved BTK inhibitors (e.g., ibrutinib, acalabrutinib and zanubrutinib), the following potential risks of remibrutinib have been identified (see below). Of note, many safety risks identified for ibrutinib and acalabrutinib, two BTK inhibitors approved for the treatment of B-cell malignancies (mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstroem's macroglobulinemia), are less likely related to the pharmacology of BTK inhibition, but rather to the underlying hemato-oncologic diseases being treated and their associated comedications and complications, such as tumor lysis syndrome, second primary malignancies, etc. Therefore, when comparing the safety risks between the approved BTK inhibitors and remibrutinib, the underlying condition of the treated patient population must be taken into consideration. Furthermore, ibrutinib and acalabrutinib have a different target selectivity profile compared to remibrutinib ([Angst et al 2020](#)).

- *Infections*: BTK is an important signaling kinase downstream of cell surface receptors and expressed in a number of cell types of the adaptive and innate immune system, including B cells, macrophages, basophils and mast cells. Thus, administration of remibrutinib might be associated with an increased risk for infections and participants should be monitored for signs and symptoms of infections and be evaluated promptly. In the completed and ongoing clinical trials with remibrutinib, infections were well balanced between the remibrutinib and placebo arms. Most of the infections observed were mild to moderate and did not lead to a change in study treatment. In the final analysis of the Phase 2b study CLOU064A2201, infection rates (defined as MedDRA SOC Infections and infestations) were comparable between any remibrutinib arm (24.0%) and the placebo arm (21.4%). Most infections



reported in the remibrutinib arms were mild in severity and did not lead to treatment discontinuation.

All participants in remibrutinib clinical trials are monitored closely for signs and symptoms of infections while in the trial. Patients with a known history of chronic recurrent or active ongoing infections are excluded from the trial (refer to [Section 5.2](#) for details). In addition, the use of live attenuated vaccines should be avoided 6 weeks before and during the study until at least 4 weeks after the last dose of the study treatment (see [Section 6.2.3](#)).

- *Response to vaccination:* In general, immunomodulatory treatments may diminish vaccine efficacy ([Farez et al 2019](#)). BTK inhibition is expected to affect the response to vaccinations and result in reduced vaccination efficacy. Due to its immunomodulatory effects, treatment with remibrutinib might be associated with reduced efficacy of vaccinations. There are limited data available on vaccination response in patients treated with BTK inhibitors and primarily reported in patients with hematologic malignancies ([Pleyer et al 2021](#), [Weber et al 2021](#)). In ongoing studies with remibrutinib, participants are advised to complete necessary vaccination before starting treatment with remibrutinib. If necessary, vaccination with non-live vaccines is allowed during the study.
- *Effect on platelet function - risk for bleeding:* BTK is a signaling molecule in one of several platelet activation pathways, and clinically relevant effects of remibrutinib on platelet functions were observed in the remibrutinib preclinical toxicology program. The mode of action by which remibrutinib could potentially cause bleeding is currently not fully understood. In vitro assessments suggest a target-related impact on platelets, similar to effects induced by the BTK inhibitor ibrutinib, which has been shown to inhibit clot retraction ([Bye et al 2015](#)).

In CSU, in the completed core CLOU064A2201 Phase 2b study, 18 (6.7%) non-serious bleeding events were reported in any remibrutinib arm compared to one event on placebo (2.4%); none of the AEs was serious or severe. All the bleeding AEs events reported were mild, except 2 moderate AEs: gingival bleeding and hematuria. Two bleeding events (petechiae and hematuria) led to study treatment discontinuation. There were no notable clinically relevant abnormalities for coagulation parameters, hemoglobin levels and platelet counts noted in these studies. In the interim analysis of the open-label long-term (up to 52 weeks) extension trial CLOU064A2201E1, the rate of bleeding events (4.4%) was comparable to that seen in the core trial; all events were non-serious, all but 2 events (the purpura and heavy menstrual bleeding in the setting of leiomyoma) were mild in severity. Potential effects of remibrutinib on hemostasis should be monitored both clinically and by standard, validated laboratory measures including complete blood count and standard coagulation parameters. Clinical monitoring should focus on skin (bruising, petechiae) and mucosa (e.g., gastro-intestinal (GI) tract bleeding including gingival, rectal, and conjunctival bleeding). Patients with a known history of bleeding disorders, or with a history of clinically relevant gastrointestinal bleeding and patients requiring anti-platelet or anticoagulant therapy (other than aspirin up to 100 mg/d or clopidogrel up to 75 mg/d) are excluded from the trial; the use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited (see details in [Section 5.2](#) and [Table 6-3](#)). In case of a significant bleeding event, study treatment must be discontinued immediately. Please, refer to the current IB for further details.

- *Effects on QT interval:* Remibrutinib is a mild inhibitor of the human ether-a-go-go related gene (hERG) channel ( $IC_{50} = 1.4 \mu M$ ; unbound  $C_{max}$ -based average safety margin of 43-fold based on 100 mg b.i.d. in humans), without affecting other ion channels in a relevant manner. Close ECG monitoring via Holter recordings in the FIH studies (CLOU064X2101 and CLOU064X1101) documented a minor exposure dependent increase in QTcF with no outliers (i.e., QT-interval with a frequency correction according to Fridericia (QTcF) > 480 msec or increases equal or greater than 60 msec) up to the maximal dose of 600 mg. At the projected suprathreshold exposure calculated based on the observed  $C_{max}$  at 25 mg b.i.d., assuming severe organ impairment and comedication with a strong CYP3A4 inhibitors such as ritonavir (“worst case” scenario), the calculated mean QTcF effect is 2.580 ms which is well below the threshold of 5 ms to rule out a relevant QT-effect. The predicted upper 90% confidence limit of the QTcF changes is well below 10 ms, the regulatory pharmacologic effect threshold for cardiac repolarization, indicating a low probability of clinically significant repolarization effects even at 2-fold higher exposure than that of the “worst-case” scenario. In the interim and final analyses of ongoing and completed Phase 2 studies in participants with CSU, SJS and asthma, no notable trend was observed for the change of ECG over time; no finding in ECG recordings or AEs suggestive of pro-arrhythmic events were noted. Patients with a history of major cardiovascular events are excluded from the trial. In addition, triplicate sequential ECG monitoring is implemented in the study to monitor potential effects of remibrutinib on QTc and other ECG parameters.
- *Myelomodulation:* Treatment emergent grade 3 or 4 cytopenias (neutropenia, thrombocytopenia and anemia) were reported in participants with hematologic malignancies treated with ibrutinib and acalabrutinib. Again, the underlying hemato-oncologic diseases of these participants and their frequent association with such events should be taken into consideration here. All cytopenias reported in the final analysis of CLOU064A2201 were mild. Participants are closely monitored for signs and symptoms of cytopenia while in the trial, and those with a history of hematological disorders or with markedly altered hematologic parameters at baseline are excluded from the study (see details in [Section 5.2](#)).
- *Drug-drug interactions:* Oxidative metabolism is the major clearance pathway of remibrutinib and expected to be predominantly mediated by CYP3A4 with minor contribution of other cytochrome P450 (CYP) enzymes (e.g., CYP2C9, CYP1A1). At the dose used in this study (25 mg remibrutinib b.i.d.), co-administration of CYP3A4 inhibitors (even of strong ones) will not result in exposure levels of remibrutinib that are associated with clinically relevant QT prolongation. Likewise, co-administration of even strong CYP3A4 inhibitors with 25 mg remibrutinib b.i.d. will not increase exposure levels of remibrutinib beyond exposure levels that can be reached with 100 mg remibrutinib b.i.d., a dose that was well-tolerated in CLOU064A2201 and was not associated with any safety signals, based on the interim analysis. Therefore, only co-administration of strong CYP3A4 inhibitors is prohibited in this study. Concomitant administration of moderate and strong inducers of CYP3A4 is also prohibited during the study (see [Table 6-3](#)). Remibrutinib can be co-administered with oral contraceptives such as ethinylestradiol or levonorgestrel without a major impact on their exposure and efficacy. Remibrutinib has been shown to inhibit some efflux and uptake transporters (such as P-glycoprotein, OATP1B, MATE1, OAT3, organic cation transporter 1 and breast cancer resistance protein (BCRP)). However, at a dose of 25 mg b.i.d., only inhibition of BCRP remains as a minor risk which is planned

to be investigated in a clinical drug-drug interaction study. Therefore, concomitant administration of remibrutinib with respective BCRP substrates with a small safety margin may be administered with caution (see [Table 6-2](#))

- *Reproductive toxicity*: Remibrutinib is not genotoxic or mutagenic in *in vitro* or *in vivo* studies. No effects on fertility or embryo-fetal development were observed in rats up to the highest dose, while in rabbits a no-observed-adverse-effect-level at 100 mg/kg/day was established. At doses  $\geq 300$  mg/kg/day body weight loss, marked low food consumption, and moribundity were noted, as well as a higher incidence of external fetal malformations (see details in Investigator's Brochure). For the approved BTK inhibitors, embryo-fetal toxicity in animals is reported (see national prescribing information). Highly effective methods of contraception must be practiced. Women of child-bearing potential will be informed that taking the study treatment may involve unknown risks to the fetus if pregnancy were to occur during the trial and must agree that in order to participate in the trial they must adhere to the contraception requirements outlined in the exclusion criteria. If there is any question that the participant will not reliably comply, they should not be entered or continue in the study.

For detailed information on potential risks associated with remibrutinib, please refer to the Investigator's Brochure.

In summary, CSU patients with inadequate response to H1-antihistamines (and other available treatment options if applicable) participating in this clinical trial may significantly benefit from treatment with remibrutinib. Additionally, this trial will help to improve the understanding of remibrutinib in the management of CSU and potentially enable the development of a novel, innovative, oral drug that could improve the quality of life of CSU patients beyond the limited treatment modalities currently available. Potential risks are mitigated as far as possible by compliance with inclusion/exclusion criteria, study procedures, very close clinical and laboratory monitoring, periodic review of safety data by an independent Data Monitoring Committee (DMC), and study drug discontinuation rules. As with investigational drugs in general, not all safety risks are known. Participants and investigators participating in this trial will be informed should important new safety information become available.


Considering all aspects, the risk-benefit assessment fully supports this trial with remibrutinib 25 mg b.i.d.

#### **4.6 Rationale for Public Health Emergency mitigation procedures**

During a Public Health emergency as declared by Local or Regional authorities, i.e., pandemic, epidemic or natural disaster, mitigation procedures to ensure participant safety and trial integrity are listed in relevant sections. Notification of the Public health emergency should be discussed with Novartis prior to implementation of mitigation procedures and permitted/approved by Local or Regional Health Authorities and Ethics Committees as appropriate.

### **5 Study Population**

The study population will consist of approximately 450 randomized female and male adult participants (300 in the active arm and 150 in the placebo arm) with CSU inadequately controlled by second generation H1-antihistamines (at least at locally label approved dose).



The screen failure rate is estimated to be 30%, meaning approximately 645 participants are expected to be screened.

Participants will be stratified based on prior exposure to anti-IgE biologics and geographic region; maximum number of participants with prior exposure to anti-IgE biologics will be limited to approximately 30% of the total study population.

Participants who drop out after they have been randomized will not be replaced.

## 5.1 Inclusion criteria

Participants eligible for inclusion in this study must meet **all** of the following criteria:

1. Signed informed consent must be obtained prior to participation in the study
2. Male and female adult participants  $\geq 18$  years of age at the time of screening
3. CSU duration for  $\geq 6$  months prior to screening (defined as the onset of CSU determined by the investigator based on all available supporting documentation)
4. Diagnosis of CSU inadequately controlled by second generation H1-antihistamines at the time of randomization defined as:
  - The presence of itch and hives for  $\geq 6$  consecutive weeks prior to screening despite the use of second generation H1-antihistamines during this time period
  - UAS7 score (range 0-42)  $\geq 16$ , ISS7 score (range 0-21)  $\geq 6$  and HSS7 score (range 0-21)  $\geq 6$  during the 7 days prior to randomization (Day 1)
5. Documentation of hives within three months before randomization (either at screening and/or at randomization; or documented in the participants' medical history)
6. Willing and able to complete an Urticaria Patient Daily Diary (UPDD) for the duration of the study and adhere to the study protocol
7. Participants must not have had more than one missing UPDD entry (either morning or evening) in the 7 days prior to randomization (Day 1)

## 5.2 Exclusion criteria

Participants meeting any of the following criteria are not eligible for inclusion in this study.

Evaluation of participant eligibility for laboratory parameters listed below must be based on central laboratory results. In case eligibility criteria are not met for specific laboratory parameters, these may be re-tested a maximum of once during the screening period.

No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible participants.

1. Use of other investigational drugs within 5 half-lives or within 30 days (for small molecules) prior to Screening or until the expected pharmacodynamic (PD) effect has returned to baseline (for biologics), whichever is longer; or longer if required by local regulations
2. Previous use of remibrutinib or other BTK inhibitors
3. History of hypersensitivity to any of the study treatments or its excipients or to drugs of similar chemical classes

4. Participants having a clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria) including urticaria factitia (symptomatic dermatographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticaria
5. Other diseases with symptoms of urticaria or angioedema, including but not limited to urticaria vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary urticaria, or drug-induced urticaria
6. Any other skin disease associated with chronic itching that might influence in the investigator's opinion the study evaluations and results, e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis
7. Participants taking medications prohibited by the protocol (see [Table 6-3](#))
8. Known history or evidence of ongoing alcohol or drug abuse within the last 6 months before randomization
9. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases
10. Pregnant or nursing (lactating) women
11. Women of child-bearing potential (WoCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 7 days after stopping of study treatment. Highly effective contraception methods include:
  - Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
  - Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) total hysterectomy or bilateral tubal ligation at least six weeks before taking investigational drug. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
  - Male sterilization (at least 6 months prior to screening). For female participants on the study, the vasectomized male partner should be the sole partner for that participant
  - Use of oral (estrogen and progesterone), injected or implanted hormonal methods of contraception

In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking investigational drug.

Women are considered post-menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms). Women are considered not of child-bearing potential if they are post-menopausal or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks ago. In the

case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of child-bearing potential.

If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the informed consent form (ICF).

12. Major surgery within 8 weeks prior to screening or planned surgery for the duration of the study
- 13.a History of live attenuated vaccine within 6 weeks prior to randomization or requirement to receive these vaccinations at any time during the study
14. Evidence of clinically significant cardiovascular (such as but not limited to myocardial infarction, unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, arrhythmia and uncontrolled hypertension within 12 months prior to Visit 1), neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant
15. Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids
16. Hematology parameters at screening:
  - Hemoglobin: < 10 g/dl
  - Platelets: < 100 000/mm<sup>3</sup>
  - Leucocytes: < 3 000/mm<sup>3</sup>
  - Neutrophils: < 1 500/mm<sup>3</sup>
17. Significant bleeding risk or coagulation disorders
- 18.a History of gastrointestinal bleeding, e.g., in association with use of nonsteroidal anti-inflammatory drugs (NSAID), that was clinically relevant (e.g., where intervention was indicated or requiring hospitalization or blood transfusion)
- 19.a Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited.
20. Requirement for anticoagulant medication (for example, warfarin or Novel Oral Anti-Coagulants (NOAC))
21. History or current hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis or hepatic failure or Aspartate Aminotransferase (AST)/ Alanine Aminotransferase (ALT) levels of more than 1.5 x upper limit of normal (ULN) or International Normalized Ratio (INR) of more than 1.5 at screening
22. History of renal disease, creatinine level above 1.5x ULN, or estimated Glomerular Filtration Rate (eGFR) <45ml/min (using the Cockcroft-Gault equation) at screening
23. Evidence of an ongoing Hepatitis C infection (e.g., defined by the detection of hepatitis C-ribonucleic acid (HCV-RNA) at screening) and/or an ongoing Hepatitis B infection (defined by the detection of Hepatitis B virus surface antigen (HBsAg) and/or hepatitis B virus (HBV)-DNA at screening; participants who are positive for anti-hepatitis B core

(HBc) antibodies but who are negative for antibodies against HBsAg and HBV-DNA can be included into the study if they agree to monitoring for HBsAg and HBV-DNA re-activation)

24. Known or suspected ongoing, chronic or recurrent infectious disease including but not limited to opportunistic infections (e.g., tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis) and/or known positivity for Human Immunodeficiency Virus (HIV) infection. HIV antigen/antibody tests will be performed to determine HIV status if required according to local regulations.


## **6 Treatment**

### **6.1 Study treatment**

Novartis Global Clinical Supply (GCS) will supply the following IMPs in the trial in appropriately labeled bottles:

- LOU064 25mg (blinded)
- LOU064 25mg placebo (blinded)
- LOU064 25mg (open-label)

No other supplies apart from these would be provided by Global Clinical Supply (GCS).





### 6.1.1 Investigational and control drugs

**Table 6-1** Investigational and control drug

| Investigational/<br>Control Drug | Pharmaceutical<br>Dosage Form | Route of<br>Administration | Presentation | Sponsor (global<br>or local) |
|----------------------------------|-------------------------------|----------------------------|--------------|------------------------------|
| LOU064 25 mg                     | Film coated tablet            | Oral use                   | Double blind | Novartis Pharma<br>AG        |
| LOU064 25 mg<br>matching Placebo | Film coated tablet            | Oral use                   | Double blind | Novartis Pharma<br>AG        |
| LOU064 25 mg                     | Film coated tablet            | Oral use                   | Open label   | Novartis Pharma<br>AG        |

### 6.1.2 Additional study treatments

No other treatment beyond investigational drug and control drug (remibrutinib and placebo) are included in this trial.

Participants will take background medication (second generation H1-antihistamines at locally label approved doses) with a stable regimen during the study ([Section 6.2.1](#)). For rescue medication, see [Section 6.2.4](#).

### 6.1.3 Treatment arms/group

Participants will be assigned at Day 1 to either remibrutinib 25 mg b.i.d. or matching placebo in a ratio of 2:1. At week 24 participants in the placebo arm will be switched to active treatment. Each participant will take one film-coated tablet in the morning and one film-coated tablet in the evening [REDACTED].

### 6.1.4 Treatment duration

The planned duration of treatment is 52 weeks. Participants may discontinue from study treatment earlier at the discretion of the investigator or the participant, e.g., due to adverse events (see [Section 9.1](#)) or lack/loss of efficacy. Eligible participants may roll over into the planned extension study at Week 52 (after completing all scheduled assessments planned at these visits). The details of the study design and procedures of the extension, if implemented, will be described in a separate protocol.

There are a total of 9 dispensing visits per participant in the trial, 6 in the double-blind period and 3 in the open-label period. The last dispensing visit occurs at Week 40.

## 6.2 Other treatment(s)

### 6.2.1 Concomitant therapy

Throughout the study, participants **must** take a second generation H1-antihistamine at a locally label approved dose (background therapy). Background therapy should not be changed until the Week 12 visit and should only be changed thereafter if medically required (i.e., adverse reactions that are attributable to background therapy as per investigator judgment). For detailed [REDACTED]



information on the background medication, refer to the corresponding national prescribing information.

Prior medication for treatment of CSU will be recorded in the Electronic Case Report Forms (eCRF). In addition, all concomitant medication at screening and prior medication that has been terminated within 4 weeks prior to screening will be recorded. The investigator should instruct the participant to notify the study site about any new medications (including medications that are not related to the treatment of CSU) he/she takes after the participant was enrolled into the study, ideally before initiating a new treatment.

All medications, procedures, and significant non-drug therapies (including physical therapy and blood transfusions) administered after the participant was enrolled into the study must be recorded on the appropriate eCRFs.

Each concomitant medication must be individually assessed against all exclusion criteria/prohibited medication. If in doubt, the investigator should contact the Novartis medical monitor before randomizing a participant or allowing a new medication to be started. If the participant is already enrolled, contact Novartis to determine if the participation in the study should be continued.

### 6.2.2 Permitted concomitant therapy requiring caution and/or action

Remibrutinib has been shown to inhibit the BCRP transporter at the intestinal level. As a consequence, co-administration with remibrutinib can lead to exposure increases area under the curve of >1.5-fold. Therefore, concomitant administration of remibrutinib with respective BCRP substrates may be accomplished with caution. BCRP substrates with a small safety margin may be administered 2 hours before or after remibrutinib (staggered dosing).

**Table 6-2 Permitted concomitant therapy requiring caution and/or action**

| Medication   | Period   | Guidance   |
|--|--|--|
| Oral BCRP substrates that may have increased exposure when co-administered with remibrutinib (pitavastatin, rosuvastatin, sulfasalazine and ubrogepan) | 1 day prior to dosing with remibrutinib until end of treatment | Use with caution, replace medication or administer 2hr before or after remibrutinib (staggered dosing) |

### 6.2.3 Prohibited medication

Use of the treatments displayed in the below table are not allowed during the specified time period.

**Table 6-3 Prohibited medication**

| Medication  | Prohibition period                                     | Action taken  |
|---|--|---|
| Biologics for treatment of CSU (including omalizumab and ligelizumab) | 4 months prior to randomization until end of treatment | Discontinue biologic treatment and closely monitor for potential associated adverse events. |



| Medication  | Prohibition period  | Action taken  |
|---|---|---|
| Routine (more than 3 doses over a 5 day period) oral corticosteroids  | 30 days prior to screening until end of treatment<br><b>Oral corticosteroids are only allowed as an additional rescue therapy for CSU AFTER Week 12</b> , on an as-needed basis for unbearable symptoms as per <a href="#">Section 6.2.4</a> . Other preparations of corticosteroids (CS) with limited systemic exposure for non-CSU indications (e.g., intra-nasal or any topical CS) can be used on an as-needed basis. | Discontinue routine corticosteroids if medically justifiable and closely monitor for potential associated adverse events. If discontinuation of routine corticosteroids is not possible, discontinue study treatment.       |
| i.v./IM/IA corticosteroids  | 30 days prior to screening until end of treatment   | Discontinue i.v./IM/IA corticosteroids if medically justifiable and closely monitor for potential associated adverse events. If discontinuation of i.v./IM/IA corticosteroids is not possible, discontinue study treatment. |
| Leukotriene antagonists (including montelukast and zafirlukast)   | From screening until end of treatment   | Discontinue Leukotriene antagonists and closely monitor for potential associated adverse events.  |
| H2-antihistamines   | From screening until end of treatment   | Discontinue H2-antihistamines and closely monitor for potential associated adverse events.  |
| First generation antihistamines   | From screening until end of treatment   | Discontinue first generation antihistamines and closely monitor for potential associated adverse events.  |
| Second generation antihistamines <b>other than</b> the participant's defined background medication and rescue medication  | From 7 days prior to randomization until end of treatment   | Discontinue all second generation H1-antihistamines but the defined background and rescue medication and closely monitor for potential associated adverse events.   |
| Other immunosuppressive/immunomodulating medication with or without known effect on CSU including but not limited to hydroxychloroquine, methotrexate, cyclosporine A, cyclophosphamide, tacrolimus and mycophenolate mofetil | 30 days or 5 half-lives (whichever is longer) prior to screening until end of treatment   | Discontinue immunosuppressive/immunomodulating medication if medically justifiable and closely monitor for potential associated adverse events. If discontinuation not possible, discontinue study treatment.               |



| <b>Medication</b>   | <b>Prohibition period</b>  | <b>Action taken</b>   |
|---|--|---|
| Intravenous (i.v.) immunoglobulins or plasmapheresis  | 30 days prior to screening until end of treatment  | Discontinue i.v. immunoglobulins or plasmapheresis if medically justifiable and closely monitor for potential associated adverse events. If discontinuation not possible, discontinue study treatment.  |
| Ultraviolet (UV) therapy  | From screening until end of treatment  | Discontinue UV therapy and closely monitor for potential associated adverse events.   |
| Any other therapy intended for the treatment of urticaria including but not limited to herbal therapies | From 2 weeks prior randomization until end of treatment                                  | Discontinue any therapy intended for the treatment of urticaria and closely monitor for potential associated adverse events.  |
| Live attenuated vaccines  | 6 weeks prior to randomization until at least 4 weeks after last dose of study treatment | Discontinue study treatment.  |
| Strong inhibitors of CYP3A4   | From 2 weeks prior randomization until end of treatment                                  | Discontinue CYP3A4 inhibitor if medically justifiable and closely monitor for potential associated adverse events. If discontinuation not possible, discontinue study treatment   |
| Moderate and strong inducers of CYP3A4  | From 2 weeks prior randomization until end of treatment                                  | Discontinue CYP3A4 inducers if medically justifiable and closely monitor for potential associated adverse events. If discontinuation not possible, discontinue study treatment.   |
| Anticoagulant medication (for example, warfarin, or Novel Oral Anti-Coagulants (NOAC))                  | From screening until end of treatment  | Only if medically justifiable, discontinue anticoagulant medication and interrupt study medication until anticoagulant effects have ended. Otherwise discontinue study treatment. Closely monitor coagulation parameters and associated adverse events.<br><br>Clinical monitoring should focus on skin (bruising, petechiae) and mucosa (e.g., gastro-intestinal tract bleeding including gingival and rectal, or conjunctival bleeding). In case of a significant bleeding event, study treatment must be discontinued immediately. |



| Medication  | Prohibition period                    | Action taken   |
|---|---------------------------------------|--|
| Anti-platelet medication except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited. | From screening until end of treatment | Only if medically justifiable, discontinue anti-platelet medication and interrupt study medication until anti-platelet effects have ended. Otherwise discontinue study treatment. Closely monitor coagulation parameters and associated adverse events. Clinical monitoring should focus on skin (bruising, petechiae) and mucosa (e.g., gastro-intestinal tract bleeding including gingival and rectal, or conjunctival bleeding). In case of a significant bleeding event, study treatment must be discontinued immediately. |

#### 6.2.4 Rescue medication

**H1-antihistamines:** In addition to being used as background medication, second generation H1-antihistamines are allowed as rescue medication, used on an as needed basis for participants with CSU flare-ups of unbearable symptoms during screening, treatment and follow-up periods. The selection of the rescue medication H1-antihistamine should be made only once for an individual participant and recorded in the source document. For each individual participant, **the H1-antihistamine used as rescue medication must differ from the H1-antihistamine used as background medication.** The daily dose of H1-antihistamine rescue medication should **not** exceed 4-fold of the approved dose, as recommended by the current urticaria treatment guidelines (Zuberbier et al 2018). For detailed information on the rescue medication, refer to the corresponding national prescribing information. A change of the rescue medication for an individual participant is only permitted in case of adverse reactions that are, in the judgment of the investigator, attributable to rescue medication.

**Oral corticosteroids: Prior to Week 12, any corticosteroid use for CSU is prohibited. After the Week 12 primary endpoint,** participants will be permitted to use oral corticosteroids such as prednisone or its equivalent, as rescue medication if needed for CSU flare-ups of unbearable symptoms. The selection of the oral corticosteroid to be used as rescue medication after Week 12, should be made only once for an individual participant. A switch of oral corticosteroids as rescue medication for an individual is not permitted except due to an AE. **Rescue oral corticosteroid use will be limited to 3 days in a 30-day period and a maximum of 9 days in total after Week 12** to avoid any confounding suppression of signs and symptoms of CSU. The recommended dose is 20 - 50 mg prednisone or equivalent per day, which is in line with the current urticaria treatment guidelines (Zuberbier et al 2018).

Rescue medication will be sourced locally. Use of H1-antihistamine rescue medication only for CSU must be recorded in the eDiary by the participant (number of tablets taken) and the name and dose will be captured on the appropriate electronic Case Report Form (eCRF). All relevant information for oral corticosteroid rescue therapy will be captured in the appropriate eCRF.

## 6.3 Preparation and dispensation

Each study site will be supplied with study drug in packaging as described under investigational and control drugs section.

A unique medication number is printed on the study medication label.

Investigator staff will identify the study medication kits to dispense to the participant by contacting the Interactive Response Technology (IRT) and obtaining the medication number(s). The study medication has a 2-part label (base plus tear-off label), immediately before dispensing the medication kit to the participant, site personnel will detach the outer part of the label from the packaging and affix it to the source document.

As per [Section 4.6](#), during a Public Health emergency as declared by Local or Regional authorities, i.e., pandemic, epidemic or natural disaster, that limits or prevents on-site study visits, delivery of Investigational Medicinal Product (IMP) directly to a participant's home may be permitted (if allowed by Local or Regional Health Authorities and Ethics Committees as appropriate) in the event the Investigator has decided that an on-site visit by the participant is no longer appropriate or possible, and that it is in the interest of the participant's health to administer the study treatment even without performing an on-site visit. The dispatch of IMP from the site to the participant's home remains under the accountability of the Investigator. Each shipment/provisioning will be for a maximum of 1-months supply. In this case, phone calls, virtual contacts (e.g., tele consult) or visits by site staff/home nursing to the participant's home at the time of a planned on-site visit will occur for instructional purposes, safety monitoring, investigation of any adverse events, ensuring participants continue to benefit from treatment, and discussion of the participant's health status until it is safe for the participant to visit the site again.

### 6.3.1 Handling of study treatment and other treatment

#### 6.3.1.1 Handling of study treatment

Study treatment must be received by a designated person at the study site, handled and stored safely and properly and kept in a secured location to which only the investigator and designated site personnel have access. Upon receipt, all study treatment must be stored according to the instructions specified on the labels.

Clinical supplies are to be dispensed only in accordance with the protocol. Technical complaints are to be reported to the respective Novartis Country Organization Quality Assurance.

Medication labels will be in the local language and comply with the legal requirements of each country. They will include storage conditions for the study treatment but no information about the participant except for the medication number.

The investigator must maintain an accurate record of the shipment and dispensing of study treatment in a drug accountability log. Monitoring of drug accountability will be performed by field monitors during regular monitoring visits, and at the completion of the trial.

Participants will be asked to return all unused study treatment and packaging at each site visit during the study and at the end of the study, or at the time of discontinuation of study treatment.

The site may destroy and document destruction of unused study treatment, drug labels and packaging as appropriate in compliance with site processes, monitoring processes, and per local regulation/guidelines. Otherwise, the investigator will return all unused study treatment, packaging, drug labels, and a copy of the completed drug accountability log to the field monitor or to the Novartis address provided in the investigator folder at each site.

### **6.3.1.2 Handling of other treatment**

Not applicable.

### **6.3.2 Instruction for prescribing and taking study treatment**

Every participant should take one film-coated tablet of remibrutinib 25 mg or placebo in the morning and in the evening, respectively, with a 12 hour interval at approximately the same time every day. The study medication may be taken with or without a meal but participants should adhere to their choice throughout the study. If taken without food, the study medication should be taken with a glass of water (250 milliliters (ml)) at least 2 hours after the last meal and 1 hour before the next meal. Participants should be instructed to swallow whole tablets and not to chew or break them.

[REDACTED]

If vomiting occurs during the course of treatment, participants should not take the study treatment again before the next scheduled dose.

Participants should be instructed not to make up missed doses. A missed dose is defined as a case when the full dose is not taken within 6 hours after the approximate time of the usually morning/evening dosing. That dose should be omitted and the participant should continue treatment with the next scheduled dose.

H1-antihistamines taken as either as background medication or rescue medication, respectively, should be taken according to the local treatment instructions.

All kits of study treatment assigned by the IRT will be recorded in the IRT system.

## **6.4 Participant numbering, treatment assignment, randomization**

### **6.4.1 Participant numbering**

Each participant is identified in the study by a Participant Number (Participant No.), that is assigned when the participant is enrolled for screening and is retained for the participant throughout his/her participation in the trial. A new Participant No. will be assigned at every subsequent enrollment if the participant is re-screened. The Participant No. consists of the Center Number (Center No.) (as assigned by Novartis to the investigative site) with a sequential participant number suffixed to it, so that each participant's participation is numbered uniquely across the entire database. Upon signing the informed consent form, the participant is assigned to the next sequential Participant No. available.

[REDACTED]

A new ICF will need to be signed if the investigator chooses to re-screen the participant after a participant has screen failed, and the participant will be assigned a new Participant No.

#### **6.4.2 Treatment assignment, randomization**

At the randomization visit, all eligible participants will be randomized via IRT to one of the treatment arms. The investigator or his/her delegate will contact the IRT after confirming that the participant fulfills all the inclusion/exclusion criteria. The IRT will assign a randomization number to the participant, which will be used to link the participant to a treatment arm and will specify a unique medication number for the first package of study treatment to be dispensed to the participant.

The randomization numbers will be generated using the following procedure to ensure that treatment assignment is unbiased and concealed from participants and investigator staff. A participant randomization list will be produced by the IRT provider using a validated system that automates the random assignment of participant numbers to randomization numbers. These randomization numbers are linked to the different treatment arms, which in turn are linked to medication numbers. A separate medication list will be produced by Novartis Global Clinical Supply (GCS) using a validated system that automates the random assignment of medication numbers to packs containing the study treatment.

Randomization will be stratified by prior anti-IgE biologic use and geographic region; maximum number of participants with prior exposure to anti-IgE biologics will be limited to approximately 30% of the total study population.

The randomization scheme for participants will be reviewed and approved by a member of the Randomization Office.

#### **6.5 Treatment blinding**

Participants, investigator staff, persons performing the assessments, and the study team directly involved with the conduct of the trial will remain blinded to the identity of the treatment during the double-blind treatment period (i.e., up to week 24) from the time of randomization until the final database lock.


The following methods will be used to maintain the blind:

(1) Randomization data will be kept strictly confidential until the time of final database lock, and will not be accessible by anyone else involved in the study with the following exceptions:

- The designated Novartis study team members involved in the primary analysis
- The bioanalyst [REDACTED] (to avoid the unnecessary analysis of placebo samples)
- An independent analysis team who need to prepare DMC reports.

(2) The identity of the treatments will be concealed by the use of study treatment that are all identical in packaging, labeling, schedule of administration, appearance, taste, and odor.

At the time of the primary analysis, a selected Novartis Team will create and review unblinded interim reports. No access will be given to the study team conducting the ongoing trial until final database lock.



[REDACTED]

Unblinding a single participant at the study site for safety reasons (necessary for participant management) will occur via an emergency system in place at the site. As a result, the participant should be discontinued from the study treatment.

The DMC will review semi-blinded interim reports created by an independent analysis team. More details will be provided in the DMC charter.

## **6.6 Dose escalation and dose modification**

Investigational or other study treatment dose adjustments are not permitted.

Study treatment interruptions are permitted in order to manage the following events:

- Management of bleeding events: in case of planned surgery with clinical significant bleeding risk, interruption of study treatment 7 days before the surgery is required; after recovery, participant may re-start study treatment after 7 days.
- Management of participants in case of Hepatitis B re-activation (new appearance of detectable HBV-DNA or positive HBsAg): participants should start antiviral treatment according to local clinical practice and interrupt study treatment until HBV-DNA and HBsAg reach an undetectable level, and then re-start study treatment.

Study treatment interruption for other than the above reasons is only permitted if, in the opinion of the investigator, a participant is deemed to be at a significant safety risk unless administration of investigational treatment is temporarily interrupted. In such cases study treatment should be interrupted only during the time that this risk is present and ongoing. Study treatment can be re-started at the next scheduled visit after resolution of the safety risk.

### **6.6.1 Follow-up for toxicities**

Not applicable.

## **6.7 Additional treatment guidance**

### **6.7.1 Treatment compliance**

The investigator must promote compliance by instructing the participant to take the study treatment exactly as prescribed and by stating that compliance is necessary for the participant's safety and the validity of the study. The participant must also be instructed to contact the investigator if he/she is unable for any reason to take the study treatment as prescribed. Compliance will be assessed by the investigator and/or study personnel at each visit using tablet counts (if applicable) and information provided by the participant. This information should be captured in the source document at each visit. All study treatment dispensed and returned must be recorded in the Drug Accountability Log.

[REDACTED]

[REDACTED]



### **6.7.2 Emergency breaking of assigned treatment code**

Emergency code breaks must only be undertaken when it is required to in order to treat the participant safely.

Most often, discontinuation from study treatment and knowledge of the possible treatment assignments are sufficient to treat a study participant who presents with an emergency condition. Emergency treatment code breaks are performed using the IRT. When the investigator contacts the system to break a treatment code for a participant, he/she must provide the requested participant identifying information and confirm the necessity to break the treatment code for the participant. The investigator will then receive details of the investigational drug treatment for the specified participant and a fax or email confirming this information. The system will automatically inform the Novartis monitor for the site and the study team that the code has been broken. If the IRT system is not available for technical reasons, the IRT help desk can facilitate emergency code break requests.

It is the investigator's responsibility to ensure that there is a dependable procedure in place to allow access to the IRT/code break cards at any time in case of emergency. The investigator will provide:

- protocol number
- participant number

In addition, oral and written information to the participant must be provided on how to contact his/her backup in cases of emergency, or when he/she is unavailable, to ensure that un-blinding can be performed at any time.

The appropriate personnel from the study site and Novartis will assess whether study treatment should be discontinued for any participant whose treatment code has been broken inadvertently for any reason.

Study treatment must be discontinued after emergency unblinding and the participant will be withdrawn from the trial and would not be eligible for enrollment into the planned open-label extension study.


### **6.7.3 Treatment of overdose**

No clinical data are available to assess the risk of overdose. Based on preclinical data it is concluded that remibrutinib has a low potential to cause acute toxicity, e.g., in case of accidental overdosing. Single and multiple ascending doses of remibrutinib up to 600 mg were studied in healthy volunteers with no dose-limiting toxicities identified. With the 25 mg b.i.d. dose used in this study, the potential of remibrutinib to cause acute toxicity is assessed as low.

There is no specific antidote to remibrutinib; therefore, adverse events will be managed symptomatically according to standard of care and applicable clinical guidelines.

In the event of an overdose, the Investigator should:

- Contact the medical monitor immediately.
- Closely monitor the participant for any AE/SAE and laboratory abnormalities.
- Document the quantity of the excess dose as well as the duration of the overdose.



## 7 Informed consent procedures

Eligible participants may only be included in the study after providing (witnessed, where required by law or regulation), Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent.

If applicable, in cases where the participant's representative(s) gives consent (if allowed according to local requirements), the participant must be informed about the study to the extent possible given his/her level of understanding. If the participant is capable of doing so, he/she must indicate agreement by personally signing and dating the written informed consent document.

Informed consent must be obtained before conducting any study-specific procedures (e.g., all of the procedures described in the protocol). The process of obtaining informed consent must be documented in the participant source documents.

Novartis will provide to investigators in a separate document a proposed informed consent form that complies with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) E6 good clinical practice (GCP) guidelines and regulatory requirements and is considered appropriate for this study. Any changes to the proposed consent form suggested by the investigator must be agreed by Novartis before submission to the IRB/IEC.

Information about common side effects already known about the investigational treatment can be found in the Investigator's Brochure (IB). This information will be included in the participant informed consent and should be discussed with the participant during the study as needed. Any new information regarding the safety profile of the investigational drug that is identified between IB updates will be communicated as appropriate, for example, via an investigator notification or an aggregate safety finding. New information might require an update to the informed consent and then must be discussed with the participant.

The following informed consents are included in this study:

- Main study consent, which also includes:
  - [REDACTED]
- As applicable, Pregnancy Outcomes Reporting Consent for female participants who took study treatment
- [REDACTED]
- [REDACTED]

Women of child-bearing potential must be informed that taking the study treatment may involve unknown risks to the fetus if pregnancy were to occur during the study and agree that in order to participate in the study they must adhere to the contraception requirements.

[REDACTED]

[REDACTED]

[REDACTED]

A copy of the approved version of all consent forms must be provided to Novartis after IRB/IEC approval.

Participants might be asked to complete an optional questionnaire to provide feedback on their clinical trial experience.

As per [Section 4.6](#), during a Public Health emergency as declared by Local or Regional authorities i.e., pandemic, epidemic or natural disaster, that may challenge the ability to obtain a standard written informed consent due to limits that prevent an on-site visit, Investigator may conduct the informed consent discussion remotely (e.g., telephone, videoconference) if allowable by a local Health Authority.

Guidance issued by local regulatory bodies on this aspect prevail and must be implemented and appropriately documented (e.g., the presence of an impartial witness, sign/dating separate ICFs by trial participant and person obtaining informed consent, etc.).

## 8 Visit schedule and assessments

The Assessment Schedule ([Table 8-1](#)) lists all of the assessments and when they are performed. All data obtained from these assessments must be supported in the participant's source documentation.

Participants should be seen for all visits/assessments as outlined in the assessment schedule ([Table 8-1](#)) or as close to the designated day/time as possible. Missed or rescheduled visits should not lead to automatic discontinuation.

For participants who discontinue from study treatment refer to [Section 9.1.1](#).


Participants who discontinue from the study or withdraw their consent/oppose the use of their data/biological samples should be scheduled for a final evaluation visit, if they agree, as soon as possible, at which time all of the assessments listed for the final visit will be performed. At this final visit, all dispensed investigational product should be reconciled, and the adverse event and concomitant medications not previously reported must be recorded on the CRF.

The "X" in the table denotes the assessments to be recorded in the clinical database or received electronically from a vendor. The "S" in the table denotes the assessments that are only in the participant's source documentation and do not need to be recorded in the clinical database.

As per [Section 4.6](#), during a Public Health emergency as declared by Local or Regional authorities i.e., pandemic, epidemic or natural disaster that limits or prevents on-site study visits, alternative methods of providing continuing care may be implemented by the investigator as the situation dictates. If allowed by local Health Authority and depending on operational capabilities, phone calls, virtual contacts (e.g., tele consult) or visits by site staff/ home nursing staff to the participant's home, can replace on-site study visits, for the duration of the disruption until it is safe for the participant to visit the site again.


[REDACTED]

The preferred sequence of assessments during study visits is PRO completion, ECG collection, followed by vital signs, and blood sampling.




**Table 8-1 Assessment Schedule**


| Period  | Screening | Treatment                               |                     |        |        |                      |         |         |         |         |         |                                       | Follow-up  | Unscheduled visit                           |                   |
|---|-----------|---|---------------------|--------|--------|----------------------|---------|---------|---------|---------|---------|---------------------------------------|--|---|-------------------|
| Visit Name  | Screening | Baseline/<br>Randomization <sup>1</sup> | week 2 <sup>1</sup> | week 4 | week 8 | week 12 <sup>1</sup> | week 16 | week 20 | week 24 | week 32 | week 40 | Early<br>treatment<br>discontinuation | week<br>52/Study<br>discontinuation <sup>1</sup> | week<br>56/Safety<br>FU/Study<br>completion | Unscheduled visit |
| Days  | -28 to -1 | 1                                       | 15                  | 29     | 57     | 85                   | 113     | 141     | 169     | 225     | 281     | -                                     | 365  | 394   | -                 |
| Informed consent  | X         |   |                     |        |        |                      |         |         |         |         |         |                                       |  |   |                   |
| IRT transaction   | X         | X                                       |                     | X      | X      | X                    | X       | X       | X       | X       | X       | X                                     | X  |   |                   |
| Inclusion /<br>Exclusion criteria                         | X         | X                                       |                     |        |        |                      |         |         |         |         |         |                                       |  |   |                   |
| Randomization   |           | X                                       |                     |        |        |                      |         |         |         |         |         |                                       |  |   |                   |
| Demography  | X         |   |                     |        |        |                      |         |         |         |         |         |                                       |  |   |                   |
| Pregnancy and<br>assessments of<br>fertility <sup>2</sup> | XS        | S                                       |                     | S      | S      | S                    | S       | S       | S       | S       | S       | S                                     | S  | S   | S                 |
| Evidence of<br>urticaria                                  | S         | S                                       |                     |        |        |                      |         |         |         |         |         |                                       |  |   |                   |
| Hepatitis screen  | X         |   |                     |        |        |                      |         |         |         |         |         |                                       |  |   |                   |
| Relevant medical<br>history                               | X         |   |                     |        |        |                      |         |         |         |         |         |                                       |  |   |                   |
| Dispense<br>participants'<br>eDiary <sup>3</sup>          | S         |   |                     |        |        |                      |         |         |         |         |         | S                                     | S  |   |                   |
| CSU History and<br>prior urticaria<br>treatment           | X         |   |                     |        |        |                      |         |         |         |         |         |                                       |  |   |                   |
| Cardiovascular<br>history                                 | X         |   |                     |        |        |                      |         |         |         |         |         |                                       |  |   |                   |



| Period   | Screening | Treatment                               |                     |        |        |                      |         |         |         |         |         |  | Follow-up   | Unscheduled visit                           |                   |
|--|-----------|---|---------------------|--------|--------|----------------------|---------|---------|---------|---------|---------|--|---|---|-------------------|
| Visit Name   | Screening | Baseline/<br>Randomization <sup>1</sup> | week 2 <sup>1</sup> | week 4 | week 8 | week 12 <sup>1</sup> | week 16 | week 20 | week 24 | week 32 | week 40 | Early<br>treatment<br>discontinu-<br>ation | week<br>52/Study<br>discontinu-<br>ation <sup>1</sup> | week<br>56/Safety<br>FU/Study<br>completion | Unscheduled visit |
| Days   | -28 to -1 | 1                                       | 15                  | 29     | 57     | 85                   | 113     | 141     | 169     | 225     | 281     | -  | 365   | 394   | -                 |
| Physical Examination <sup>4</sup>  | S         | S                                       | S                   | S      | S      | S                    | S       | S       | S       | S       | S       | S  | S   | S   | S                 |
| Height and Weight <sup>5</sup>   | X         | X                                       |                     |        |        | X                    |         |         | X       |         |         | X  | X   | X   | X                 |
| Vital Signs  | X         | X                                       | X                   | X      | X      | X                    | X       | X       | X       | X       | X       | X  | X   | X   | X                 |
| Electrocardiogram (ECG)  | X         | X                                       | X <sup>6</sup>      |        |        | X <sup>6</sup>       |         |         | X       |         |         | X  | X <sup>6</sup>  | X   | X                 |
| Subject's eDiary review <sup>7</sup>                                       |           | S                                       | S                   | S      | S      | S                    | S       | S       | S       | S       | S       | S  | S   |   | S                 |
| DLQI <sup>8</sup>  |           | X                                       |                     | X      |        | X                    |         |         | X       |         |         | X  | X   |   | X                 |
|  |           |   |                     |        |        |                      |         |         |         |         |         |  |   |   |                   |
| Study drug dispensation  |           | X                                       |                     | X      | X      | X                    | X       | X       | X       | X       | X       |  |   |   |                   |
| Background medication dispensation and compliance assessment <sup>17</sup> | X         | X                                       |                     | X      | X      | X                    | X       | X       | X       | X       | X       | X  | X   | X   |                   |
| Rescue medication  | X         | X                                       |                     | X      | X      | X                    | X       | X       | X       | X       | X       | X  | X   |   |                   |



| Period  | Screening | Treatment                               |                     |        |        |                      |         |         |         |         |         |  | Follow-up   | Unscheduled visit                           |                   |
|---|-----------|---|---------------------|--------|--------|----------------------|---------|---------|---------|---------|---------|--|---|---|-------------------|
| Visit Name  | Screening | Baseline/<br>Randomization <sup>1</sup> | week 2 <sup>1</sup> | week 4 | week 8 | week 12 <sup>1</sup> | week 16 | week 20 | week 24 | week 32 | week 40 | Early<br>treatment<br>discontinu-<br>ation | week<br>52/Study<br>discontinu-<br>ation <sup>1</sup> | week<br>56/Safety<br>FU/Study<br>completion | Unscheduled visit |
| Days  | -28 to -1 | 1                                       | 15                  | 29     | 57     | 85                   | 113     | 141     | 169     | 225     | 281     | -  | 365   | 394   | -                 |
| dispensation and<br>usage <sup>10</sup>                   |           |   |                     |        |        |                      |         |         |         |         |         |  |   |   |                   |
| Clinical Chemistry  | X         | X                                       | X                   | X      | X      | X                    | X       | X       | X       | X       | X       | X  | X   | X   | X                 |
| Hematology  | X         | X                                       | X                   | X      | X      | X                    | X       | X       | X       | X       | X       | X  | X   | X   | X                 |
| Urinalysis  | X         | X                                       | X                   | X      | X      | X                    | X       | X       | X       | X       | X       | X  | X   | X   | X                 |
| Coagulation Panel   | X         | X                                       |                     | X      |        | X                    |         |         | X       |         | X       | X  | X   | X   | X                 |
| Hepatitis B re-<br>activation<br>monitoring <sup>15</sup> |           |   |                     | X      | X      | X                    | X       | X       | X       | X       | X       | X  | X   | X   | X                 |



| Period   | Screening | Treatment                               |                     |        |        |                      |         |         |         |         |         |  | Follow-up   | Unscheduled visit                           |                   |
|--|-----------|---|---------------------|--------|--------|----------------------|---------|---------|---------|---------|---------|--|---|---|-------------------|
| Visit Name   | Screening | Baseline/<br>Randomization <sup>1</sup> | week 2 <sup>1</sup> | week 4 | week 8 | week 12 <sup>1</sup> | week 16 | week 20 | week 24 | week 32 | week 40 | Early<br>treatment<br>discontinu-<br>ation | week<br>52/Study<br>discontinu-<br>ation <sup>1</sup> | week<br>56/Safety<br>FU/Study<br>completion | Unscheduled visit |
| Days   | -28 to -1 | 1                                       | 15                  | 29     | 57     | 85                   | 113     | 141     | 169     | 225     | 281     | -  | 365   | 394   | -                 |
| Eligibility assessment for extension study <sup>18</sup> |           |   |                     |        |        |                      |         |         |         |         |         |  | X   |   |                   |
| Prior and concomitant medication                         |           |   |                     |        |        |                      |         |         |         |         | X       |  |   |   |                   |
| Adverse Events   |           |   |                     |        |        |                      |         |         |         |         | X       |  |   |   |                   |
| Study completion information                             |           |   |                     |        |        |                      |         |         |         |         | X       |  |   |   |                   |

<sup>1</sup> Participant to come fasting for ≥8 h (ideally overnight) to visits: Baseline/Randomization, week 2, week 12 and week 52

<sup>2</sup> Serum pregnancy test and fertility assessment will be done at Screening. Urine pregnancy test to be completed every 4 weeks by WoCBP from Randomization through to Study completion visit. At Weeks 28, 36, 44 and 48 test may be performed at home - sites must contact participants to obtain test results. Any positive or undetermined test result must be confirmed by a serum pregnancy test done by central lab and results received electronically. Urine pregnancy results are reported as source.

<sup>3</sup> Participants eDiary will be returned to site at either Week 52/study discontinuation

<sup>4</sup> Complete physical exam at screening, short physical exam at all subsequent visits including body temperature monitoring (per local practice)

<sup>5</sup> Height collected at screening visit only

<sup>6</sup> pre and post dose

<sup>7</sup> eDiary includes UPDD (Urticaria Patient Daily Diary) with UAS (Urticaria Activity Score, part of UPDD) and AAS (Angioedema Activity Score), eDiary to be completed from screening to week 52/study discontinuation

<sup>8</sup> Completed in the patient's eDiary during site visit. Order of completion: DLQI [REDACTED]. All questionnaires should be completed prior to any other physician assessment.

[REDACTED]

<sup>14</sup> At selected sites only

[REDACTED]




| Period     | Screening | Treatment                               |                     |        |        |                      |         |         |         |         |         |  | Follow-up   | Unscheduled visit                           |                   |
|------------|-----------|---|---------------------|--------|--------|----------------------|---------|---------|---------|---------|---------|--|---|---|-------------------|
| Visit Name | Screening | Baseline/<br>Randomization <sup>1</sup> | week 2 <sup>1</sup> | week 4 | week 8 | week 12 <sup>1</sup> | week 16 | week 20 | week 24 | week 32 | week 40 | Early<br>treatment<br>discontinu-<br>ation | week<br>52/Study<br>discontinu-<br>ation <sup>1</sup> | week<br>56/Safety<br>FU/Study<br>completion | Unscheduled visit |
| Days       | -28 to -1 | 1                                       | 15                  | 29     | 57     | 85                   | 113     | 141     | 169     | 225     | 281     | -  | 365   | 394   | -                 |

<sup>15</sup> Hepatitis B re-activation monitoring only for participants who were HBsAg negative and HBcAb (anti-HBc) positive with a negative HBV DNA test at Screening.

<sup>17</sup>Dispensation for background medication covers prescription, dispensation and/or instruction of the participant on dosing and use of background medication and protocol requirements, considering different procedures for the provision of background medication at investigational sites. At Week 56/Safety FU/Study completion visit only compliance to be checked

<sup>18</sup> Only for participants who have completed Week 52 visit, not applicable at Study discontinuation visit



## 8.1 Screening

### Screening and re-screening

Participants will have a screening period of 7 up to a maximum of 28 days to establish eligibility for the study.

Once all eligibility criteria have been assessed and the participant is eligible for enrollment in the study the baseline visit can be scheduled (this may be prior to the maximum 28 day screening period duration).

Evaluation of participant eligibility for laboratory parameters listed in [Section 5.2](#) must be based on central laboratory results. In case eligibility criteria are not met for specific laboratory parameters, these may be re-tested a maximum of once during the screening period.

If for any reason a participant is a screen failure, the participant may be re-screened. Re-screening is only allowed once. There is no restriction on how much time must pass from the date of screen failure to the date of re-screening.

If a participant re-screens for the study, then they must sign a new ICF and be issued a new participant number prior to any screening assessment being conducted for the participant under the new screening subject number. The investigator/qualified site staff will record if the participant was re-screened on the re-screening eCRF and any applicable screening numbers the participant was issued prior to the current screening number.

The date of the new informed consent signature must be entered on the informed consent eCRF to correspond to the new screening subject number. For re-screening, all screening assessments must be performed per protocol.


#### 8.1.1 Information to be collected on screening failures

Participants who sign an informed consent form and are subsequently found to be ineligible prior to randomization will be considered a screen failure. The reason for screen failure should be recorded on the appropriate Case Report Form. The demographic information, informed consent, and Inclusion/Exclusion pages must also be completed for screen failure participants. No other data will be entered into the clinical database for participants who are screen failures, unless the participant experienced a serious adverse event (SAE) during the screening phase (see SAE section for reporting details). If the participant fails to be randomized, the IRT must be notified within 2 days of the screen fail that the participant was not randomized.

Participants who are randomized and fail to start treatment, e.g., participants randomized in error, will be considered an early terminator. The reason for early termination should be recorded on the appropriate Case Report Form.

## 8.2 Participant demographics/other baseline characteristics

Baseline CSU activity will be assessed using the eDiary from Day -7 to Day -1. Participant demographic and baseline characteristic data to be collected on all participants include age, sex, race and ethnicity. Participant race and ethnicity, as required by some Health Authorities, are collected to assess the diversity of the study population and to evaluate their impact on the



safety and efficacy parameters in the study. Relevant medical history (including evaluation of inclusion/exclusion criteria, CSU history and cardiovascular history) and current medical condition present before signing the informed consent will be captured. Where possible, diagnoses, and not symptoms, will be recorded. Data on participants' family history of malignancies will be collected on the respective eCRF page, only when a participant has a malignancy event reported during the study, to assess possible risk factors related to any malignancies.

Country-specific regulations should be considered for the collection of demographic and baseline characteristics in alignment with CRF.

## 8.3 Efficacy

### 8.3.1 eDiary assessments

All participants will be provided with an electronic device (eDiary) that contains the following Patient Reported Outcomes (PRO) assessments: Urticaria Patient Daily Diary (UPDD) and Angioedema Activity Score (AAS).

Site and participants will receive appropriate training and guidance on the use of the eDiary and will receive clear instructions on the completion of the assessments.

Assessments will be completed twice daily (UPDD), once daily (AAS, if triggered by opening question within the UPDD) from screening to week 52/study discontinuation.

In general, participants complete eDiary questionnaires at home and independent of study visits. Participants will be instructed to complete eDiary entries after they took their study medication throughout the treatment period.


The DLQI, [REDACTED] questionnaires will be administered during respective visits on site and should be completed prior to any other study specific procedure. Site personnel must allow participants to complete the questionnaire on their own without any assistance from the site staff. In the case that participants cannot come to site (see [Section 4.6](#)), the DLQI, [REDACTED] will be available on their electronic device.

#### 8.3.1.1 Urticaria Patient Daily Diary (UPDD)

UPDD includes Urticaria Activity Score (UAS) which assesses twice daily severity of itch and number of hives, use of rescue medication, sleep and activity interference, angioedema occurrence, its management and records the calls to a healthcare professional (HCP) (see [Section 16.4](#)). The components are presented in the [Table 8-2](#) and the relevant weekly scores are described below.

**Table 8-2 UPDD**

| Diary component  | When assessed       |
|--|---------------------|
| Urticaria Activity Score (UAS) <ul style="list-style-type: none"><li>• Itch severity</li><li>• Number of hives</li></ul> | Morning and evening |



| Diary component   | When assessed |
|---|---------------|
| Sleep interference  | Morning       |
| Daily activity interference   | Evening       |
| Rescue medication use   | Evening       |
| Angioedema: <ul style="list-style-type: none"> <li>Whether patient had an episode</li> <li>If patient had an episode, how did they manage it</li> </ul> | Evening       |
| Contact health care provider  | Evening       |

#### 8.3.1.1.1 Weekly Hives Severity Score (HSS7)

The hives (wheals) severity score, defined by number of hives, will be recorded by the participant twice daily in their eDiary, on a scale of 0 (none) to 3 (> 12 hives/12 hours; [Table 8-3](#)). A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 – 21.

**Table 8-3 Hives Severity Score**

| Score | Hives (Wheals) (every 12 hours) |
|-------|---------------------------------|
| 0     | None                            |
| 1     | 1-6 hives/12 hours              |
| 2     | 7-12 hives/12 hours             |
| 3     | >12 hives/12 hours              |

#### 8.3.1.1.2 Weekly Itch Severity Score (ISS7)


The severity of the itch will be recorded by the participant twice daily in their eDiary, on a scale of 0 (none) to 3 (severe) ([Table 8-4](#)). A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 - 21.

**Table 8-4 Itch Severity Score**

| Score | Pruritus (Itch) (every 12 hours)                        |
|-------|---|
| 0     | None  |
| 1     | Mild (minimal awareness, easily tolerated)              |
| 2     | Moderate (definite awareness, bothersome but tolerable) |
| 3     | Severe (difficult to tolerate)                          |

#### 8.3.1.1.3 Weekly Urticaria Activity Score (UAS7)

The UAS7 is the sum of the HSS7 score and the ISS7 score. The possible range of the weekly UAS7 score is 0 – 42 (highest activity).



#### 8.3.1.1.7 Angioedema occurrence

Angioedema occurrence is recorded once daily in the evening in the eDiary by the participant. Reporting the occurrence of angioedema will be used as opening question for the assessment of the AAS (see [Section 8.3.1.2](#)). Actions and/or treatments related to those angioedema occurrences will be also recorded in the eDiary as follows (multiple answers possible):

- Did nothing
- Took some prescription or non-prescription medication
- Called my doctor, nurse or nurse practitioner
- Went to see my doctor, nurse or nurse practitioner
- Went to the emergency room at the hospital
- Was hospitalized

### 8.3.1.1.8 Number of calls to doctor or nurse

The number of calls to doctor, nurse or nurse practitioner because of the participant's skin condition will be recorded once daily in the eDiary by the participant.

### 8.3.1.2 Angioedema Activity Score (AAS)

AAS is recorded once daily in the evening in the eDiary by the participant. This validated tool assesses occurrence of episodes of angioedema. As an opening question, the occurrence of angioedema in the UPDD (see [Section 8.3.1.1.7](#)) will be used. If participants answer this opening question in the UPDD with "no", AAS score for this day is 0. If "yes" is the answer to the opening question in the UPDD, the participant will continue to answer questions about the duration, severity and impact on daily functioning and appearance of the angioedema (see [Section 16.4](#)). A score between 0 and 3 is assigned to every answer field. The AAS score in this study will be reported as weekly AAS (AAS7). Minimum and maximum possible AAS7 scores are 0–105. A higher score means higher severity.

## 8.3.2 Other Patient Reported Outcomes (PRO) assessments

### 8.3.2.1 Dermatology Life Quality Index (DLQI)

The Dermatology Life Quality Index (DLQI) is a 10-item (grouped in 6 domains) dermatology-specific quality of life (QoL) measure ([Finlay and Khan 1994](#)). The DLQI was validated for patients aged 16 and above. Participants rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days.



An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL). Domain scores are calculated for: Symptoms and Feelings (0-6), Daily Activities (0-6), Leisure (0-6), Work and School (0-3), Personal Relationships (0-6), Treatment (0-3).

The overall DLQI score range was split into score bands ([Hongbo et al 2005](#)) and validated in terms of their meaning/relevance to patients as follows:

**Table 8-7 DLQI score bands and impact on patient's life**

| DLQI band | Significance of score                    |
|-----------|--|
| 0-1       | No effect on patient's life              |
| 2-5       | Small effect on patient's life           |
| 6-10      | Moderate effect on patient's life        |
| 11-20     | Very large effect on patient's life      |
| 21-30     | Extremely large effect on patient's life |

A DLQI score of > 10 is relevant for a very large impact on patients' life and justification for a biologic prescription for example in psoriasis ([Finlay 2005](#)). The DLQI questionnaires are completed at visits detailed in [Table 8-1](#) in the eDiary. The DLQI should be completed prior to any other assessment and prior to administration of investigational medication.



[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

### 8.3.3 Appropriateness of efficacy assessments

**UAS7:** The UAS7 score is a unified, simple, well-established and validated tool, recommended by the current urticaria guidelines for the assessment of disease activity and treatment response in real-world clinical practice as well as in clinical trials with urticaria patients (Mlynek et al 2008, Hawro et al 2018, Zuberbier et al 2018). It is based on the assessment of the two key urticaria signs and symptoms, wheals and pruritus, which are documented by the patient, making this score especially valuable. The use of the UAS7 facilitates comparison of study results across different trials, since it is used in other major Phase 3 trials in the CSU indication as well (e.g., with ligelizumab).

**AAS7:** The AAS7 score is a unified, simple and validated tool, recommended by the current urticaria guidelines for the assessment of disease activity and treatment response in patients with angioedema (Weller et al 2013, Zuberbier et al 2018). The use of the AAS7 facilitates comparison of study results across different trials, since it is used in other major Phase 3 trials in the CSU indication as well (e.g., with ligelizumab).

[REDACTED]


[REDACTED]

### 8.3.4 Other assessments: evidence of urticaria

The investigator must confirm the presence of urticaria (i.e., the presence of hives) in each participant before randomization by direct physical examination. In the absence of active disease at the screening and/or randomization visit, the following will be acceptable: (a) a clearly identifiable photograph of the participant that is no older than 3 months showing the presence of urticaria, (b) the investigator must have seen the participant with active CSU in the past 3 months, or (c) the presence of hives/wheals must have been documented in the medical record of the participant by a physician trained in the management of urticaria in the past 3 months.


[REDACTED]





#### **8.4 Safety**

Safety assessments are specified below with the assessment schedule detailing when each assessment is to be performed.



For details on AE collection and reporting, refer to AE section.

As per [Section 4.6](#), during a Public Health emergency as declared by Local or Regional authorities i.e., pandemic, epidemic or natural disaster, that limits or prevents on-site study visits, regular phone or virtual calls can occur (every 4 weeks or more frequently if needed) for safety monitoring and discussion of the participant's health status until it is safe for the participant to visit the site again.

**Table 8-8 Physical assessments**

| Assessment           | Specification  |
|----------------------|--|
| Physical examination | <p>A complete physical examination (performed at Screening) will include the examination of general appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities, vascular, neurological and body temperature measurement (per local practice). If indicated based on medical history and/or symptoms, rectal, external genitalia, breast, and pelvic exams will be performed.</p> <p>A short physical exam (performed at all visits except Screening) will include the examination of general appearance, assessment of the skin for signs of urticaria and other skin lesions, body temperature measurement (per local practice) and vital signs (blood pressure (BP) [systolic blood pressure (SBP) and diastolic blood pressure (DBP)] and pulse).</p> <p>Information for all physical examinations must be included in the source documentation at the study site. Clinically relevant findings that are present prior to signing informed consent must be recorded on the appropriate CRF that captures medical history. Significant findings made after signing informed consent which meet the definition of an Adverse Event must be recorded as an adverse event.</p> |
| Vital signs          | <p>Vital signs include BP and pulse measurements. After the participant has been sitting for five minutes, with back supported and both feet placed on the floor, systolic and diastolic blood pressure will be measured three times using an automated validated device, e.g., OMRON, with an appropriately sized cuff. The repeat sitting measurements will be made at 1 - 2 minute intervals and the mean of the three measurements will be used. In case the cuff sizes available are not large enough for the participant's arm circumference, a sphygmomanometer with an appropriately sized cuff may be used.</p>   |



| Assessment        | Specification  |
|-------------------|--|
|                   | Clinically notable vital signs are defined in <a href="#">Section 16.1</a> .   |
| Height and weight | Height in centimeters (cm) and body weight (to the nearest 0.1 kilogram (kg) in indoor clothing, but without shoes) will be measured as specified in <a href="#">Table 8-1</a> . |

#### 8.4.1 Laboratory evaluations

A central laboratory will be used for analysis of all specimens detailed in this section ([Table 8-9](#)) unless noted otherwise. Details on the collections, shipment of samples and reporting of results by the central laboratory are provided to investigators in the laboratory manual.


If participants cannot visit the site for protocol specified safety lab assessments (per [Section 4.6](#)), an alternative lab (local) collection may be used.

Clinically notable laboratory findings are defined in [Section 16.1](#).

Clinically significant abnormalities must be recorded on the relevant section of the eCRF capturing medical history/current medical conditions/AEs.

**Table 8-9 Laboratory assessments**

| Test Category | Test Name   |
|---------------|---|
| Hematology    | Hematocrit, Hemoglobin, [in the case of clinically significant anemia the following parameters will be assessed: Ery. Mean Corpuscular Hemoglobin (MCH), Ery. Mean Corpuscular Hemoglobin Concentration (MCHC), Ery. Mean Corpuscular Volume (MCV)], Platelets, Erythrocytes, Leukocytes, and Differential (Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Bands)   |
| Chemistry     | Albumin, Alkaline phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma-glutamyl transferase (GGT), Lactate dehydrogenase (LDH), Calcium, Magnesium, Phosphate, Chloride, Sodium, Potassium, Creatinine, Creatine Kinase (CK), Direct Bilirubin, Indirect Bilirubin (in case of clinically significant elevation), Total Bilirubin, Total Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Total Protein, Triglycerides, Urea Nitrogen or Urea, Uric Acid, Amylase, Lipase<br><br>C-reactive protein (CRP), estimated Glomerular Filtration Rate (eGFR): in all patients at screening, baseline, weeks 12, 24 and 52 and when deemed necessary by the investigator at later visits. |



| Test Category                        | Test Name  |
|--------------------------------------|--|
|                                      | Fasting glucose assessed at randomization, weeks 2, 12 and 52.   |
| Urinalysis                           | Done on site: Macroscopic Panel (Dipstick) (Color, Bilirubin, Occult Blood, Macroscopic Blood, Glucose, Ketones, Leukocytes esterase, Nitrite, pH, Protein, Specific Gravity, Urobilinogen)  |
| Coagulation                          | Prothrombin time (PT), International normalized ratio (INR), Activated partial thromboplastin time (APTT)  |
| Hepatitis screening                  | Hepatitis B screening: Antibodies against Hepatitis B virus core antigen (HBcAb or anti-HBc); antibodies against Hepatitis B virus surface antigen (anti-HBs or HBs-Ab); Hepatitis B virus surface antigen (HBsAg).<br><br>Hepatitis B-Deoxyribonucleic acid (HBV-DNA, only in participants who are positive for anti-Hepatitis B virus Core HBc-Ab or anti-HBc).<br><br>Hepatitis C screening: Hepatitis C virus antibodies (anti-HCVAb) and Hepatitis C-Ribonucleic acid (HCV-RNA, only in participants who are positive for anti-HCVAb) |
| Hepatitis B re-activation monitoring | Only in participants who are positive for HBc-Ab (anti-HBc positive) and negative for anti-HBsAg and HBV-DNA at screening: HBsAg, HBV- DNA   |
| HIV testing                          | HIV test performed at screening, only when required by local regulations.  |
| Additional tests                     | [REDACTED]<br>Follicle-stimulating hormone (FSH) (for female participants with unclear fertility status)<br>[REDACTED]   |
| Pregnancy Test                       | Serum / Urine pregnancy test for WoCBP (refer to <a href="#">Section 8.4.3</a> )   |

#### 8.4.2 Electrocardiogram (ECG)

Electrocardiograms (ECGs) must be recorded according to the ECG investigator manual. The preferred sequence of cardiovascular data collection during study visits is ECG collection first, followed by vital signs, and blood sampling. The Fridericia QT correction formula (QTcF) should be used for clinical decisions.

Triplicate 12-lead ECGs are to be collected approximately 2 minutes apart for central analysis with ECG machines supplied by the core laboratory. The mean QTcF value for each visit will be calculated from the triplicate ECGs for each participant. At weeks 2, 12 and 52 pre and post-dose assessments should be collected (refer to [Table 8-1](#) ), post dose assessment should be measured [REDACTED]



██████████ and the mean QTcF value for each timepoint will be calculated from the triplicate ECGs for each participant.

All ECGs, including unscheduled safety ECGs with clinically relevant findings collected during the study needs to be transmitted to the central ECG laboratory for review.

A monitoring or review process should be in place for clinically significant ECG findings throughout the study and especially at baseline before administration of study treatment.

In the event that a clinically significant ECG abnormality is identified at the site (e.g., severe arrhythmia, conduction abnormality of QTcF > 450 ms (males)/ 460 ms (females)), a copy of the assessment is sent to the core laboratory for expedited review if applicable, and the ECG is repeated to confirm the diagnosis. If the participant is hemodynamically compromised, the investigator or a medically qualified person must initiate appropriate safety procedures without delay (for example cardioversion).

Additional, unscheduled, safety ECGs may be repeated at the discretion of the investigator at any time during the study as clinically indicated. For any ECGs with participant safety concerns, two additional ECGs must be performed to confirm the safety finding.

Clinically significant abnormalities must be recorded on the CRF as either medical history/current medical conditions or adverse events as appropriate.

### **8.4.3 Pregnancy and assessments of fertility**

All pre-menopausal women who are not surgically sterile will have pregnancy testing at screening (serum), at randomization (Day 1, before administration of study medication (urine)), and every 4 weeks thereafter (urine). Where the visit interval is greater than 4 weeks, or in the case that the participants cannot visit the site, the participants will be provided with urine pregnancy tests kits to be used at home. Results must be provided to the investigator at the next scheduled visit. Participants should be instructed to perform the urine pregnancy test first and only if the test result is negative proceed with the administration of the study treatment.

A positive urine pregnancy test needs to be confirmed with a serum test. Where a home urine pregnancy test is positive the participant must contact the investigator and return to site for a serum pregnancy test, in the case that participants cannot visit the site an alternative (local lab) can be used. If positive the participant must be discontinued from study treatment.


A communication process should be established with the participant so that the site is informed and can verify the pregnancy test results (e.g., following country-specific measures).

Additional pregnancy testing might be performed if requested by local requirements.

#### **Assessments of fertility**

Medical documentation of oophorectomy, hysterectomy, or bilateral tubal ligation must be retained as source documents. Subsequent hormone level assessment to confirm the woman is not of child-bearing potential must also be available as source documentation in the following cases:

1. Surgical bilateral oophorectomy without a hysterectomy
2. Reported 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile.



In the absence of the above medical documentation, FSH testing is required of any female participant regardless of reported reproductive/menopausal status at screening/baseline.

#### **8.4.4 Appropriateness of safety measurements**

The selected safety monitoring assessments (including laboratory assessments covering clinical chemistry, hematology, coagulation status [REDACTED], as well as clinical and physical assessments, triplicate ECG monitoring and general AE assessments) are reliable and well-established standard measures which allow valid and close safety monitoring of the trial's patient population, with regards to their disease, to the compound they are treated with, remibrutinib, and also to their overall medical safety.

### **8.5 Additional assessments**

#### **8.5.1 Clinical Outcome Assessments (COAs)**



##### **Trial Feedback**


This study includes an optional anonymized questionnaire, the 'Trial Feedback Questionnaire' for trial participants to provide feedback on their clinical trial experience at 3 timepoints: at the start, during and at the end of the trial. Individual trial participant responses will not be reviewed by investigators. Responses may be used by the sponsor to understand where improvements can be made in the clinical trial process. This questionnaire does not ask questions about the trial participant's disease, symptoms, treatment effect or adverse events and therefore is not considered as trial data.

[REDACTED]

[REDACTED]

[REDACTED]





## **9 Discontinuation and completion**

### **9.1 Discontinuation from study treatment and from study**

#### **9.1.1 Discontinuation from study treatment**

Discontinuation of study treatment for a participant occurs when study treatment is permanently stopped for any reason (prior to the protocol planned completion of study drug administration) and can be initiated by either the participant or the investigator.

The investigator must discontinue study treatment for a given participant if, he/she believes that continuation would negatively impact the participant's well-being.

Discontinuation from study treatment is required under the following circumstances:

- Participant decision (requested in writing or verbally)
- Pregnancy
- Use of prohibited treatment requiring study treatment discontinuation as detailed in [Table 6-3](#) or discontinuation of highly effective methods of contraception as detailed in [Section 5.2](#)





- Any situation in which continued study participation might result in a safety risk to the participant
- Following emergency unblinding
- Emergence of the following AEs:
  - any adverse events that in the judgement of investigator, taking into consideration the participant's overall status, prevents the participant from continuing participation in the study, including:
    - hypersensitivity reactions,
    - severe/serious infections
    - clinically significant spontaneous bleeding events
    - new confirmed diagnosis of malignancy of any organ system  
(other than localized basal cell carcinoma of the skin or in situ cervical cancer)
  - Platelets < 75 000/mm<sup>3</sup>
  - Abnormal renal laboratory results requiring discontinuation (see [Section 16.3](#))
  - Abnormal liver laboratory results requiring discontinuation (see [Section 16.2](#))
  - Any other laboratory abnormalities that in the judgment of the investigator, taking into consideration the participant's overall status, prevents the participant from continuing participation in the study
  - participant received a live virus vaccination during the study

If discontinuation from study treatment occurs, the investigator should make a reasonable effort to understand the primary reason for the participant's discontinuation from study treatment and record this information.

**All participants who discontinue from study treatment prematurely should complete the Early treatment discontinuation visit at the time of treatment discontinuation.**

For participants who discontinue from study treatment prior to week 12, where possible they should be requested to return for visits after the Early treatment discontinuation visit as per the Assessment Schedule ([Table 8-1](#)) up to and including the week 12 timepoint. At the week 12 timepoint the study discontinuation visit should be performed [REDACTED]. If the participant declines to continue with assessments as per the visit schedule up to week 12, then they should complete the safety follow-up visit after the Early treatment discontinuation visit.

Participants who discontinue from study treatment after week 12 should complete the safety follow-up visit indicated in the Assessment Schedule ([Table 8-1](#)) whenever possible.

If the participant cannot or is unwilling to attend any visit(s), the site staff should maintain regular telephone contact with the participant, or with a person pre-designated by the participant. This telephone contact should preferably be done according to the study visit schedule.

After discontinuation from study treatment, at a minimum, in abbreviated visits, the following data should be collected at clinic visits or via telephone/email contact:

- New / concomitant treatments
  - Adverse Events / Serious Adverse Events
- [REDACTED]

The investigator must also contact the IRT to register the participant's discontinuation from study treatment.

If discontinuation occurs because treatment code has been broken, please refer to Emergency breaking of treatment code section.

### **9.1.2 Discontinuation from study**

Discontinuation from study is when the participant permanently stops receiving the study treatment, and further protocol-required assessments or follow-up, for any reason, including participant's decision (requested in writing or verbally).

If the participant agrees, a final evaluation at the time of the participant's study discontinuation should be made as detailed in the assessment table (refer to [Section 8](#)).

### **9.1.3 Lost to follow-up**

For participants whose status is unclear because they fail to appear for study visits without stating an intention to discontinue from study treatment or discontinue from study or withdraw consent/oppose to the use of their data/biological samples, the investigator must show "due diligence" by documenting in the source documents steps taken to contact the participant, e.g., dates of telephone calls, registered letters, etc. A participant should not be considered as lost to follow-up until due diligence has been completed or until the end of the study.

## **9.2 Withdrawal of informed consent/Opposition to use data/biological samples**

Withdrawal of consent/opposition to use data/biological samples occurs when a participant:

- Explicitly requests to stop use of their biological samples and/or data (opposition to use participant's data and biological samples)

and

- No longer wishes to receive study treatment

and


- Does not want any further visits or assessments (including further study-related contacts)

This request should be in writing or verbally (depending on local regulations) and recorded in the source documentation.

In this situation, the investigator should make a reasonable effort (e.g., telephone, e-mail, letter) to understand the primary reason for the participant's decision to withdraw their consent/opposition to use data/biological samples and record this information.

Where consent to the use of Personal and Coded Data is not required in a certain country's legal framework, the participant therefore cannot withdraw consent. However, they still retain the right to object to the further collection or use of their Personal Data.

Study treatment must be discontinued and no further assessments conducted, and the data that would have been collected at subsequent visits will be considered missing.



Further attempts to contact the participant are not allowed unless safety findings require communicating or follow-up.

If the participant agrees, a final evaluation at the time of the participant's withdrawal of consent/opposition to use data/biological samples should be made as detailed in the assessment table (refer to [Section 8](#)).

Novartis will continue to retain and use all research results (data) that have already been collected for the study evaluation, including processing of biological samples that has already started at time of consent withdrawal/opposition. No new Personal Data (including biological samples) will be collected following withdrawal of consent/opposition.

### **9.3 Study completion and post-study treatment**

Study completion is defined as when the last participant finishes their Study Completion visit and any repeat assessments associated with this visit have been documented and followed-up appropriately by the Investigator, enrolls into the planned open-label extension study following completion of the 52-week treatment period or, in the event of an early study termination decision, the date of that decision.

Participants who complete participation in the 52-week treatment period of this trial may be eligible to receive remibrutinib as part of an open-label extension study (under development) if they meet the eligibility criteria defined in the extension study protocol.

The open-label extension will require endorsement in participating countries and sites as per local laws and regulations.

For participants not willing or ineligible to roll over into the extension study and who want to continue receiving remibrutinib every effort will be made to continue provision of study treatment prior to the investigational treatment becoming available in the respective country, if in the opinion of the investigator, they are still deriving clinical benefit from remibrutinib.

### **9.4 Early study termination by the sponsor**

The study can be terminated by Novartis at any time.

Reasons for early termination:

- Unexpected, significant, or unacceptable safety risk to participants enrolled in the study
- Decision based on recommendations from applicable board(s) after review of safety and efficacy data
- Discontinuation of study drug development

In taking the decision to terminate, Novartis will always consider participant welfare and safety. Should early termination be necessary, participants must be seen as soon as possible and treated as a participant who discontinued from study treatment. Following instruction from Novartis, investigators must contact the participant to schedule the study discontinuation and study completion visits (as appropriate) and provide instruction regarding study drug intake. The investigator may be informed of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the participant's interests. The investigator

or sponsor depending on local regulation will be responsible for informing IRBs/IECs of the early termination of the trial.

## **10 Safety monitoring, reporting and committees**

### **10.1 Definition of adverse events and reporting requirements**

#### **10.1.1 Adverse events**

An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.

The investigator has the responsibility for managing the safety of individual participant and identifying adverse events.


Novartis qualified medical personnel will be readily available to advise on trial related medical questions or problems.

The occurrence of adverse events must be sought by non-directive questioning of the participant at each visit during the study. Adverse events also may be detected when they are volunteered by the participant during or between visits or through physical examination findings, laboratory test findings, or other assessments.

Adverse events must be recorded under the signs, symptoms, or diagnosis associated with them, accompanied by the following information (as far as possible) (if the event is serious refer to [Section 10.1.2](#)):

1. The severity grade:
  - mild: usually transient in nature and generally not interfering with normal activities
  - moderate: sufficiently discomforting to interfere with normal activities
  - severe: prevents normal activities
2. Its relationship to the study treatment. If the event is due to lack of efficacy or progression of underlying illness (i.e., progression of the study indication) the assessment of causality will usually be 'Not suspected.' The rationale for this guidance is that the symptoms of a lack of efficacy or progression of underlying illness are not caused by the trial drug, they happen in spite of its administration and/or both lack of efficacy and progression of underlying disease can only be evaluated meaningfully by an analysis of cohorts, not on a single participant
3. Its duration (start and end dates or ongoing) and the outcome must be reported
4. Whether it constitutes a SAE (see [Section 10.1.2](#) for definition of SAE) and which seriousness criteria have been met
5. Action taken regarding with study treatment.

All adverse events must be treated appropriately. Treatment may include one or more of the following:



- Dose not changed
  - Drug interrupted/permanently discontinued
6. Its outcome (i.e., recovery status or whether it was fatal)

Conditions that were already present at the time of informed consent should be recorded in medical history of the participant.

Adverse events (including lab abnormalities that constitute AEs) should be described using a diagnosis whenever possible, rather than individual underlying signs and symptoms.

Adverse event monitoring should be continued for at least 30 days following the last dose of study treatment.

Once an adverse event is detected, it must be followed until its resolution or until it is judged to be permanent (e.g., continuing at the end of the study), and assessment must be made at each visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the interventions required to treat it, and the outcome.

Information about adverse drug reactions for the investigational drug can be found in the Investigator's Brochure (IB).

Abnormal laboratory values or test results constitute adverse events only if they fulfill at least one of the following criteria:

- they induce clinical signs or symptoms
- they are considered clinically significant
- they require therapy

Clinically significant abnormal laboratory values or test results must be identified through a review of values outside of normal ranges/clinically notable ranges, significant changes from baseline or the previous visit, or values which are considered to be non-typical in participant with the underlying disease. See [Section 16.1](#) , [Section 16.2](#) and [Section 16.3](#) for alert ranges for laboratory and other test abnormalities.

### **10.1.2 Serious adverse events**

An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following criteria:

- fatal
- life-threatening

Life-threatening in the context of a SAE refers to a reaction in which the participant was at risk of death at the time of the reaction; it does not refer to a reaction that hypothetically might have caused death if it were more severe (please refer to the ICH-E2D Guidelines).

- results in persistent or significant disability/incapacity
- constitutes a congenital anomaly/birth defect
- requires inpatient hospitalization or prolongation of existing hospitalization, unless hospitalization is for:



- routine treatment or monitoring of the studied indication, not associated with any deterioration in condition
- elective or pre-planned treatment for a pre-existing condition that is unrelated to the indication under study and has not worsened since signing the informed consent
- social reasons and respite care in the absence of any deterioration in the participant's general condition
- treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospital admission
- is medically significant, e.g., defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above

Medical and scientific judgment should be exercised in deciding whether other situations should be considered serious reactions, such as important medical events that might not be immediately life threatening or result in death or hospitalization but might jeopardize the participant or might require intervention to prevent one of the other outcomes listed above. Such events should be considered as “medically significant.” Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias, or convulsions that do not result in hospitalization or development of dependency or abuse (please refer to the ICH-E2D Guidelines).

All new malignant neoplasms will be assessed as serious under “medically significant” if other seriousness criteria are not met.

Any suspected transmission via a medicinal product of an infectious agent is also considered a serious adverse reaction.

All reports of intentional misuse and abuse of the product are also considered serious adverse event irrespective if a clinical event has occurred (see [Section 10.1.5](#)).

### 10.1.3 SAE reporting

To ensure participant safety, every SAE, regardless of causality, occurring after the participant has provided informed consent and until 30 days following the last administration of study treatment must be reported to Novartis safety immediately, without undue delay, but under no circumstances later than within 24 hours of obtaining knowledge of the events (Note: If more stringent, then local regulations regarding reporting timelines prevail). Detailed instructions regarding the submission process and requirements are to be found in the investigator folder provided to each site. Information about all SAEs is collected and recorded on the electronic serious adverse event (eSAE) (with paper backup if required) Serious Adverse Event Report Form; all applicable sections of the form must be completed in order to provide a clinically thorough report.

1. Screen Failures (e.g., a participant who is screened but is not treated or randomized): SAEs occurring after the participant has provided informed consent until the time the participant is deemed a Screen Failure must be reported to Novartis with 24 hours of learning of its occurrence.
2. Randomized OR Treated Participants: SAEs collected between time participant signs ICF until 30 days after the participant has discontinued from study treatment.

All follow-up information for the SAE including information on complications, progression of the initial SAE and recurrent episodes must be reported as follow-up to the original episode immediately, without undue delay, but under no circumstances later than within 24 hours of the investigator receiving the follow-up information (Note: If more stringent, then local regulations regarding reporting timelines prevail). An SAE occurring at a different time interval or otherwise considered completely unrelated to a previously reported one must be reported separately as a new event.

If the SAE is not previously documented in the Investigator's Brochure or Package Insert (new occurrence) and is thought to be related to the study treatment, a Chief Medical Office and Patient Safety (CMO & PS) Department associate may urgently require further information from the investigator for health authority reporting. Novartis may need to issue an Investigator Notification (IN) to inform all investigators involved in any study with the same study treatment that this SAE has been reported.

Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to the competent authorities and relevant ethics committees in accordance with EU Guidance 2011/C 172/01 or as per national regulatory requirements in participating countries.

Any SAEs experienced after the 30 day period following the last administration of study treatment should only be reported to Novartis Safety if the investigator suspects a causal relationship to study treatment, unless otherwise specified by local law/regulations.


#### **10.1.4 Pregnancy reporting**

##### **Pregnancies**

If a female trial participant becomes pregnant, the study treatment should be stopped, and the pregnancy consent form should be presented to the trial participant. The participant must be given adequate time to read, review and sign the pregnancy consent form. This consent form is necessary to allow the investigator to collect and report information regarding the pregnancy. To ensure participant safety, each pregnancy occurring after signing the informed consent must be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy should be followed up to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications.

Pregnancy should be recorded and reported by the investigator to the Novartis Chief Medical Office and Patient Safety (CMO&PS). Pregnancy follow-up should be recorded on the Targeted Follow-up pregnancy - Infant status form and should include an assessment of the possible relationship to the study treatment any pregnancy outcome. Any SAE experienced during pregnancy must be reported.

After consent is provided, the pregnancy reporting will occur up to one year after the estimated date of delivery.





### 10.1.5 Reporting of study treatment errors including misuse/abuse

Medication errors are unintentional errors in the prescribing, dispensing, administration or monitoring of a medicine while under the control of a healthcare professional, participant or consumer (European Medicines Agency definition).

Misuse refers to situations where the medicinal product is intentionally and inappropriately used not in accordance with the protocol.

Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, which is accompanied by harmful physical or psychological effects.

Study treatment errors and uses outside of what is foreseen in the protocol will be recorded on the appropriate CRF irrespective of whether or not associated with an AE/SAE and reported to Safety only if associated with an SAE. Misuse or abuse will be collected and reported in the safety database irrespective of it being associated with an AE/SAE within 24 hours of Investigator's awareness.

**Table 10-1 Guidance for capturing the study treatment errors including misuse/abuse**

| Treatment error type                | Document in Dosing CRF (Yes/No) | Document in AE eCRF           | Complete SAE form                      |
|-------------------------------------|---------------------------------|-------------------------------|--|
| Unintentional study treatment error | Yes                             | Only if associated with an AE | Only if associated with an SAE         |
| Misuse/Abuse                        | Yes                             | Yes                           | Yes, even if not associated with a SAE |

For more information on AE and SAE definition and reporting requirements, please see the respective sections.

## 10.2 Additional Safety Monitoring


### 10.2.1 Liver safety monitoring

To ensure participant safety and enhance reliability in determining the hepatotoxic potential of an investigational drug, a standardized process for identification, monitoring and evaluation of liver events has to be followed.

Please refer to [Table 16-1](#) in [Section 16.2](#) for complete definitions of liver laboratory triggers.

Once a participant is exposed to study treatment, every liver event defined in [Table 16-1](#) should be followed up by the investigator or designated personnel at the trial site, as summarized below. Additional details on actions required in case of liver events are outlined in [Table 16-2](#) and [Table 16-3](#). Repeat liver chemistry tests (i.e., ALT, AST, TBL, PT/INR, ALP and GGT) to confirm elevation.

These liver chemistry repeats will be performed using the central laboratory. If results will not be available from the central laboratory, then the repeats can also be performed at a local laboratory to monitor the safety of the participant. If a liver event is subsequently reported, any local liver chemistry tests previously conducted that are associated with this event should have results recorded on the appropriate CRF.





- If the initial elevation is confirmed, close observation of the participant will be initiated, including consideration of treatment interruption if deemed appropriate.
- Discontinuation of the investigational drug (refer to [Section 9.1](#) and [Section 16.2](#)), if appropriate
- Hospitalization of the participant if appropriate
- Causality assessment of the liver event
- Thorough follow-up of the liver event should include, based on investigator's discretion:
  - serology tests, imaging and pathology assessments, hepatologist's consultancy; obtaining more detailed history of symptoms and prior or concurrent diseases, history of concomitant drug use, exclusion of underlying liver disease

All follow-up information and procedures performed must be recorded as appropriate in the CRF.

### 10.2.2 Renal safety monitoring

Once a participant is exposed to study treatment, the following two categories of abnormal renal laboratory alert values should be assessed during the study period:

- Serum creatinine increase  $\geq 25\%$  compared to baseline during normal hydration status
- Any one of the following:
  - Urine protein-creatinine ratio (PCR)  $\geq 1\text{g/g}$  or  $\geq 100\text{ mg/mmol}$ , OR
  - New onset dipstick proteinuria  $\geq 3+$ , OR
  - New onset dipstick hematuria  $\geq 3+$  (after excluding menstruation, UTI, extreme exercise, or trauma)

Abnormal renal event findings must be confirmed after  $\geq 24$  hours but  $\leq 5$  days after first assessment.


Once a participant is exposed to study treatment, renal laboratory alerts or renal safety events as defined in [Table 16-4](#) should be followed up by the investigator or designated personnel at the trial site as summarized in [Table 16-5](#).

## 10.3 Committees

### 10.3.1 Data Monitoring Committee

This study will include a data monitoring committee (DMC) which will function independently of all other individuals associated with the conduct of this clinical trial, including the site investigators participating in the study. The DMC will assess at defined intervals the progress of a clinical trial, safety data, and critical efficacy variables and recommend to the sponsor whether to continue, modify, or terminate a trial.

Specific details regarding composition, responsibilities, data monitoring, and meeting frequency, and documentation of DMC reports, minutes, and recommendations will be described in a separate charter that is established between the sponsor and the DMC.



### **10.3.2 Steering Committee**

A steering committee has been established comprising of investigators participating in the trial, that are not members of the DMC, and Novartis representatives from the Clinical Trial Team.

The steering committee will ensure transparent management of the study according to the protocol through recommending and approving modifications as circumstances require. The steering committee will review the initial protocol and protocol amendments as appropriate.

Together with the clinical trial team, the steering committee will also develop recommendations for publications of study results including authorship rules.

## **11 Data Collection and Database management**

### **11.1 Data collection**

Designated investigator staff will enter the data required by the protocol into the eCRF. The eCRFs have been built using fully validated secure web-enabled software that conforms to 21 CFR Part 11 requirements, Investigator site staff will not be given access to the EDC system until they have been trained. Automatic validation programs check for data discrepancies in the eCRFs, allow modification and/or verification of the entered data by the investigator staff.

The investigator/designee is responsible for assuring that the data (entered into eCRF) is complete, accurate, and that entry and updates are performed in a timely manner. The Investigator must certify that the data entered are complete and accurate.

After final database lock, the investigator will receive copies of the participant data for archiving at the investigational site.

All data should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation, and verification.

### **11.2 Database management and quality control**

Novartis personnel (or designated Contract Research Organization (CRO)) will review the data entered by investigational staff for completeness and accuracy. Electronic data queries stating the nature of the problem and requesting clarification will be created for discrepancies and missing values and sent to the investigational site via the EDC system. Designated investigator site staff are required to respond promptly to queries and to make any necessary changes to the data.

Concomitant treatments and prior medications entered into the database will be coded using the World Health Organization (WHO) Drug Reference List, which employs the Anatomical Therapeutic Chemical (ATC) classification system. Medical history/current medical conditions and adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology.

Dates of screenings, randomizations, screen failures and study completion, as well as randomization codes and data about all study treatment(s) dispensed to the participant and all dosage changes will be tracked using an Interactive Response Technology (IRT). The system

will be supplied by a vendor, who will also manage the database. The data will be sent electronically to Novartis (or a designated CRO) at specific timelines.

Each occurrence of a code break via IRT will be reported to the clinical team and monitor. The code break functionality will remain available until study shut down or upon request of Novartis.

Once all the necessary actions have been completed and the database has been declared to be complete and accurate, it will be locked **and the treatment codes will be unblinded** and made available for data analysis. Any changes to the database after that time can only be made after written agreement by Novartis development management.

### 11.3 Site monitoring

Before study initiation, at a site initiation visit or at an investigator's meeting, a Novartis/delegated CRO representative will review the protocol and data capture requirements (i.e., electronic source (eSource) DDE or eCRFs) with the investigators and their staff. During the study, Novartis employs several methods of ensuring protocol and GCP compliance and the quality/integrity of the sites' data. The field monitor will visit the site to check the completeness of participant records, the accuracy of data capture / data entry, the adherence to the protocol and to Good Clinical Practice, the progress of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist the field monitor during these visits. Continuous remote monitoring of each site's data may be performed by a centralized Novartis/delegated CRO/CRA organization. Additionally, a central analytics organization may analyze data & identify risks & trends for site operational parameters, and provide reports to Novartis clinical teams to assist with trial oversight.

The investigator must maintain source documents for each participant in the study, consisting of case and visit notes (hospital or clinic medical records) containing demographic and medical information, laboratory data, electrocardiograms, and the results of any other tests or assessments. All information on CRFs must be traceable to these source documents in the participant's file. The investigator must also keep the original informed consent form signed by the participant (a signed copy is given to the participant).

The investigator must give the monitor access to all relevant source documents to confirm their consistency with the data capture and/or data entry. Novartis monitoring standards require full verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all primary variables. Additional checks of the consistency of the source data with the CRFs are performed according to the study-specific monitoring plan. No information in source documents about the identity of the participants will be disclosed.

## 12 Data analysis and statistical methods

The analysis will be conducted at the time of the primary analysis and on all participants' data at the time the trial ends. Any data analysis carried out independently by the investigator should be submitted to Novartis before publication or presentation.



## 12.1 Analysis sets

The following analysis sets will be used in this trial:

- Randomized set (RAS): The RAS set consists of all randomized participants, regardless of whether or not they receive a dose of study drug. Participants will be analyzed according to the treatment they are assigned.
- The Full Analysis Set (FAS) comprises all participants to whom study treatment has been assigned by randomization. FAS will be used for all efficacy variables, unless otherwise stated. Mis-randomized participants (mis-randomized in IRT) will be included in the Randomized set but will be excluded from FAS.
- Mis-randomized participants are defined as cases where IRT contacts were made by the site either prematurely or inappropriately prior to confirmation of the participant's final randomization eligibility and no study medication was administered to the participant.
- The Safety Set (SAF) includes all participants who received at least one dose of study treatment, whether or not being randomized. Participants will be analyzed according to the study treatment received. The safety set will be used in the analysis of all safety variables. The actual treatment will be defined as the treatment received over the study. In case of error in dispensation, the actual treatment will correspond to the treatment which was given most often.

## 12.2 Participant demographics and other baseline characteristics

Demographic and other baseline data including disease characteristics will be summarized descriptively by treatment group for the randomized set.

Categorical data will be presented as frequencies and percentages. For continuous data, mean, standard deviation, median, minimum, and maximum will be presented. For selected parameters, 25th and 75th percentiles will also be presented.


Relevant medical histories and current medical conditions at baseline will be summarized combined by system organ class and preferred term, by treatment group for the randomized set.

## 12.3 Treatments

The Safety set will be used for the analyses below. Categorical data will be summarized as frequencies and percentages. For continuous data, mean, standard deviation, median, 25th and 75th percentiles, minimum, and maximum will be presented.

The duration of exposure in weeks to remibrutinib and placebo will be summarized by treatment group, by study period and for entire study. The duration of study will also be summarized by treatment group.

Concomitant medications and significant non-drug therapies prior to and after the start of the study treatment will be summarized according to the Anatomical Therapeutic Chemical (ATC) classification system, by treatment group.



## 12.4 Analysis supporting primary objectives

This section will detail the statistical analysis of the primary estimand. Details of the hypothesis testing strategy including primary and secondary endpoints to handle multiplicity are provided in [Section 12.5.1](#).

### 12.4.1 Definition of primary endpoint(s)

#### Primary estimand for scenario with UAS7 as the primary efficacy endpoint

The primary clinical question of interest is: What is the effect of remibrutinib treatment versus placebo on the change from baseline in UAS7 score at Week 12 after treatment in adult participants with CSU who are inadequately controlled by H1-antihistamine and receiving a stable locally label approved dose of a second generation H1-antihistamine, regardless of treatment discontinuation for any reason and regardless of intake of a different second generation H1-antihistamine as rescue medication and considering strongly confounding prohibited medication as an unfavourable outcome?

The primary efficacy endpoint is the absolute change from baseline in UAS7 score at Week 12, which is the UAS7 score at Week 12 minus the UAS7 score at baseline. The UAS7 is the sum of the HSS7 score and the ISS7 score, and ranges from 0-42. Weekly scores (HSS7 and ISS7 scores) will be derived by adding up the average daily scores of the 7 days preceding the visit.

#### Primary estimand for scenario with ISS7 and HSS7 as the co-primary efficacy endpoints

The primary clinical question of interest is: What is the effect of remibrutinib treatment versus placebo on the change from baseline in ISS7 and change from baseline in HSS7 score at Week 12 after treatment in adult participants with CSU who are inadequately controlled by H1-antihistamine and receiving a stable locally label approved dose of a second generation H1-antihistamine, regardless of treatment discontinuation for any reason and regardless of intake of a different second generation H1-antihistamine as rescue medication and considering strongly confounding prohibited medication as an unfavourable outcome?

The co-primary efficacy endpoints are the absolute change from baseline in ISS7 score at Week 12 and absolute change from baseline in HSS7 score at Week 12, which is the ISS7 score (respectively HSS7 score) at Week 12 minus the ISS7 score (respectively HSS7 score at baseline). The weekly scores ISS7 and HSS7 range from 0-21, and will be derived by adding up the average daily scores of the 7 days preceding the visit.

### 12.4.2 Statistical model, hypothesis, and method of analysis

#### Statistical model, hypothesis, and method of analysis for scenario with UAS7 as the primary efficacy endpoint

The statistical hypothesis test for the primary endpoint being tested is that the absolute change from baseline in UAS7 score at Week 12 in remibrutinib is not superior to the placebo group i.e.:

$$H_{01}: \mu_{\text{remibrutinib}} \geq \mu_{\text{Placebo}} \text{ versus } H_{A1}: \mu_{\text{remibrutinib}} < \mu_{\text{Placebo}}$$

where  $\mu$  is the mean change from baseline in UAS7 at Week 12.

A linear mixed model with repeated measures (MMRM) will be used to estimate treatment differences for change from baseline in UAS7 score at Week 12, based on the FAS. The MMRM model will include treatment group, baseline UAS7 score, randomization strata variables, week and both interaction of treatment by week and interaction of baseline UAS7 score by week as fixed effects. Repeated measures within participant are modeled using an unstructured covariance of the error terms. Additional important covariates may be added to the model. For the primary analysis, data up to Week 12 will be used in the model.

The detailed testing strategy including the primary endpoint analysis is provided in [Section 12.5](#).

### **Statistical model, hypothesis, and method of analysis for scenario with ISS7/HSS7 as the co-primary efficacy endpoints**

The statistical hypothesis test for the co-primary endpoints tests the union null hypothesis that the absolute change from baseline in ISS7 score at Week 12 in remibrutinib is not superior to the placebo group or the absolute change from baseline in HSS7 score at Week 12 in remibrutinib is not superior to the placebo group i.e.:

$$H_{01a}: \mu_{\text{remibrutinib}} \geq \mu_{\text{Placebo}} \text{ versus } H_{A1a}: \mu_{\text{remibrutinib}} < \mu_{\text{Placebo}}$$

where  $\mu$  is the mean change from baseline in ISS7 at Week 12.

$$H_{01b}: \mu_{\text{remibrutinib}} \geq \mu_{\text{Placebo}} \text{ versus } H_{A1b}: \mu_{\text{remibrutinib}} < \mu_{\text{Placebo}}$$

where  $\mu$  is the mean change from baseline in HSS7 at Week 12.

The union null hypothesis is rejected if both elementary null hypotheses ( $H_{01a}$ ,  $H_{01b}$ ) are rejected.

A linear mixed model with repeated measures (MMRM) will be used to estimate treatment differences for change from baseline in ISS7 score (respectively HSS7) at Week 12, based on the FAS. The MMRM model will include treatment group, baseline ISS7 score (respectively HSS7), randomization strata variables, week and both interaction of treatment by week and interaction of baseline ISS7 score (respectively HSS7) by week as fixed effects. Repeated measures within participant are modeled using an unstructured covariance of the error terms. Additional important covariates may be added to the model. For the primary analysis, data up to Week 12 will be used in the model.

The detailed testing strategy including the primary endpoint analysis is provided in [Section 12.5](#).

#### **12.4.3 Handling of intercurrent events of primary estimand**

Participants who discontinue from study treatment early due to any reason will be encouraged to stay in the study following the procedures. Every effort will be made to continue to follow participants who discontinued from study treatment up to Week 12. These are considered as Retrieved drop out (RDO) participants.

The analysis will account for different intercurrent events as explained in the following:

- Discontinuation of study treatment prior to Week 12 due to any reason: ignore (Treatment policy strategy), i.e., data collection will be maintained and available measurements post-treatment discontinuation will be used as if they had been obtained under the treatment assigned at randomization: RDO data collected after study treatment discontinuation will be used for analysis.

- Intake of rescue medication as per protocol, or switch of background medication, or intake of other prohibited medication, or participants non-compliant to treatment prior to Week 12: ignore (Treatment policy strategy), data collected after these events will be used for analysis.
- Intake of strongly confounding prohibited medication (e.g., biologics treatment at any time before Week 12, cyclosporin after Week 8, systemic corticosteroids after Week 8): (Composite strategy) measurements after this event will be excluded from the analysis and will be imputed using the worst value of the endpoint (e.g., 42 for UAS7 score at week 12 and 21 for co-primary endpoints ISS7 score or HSS7 score at week 12).

#### **12.4.4 Handling of missing values not related to intercurrent event**

The UAS7 score is derived from the sum of the HSS7 score and the ISS7 score. The HSS7 and ISS7 score will be derived by adding up the daily HSS and ISS scores of the 7 days preceding the visit, respectively. The daily score (HSS and ISS) will be calculated by averaging the morning and evening HSS and ISS score, respectively. If one of the morning or evening scores is missing, the non-missing score for that day (morning or evening) will then be used as the daily score.

For each weekly score from the UPDD (i.e., HSS7, ISS7), if one or more of the daily scores are missing, the following principles will be applied to handle the missing data:

- The weekly UAS7 is the sum of both the HSS7 score and the ISS7 score and will be missing if at least one of them is missing.
- If a participant has at least 4 non-missing daily (morning or evening) scores within the 7 days prior to the study visit, the weekly score for HSS or ISS will be calculated as the sum of the available eDiary scores of that week, divided by the number of non-missing days, multiplied by 7.
- If there are less than 4 non-missing daily scores within the prior 7 days, then the weekly score for HSS or ISS will be considered as missing for that week. Accordingly, no UAS7 can be calculated.

Participants who discontinue from study treatment early due to any reason will be encouraged to stay in the study following the procedures. Every effort will be made to continue to follow participants who discontinued from study treatment. These are considered as RDO participants.

For any intercurrent events handled with treatment policy strategy: If no RDO data was collected after study treatment permanent discontinuation, missing data will be imputed based on the following rules:

- For participants in the active treatment arms, if sufficient RDO data, missing data will be imputed using MI based on observed RDO data in the corresponding active arm. If not feasible (e.g., very limited RDO data), missing data will be imputed based on observed data in the placebo arm under the assumption of jump to reference (J2R) using MI.
- For participants in the placebo arm, if sufficient RDO data, missing data will be imputed using MI based on observed RDO placebo arm data. If not feasible (e.g., very limited RDO data), missing data will be imputed using MI under the MAR assumption based on the observed placebo arm data.



#### 12.4.5 Sensitivity analyses

The following sensitivity analysis will be performed for the primary estimand to assess the robustness of the estimation in the presence of deviations from the assumptions specified in the primary analysis. The sensitivity analysis will be implemented with the same target population, the primary variables and the summary measure as for the primary estimand, but using the different assumptions or handling of intercurrent events.

**Sensitivity analysis:** The change from baseline in UAS7, ISS7 and HSS7 score at week 12 will be imputed using zero (i.e., no clinical improvement from baseline) for the intercurrent event of “Intake of strongly confounding prohibited medication (e.g., biologics treatment at any time before Week 12, cyclosporin after Week 8, systemic corticosteroids after Week 8)” handled with composite strategy.

#### 12.4.6 Supplementary analysis

##### Supplementary estimand

The clinical question of interest is: What is the effect of remibrutinib treatment versus placebo on the change from baseline in UAS7 score (respectively for co-primary endpoints ISS7 and HSS7) after 12 weeks treatment in adult patients with CSU who are inadequately controlled by H1-antihistamine and receiving a stable locally label approved dose of a second generation H1-antihistamine, regardless of treatment discontinuation for any reason and regardless of intake of a different second generation H1-antihistamine and rescue medication, and as if strongly confounding prohibited medication was not taken?

The supplementary estimand is described by the following attributes:

1. **Population:** patients with inadequately controlled CSU despite treatment with second generation H1-antihistamine who have CSU duration  $\geq 6$  months, a UAS7 score  $\geq 16$ , ISS7 score  $\geq 6$  and HSS7 score  $\geq 6$  in the last 7 days prior to randomization.
2. **Endpoint:** Change in UAS7 (respectively for co-primary endpoints ISS7 and HSS7) from baseline at Week 12.
3. **Treatment of interest:** the randomized study treatment (remibrutinib 25 mg b.i.d. or placebo) regardless of treatment compliance, with background medication of local approved second generation H1-antihistamine, and a different second generation H1-antihistamine as rescue medication.
4. **Summary Measurement:** the mean difference between treatment groups.
5. **Handling of intercurrent events:**
  - Discontinuation of study treatment due to any reason: Treatment policy strategy
  - Intake of strongly confounding prohibited medication (e.g., biologics treatment at any time before Week 12, cyclosporin after Week 8, systemic corticosteroids after Week 8): Hypothetical strategy (irrespective of potential occurrence of other intercurrent events)
  - Intake of rescue medication, switch of background medication, intake of other prohibited medication: Treatment policy strategy



## 12.5 Analysis supporting secondary objectives

### 12.5.1 Efficacy and/or Pharmacodynamic endpoint(s)

- Improvement of UAS7, assessed as absolute change from baseline in UAS7 score at Week 12 (For scenario with ISS7/HSS7 as the co-primary efficacy endpoints).

The absolute change from baseline in UAS7 score at Week 12 will be analyzed using MMRM modeling including treatment group, baseline UAS7 score, randomization strata variables, week and both interaction of treatment by week and interaction of baseline UAS7 score by week as fixed effects.

- Disease activity control at Week 12, assessed as % of participants achieving  $UAS7 \leq 6$ .

The proportion of participants with  $UAS7 \leq 6$  at Week 12 will be analyzed using a logistic regression model including treatment group, region, prior exposure to anti-IgE biologics and baseline UAS7 score as covariate.

- Complete absence of hives and itch at Week 12, assessed as % of participants achieving  $UAS7 = 0$ .

The proportion of participants with  $UAS7 = 0$  at Week 12 will be analyzed using a logistic regression model including treatment group, region, prior exposure to anti-IgE biologics and baseline UAS7 score as covariate.

- Improvement of severity of itch, assessed as absolute change from baseline in ISS7 score at Week 12 (For scenario with UAS7 as the primary efficacy endpoint).

The absolute change from baseline in ISS7 score at Week 12 will be analyzed using MMRM modeling including treatment group, baseline ISS7 score, randomization strata variables, week and both interaction of treatment by week and interaction of baseline ISS7 score by week as fixed effects.

- Improvement of severity of hives, assessed as absolute change from baseline in HSS7 score at Week 12 (For scenario with UAS7 as the primary efficacy endpoint).


The absolute change from baseline in HSS7 score at Week 12 will be analyzed using MMRM modeling including treatment group, baseline HSS7 score, randomization strata variables, week and both interaction of treatment by week and interaction of baseline HSS7 score by week as fixed effects.

- Disease activity control at Week 2, assessed as proportion of participants achieving  $UAS7 \leq 6$ .

The proportion of participants with  $UAS7 \leq 6$  at Week 2 will be analyzed using a logistic regression model including treatment group, region, prior exposure to anti-IgE biologics and baseline UAS7 score as covariate.

- No impact on participants' dermatology quality of life at Week 12, assessed as proportion of participants achieving  $DLQI = 0-1$ .

An overall score will be calculated according to the scoring manual. The proportion of participants with overall DLQI scores  $\leq 1$  at Week 12 will be analyzed using a logistic regression model which includes treatment group, region, prior exposure to anti-IgE biologics and baseline DLQI score.



- Cumulative number of weeks that participants achieve  $UAS7 \leq 6$  responses between baseline and Week 12.

The cumulative number of weeks achieving  $UAS7 \leq 6$  response between baseline and Week 12 will be derived based on the eDiary. The cumulative number of weeks achieving  $UAS7 \leq 6$  response between baseline and Week 12 will be modelled using a negative binomial regression model with log link, using treatment group, region, and prior exposure to anti-IgE biologics. The number of weeks stay on the trial will be used as an offset.

- Cumulative number of weeks that participants achieve  $AAS7 = 0$  responses between baseline and Week 12.

The cumulative number of weeks achieving  $AAS7 = 0$  response between baseline and Week 12 will be derived based on the AAS eDiary and UPDD diary. A weekly  $AAS7$  score will be derived by adding up the daily scores of the 7 days preceding the visit, and ranges from 0 to 105. If the  $AAS7$  assessment is missing, it will be considered as a non-response for the cumulative number of weeks that participants achieve  $AAS7 = 0$  response calculation.

The cumulative number of weeks achieving  $AAS7 = 0$  response between baseline and Week 12 will be modelled using a negative binomial regression model with log link, using treatment group, region, prior exposure to anti-IgE biologics and baseline  $AAS7 = 0$  status.

### **Statistical model, hypothesis, and method of analysis for scenario with $UAS7$ as the primary efficacy endpoint**

#### **Testing strategy**

The following null hypotheses ( $H_0$ ) will be tested against the respective alternative hypotheses ( $H_A$ ) in a closed testing procedure ([Bretz et al 2009](#)), thus controlling the family-wise type I error which is set to 0.025 (one-sided):

#### **Primary:**

##### **$UAS7$ score change from baseline at Week 12**

$H_{01}: \mu_{\text{remibrutinib}} \geq \mu_{\text{Placebo}}$  versus  $H_{A1}: \mu_{\text{remibrutinib}} < \mu_{\text{Placebo}}$

where  $\mu$  is the mean change from baseline in  $UAS7$  at Week 12,

#### **Secondaries:**

- **$UAS7 \leq 6$  at Week 12**

$H_{02}: p_{\text{remibrutinib}} \leq p_{\text{Placebo}}$  versus  $H_{A2}: p_{\text{remibrutinib}} > p_{\text{Placebo}}$

where  $p$  is the proportion of participants achieving  $UAS7 \leq 6$  at Week 12,

- **$UAS7 = 0$  at Week 12**

$H_{03}: p_{\text{remibrutinib}} \leq p_{\text{Placebo}}$  versus  $H_{A3}: p_{\text{remibrutinib}} > p_{\text{Placebo}}$

where  $p$  is the proportion of participants achieving  $UAS7 = 0$  at Week 12,

- **ISS7 score change from baseline at Week 12**

$H_{04}: \mu_{\text{remibrutinib}} \geq \mu_{\text{Placebo}}$  versus  $H_{A4}: \mu_{\text{remibrutinib}} < \mu_{\text{Placebo}}$

where  $\mu$  is the mean change from baseline in ISS7 at Week 12,

- **HSS7 score change from baseline at Week 12**

$H_{05}: \mu_{\text{remibrutinib}} \geq \mu_{\text{Placebo}}$  versus  $H_{A5}: \mu_{\text{remibrutinib}} < \mu_{\text{Placebo}}$

where  $\mu$  is the mean change from baseline in HSS7 at Week 12,

- **UAS7  $\leq 6$  at Week 2**

$H_{06}: p_{\text{remibrutinib}} \leq p_{\text{Placebo}}$  versus  $H_{A6}: p_{\text{remibrutinib}} > p_{\text{Placebo}}$

where  $p$  is the proportion of participants achieving  $UAS7 \leq 6$  at Week 2,

- **DLQI = 0/1 at Week 12**

$H_{07}: p_{\text{remibrutinib}} \leq p_{\text{Placebo}}$  versus  $H_{A7}: p_{\text{remibrutinib}} > p_{\text{Placebo}}$

where  $p$  is the proportion of participants achieving  $DLQI = 0/1$  at Week 12,

- **Cumulative number of weeks with an UAS7  $\leq 6$  response between baseline and Week 12**

$H_{08}: \mu_{\text{remibrutinib}} \leq \mu_{\text{Placebo}}$  versus  $H_{A8}: \mu_{\text{remibrutinib}} > \mu_{\text{Placebo}}$

where  $\mu$  is the mean cumulative number of weeks that participants achieve  $UAS7 \leq 6$  response between baseline and Week 12,


- **Cumulative number of weeks with an AAS7 = 0 response between baseline and Week 12**

$H_{09}: \mu_{\text{remibrutinib}} \leq \mu_{\text{Placebo}}$  versus  $H_{A9}: \mu_{\text{remibrutinib}} > \mu_{\text{Placebo}}$

where  $\mu$  is the mean cumulative number of weeks that participants achieve  $AAS7 = 0$  response between baseline and Week 12,

A graphical representation of the testing strategy is presented in [Figure 12-1](#)

**Figure 12-1 Testing strategy with UAS7 as the primary endpoint**




The value inside the circle represents the significance level. The arrow and value inside the square represent the "alpha-propagation".

The first hypothesis is tested with full level alpha (0.025 one-sided). If significant, the second hypothesis is tested with full-level alpha; otherwise, the testing procedure stops. The testing is strictly hierarchical, so that null hypotheses can be tested along the pre-defined order at the level assigned until a null hypothesis cannot be rejected, at which point the testing stops. Furthermore, the testing strategy reflects the separation of primary and secondary endpoints, so that hypotheses related to secondary endpoints will only be tested if the null hypothesis related to the primary endpoint is rejected.

### Statistical model, hypothesis, and method of analysis for scenario with ISS7/HSS7 as the co-primary efficacy endpoints

#### Testing strategy



The following null hypotheses ( $H_0$ ) will be tested against the respective alternative hypotheses ( $H_A$ ) in a closed testing procedure (Bretz et al 2009), thus controlling the family-wise type I error which is set to 0.025 (one-sided):

**Co-Primary:**

- **ISS7 score change from baseline at Week 12**

$H_{01a}$ :  $\mu_{\text{remibrutinib}} \geq \mu_{\text{Placebo}}$  versus  $H_{A1a}$ :  $\mu_{\text{remibrutinib}} < \mu_{\text{Placebo}}$

where  $\mu$  is the mean change from baseline in ISS7 at Week 12,

- **HSS7 score change from baseline at Week 12**

and  $H_{01b}$ :  $\mu_{\text{remibrutinib}} \geq \mu_{\text{Placebo}}$  versus  $H_{A1b}$ :  $\mu_{\text{remibrutinib}} < \mu_{\text{Placebo}}$

where  $\mu$  is the mean change from baseline in HSS7 at Week 12,

**Secondaries:**

- **UAS7 score change from baseline at Week 12**

$H_{02}$ :  $\mu_{\text{remibrutinib}} \geq \mu_{\text{Placebo}}$  versus  $H_{A2}$ :  $\mu_{\text{remibrutinib}} < \mu_{\text{Placebo}}$

where  $\mu$  is the mean change from baseline in UAS7 at Week 12,

- **UAS7  $\leq$  6 at Week 12**

$H_{03}$ :  $p_{\text{remibrutinib}} \leq p_{\text{Placebo}}$  versus  $H_{A3}$ :  $p_{\text{remibrutinib}} > p_{\text{Placebo}}$

where  $p$  is the proportion of participants achieving UAS7 $\leq$ 6 at Week 12,

- **UAS7 = 0 at Week 12**

$H_{04}$ :  $p_{\text{remibrutinib}} \leq p_{\text{Placebo}}$  versus  $H_{A4}$ :  $p_{\text{remibrutinib}} > p_{\text{Placebo}}$

where  $p$  is the proportion of participants achieving UAS7=0 at Week 12,

- **UAS7  $\leq$  6 at Week 2**

$H_{05}$ :  $p_{\text{remibrutinib}} \leq p_{\text{Placebo}}$  versus  $H_{A5}$ :  $p_{\text{remibrutinib}} > p_{\text{Placebo}}$

where  $p$  is the proportion of participants achieving UAS7 $\leq$ 6 at Week 2,

- **DLQI = 0/1 at Week 12**

$H_{06}$ :  $p_{\text{remibrutinib}} \leq p_{\text{Placebo}}$  versus  $H_{A6}$ :  $p_{\text{remibrutinib}} > p_{\text{Placebo}}$

where  $p$  is the proportion of participants achieving DLQI = 0/1 at Week 12,

- **Cumulative number of weeks with an UAS7  $\leq$  6 response between baseline and Week 12**

$H_{07}$ :  $\mu_{\text{remibrutinib}} \leq \mu_{\text{Placebo}}$  versus  $H_{A7}$ :  $\mu_{\text{remibrutinib}} > \mu_{\text{Placebo}}$

where  $\mu$  is the mean cumulative number of weeks that participants achieve UAS7  $\leq$  6 response between baseline and Week 12,


- **Cumulative number of weeks with an AAS7= 0 response between baseline and Week 12**

$H_{08}$ :  $\mu_{\text{remibrutinib}} \leq \mu_{\text{Placebo}}$  versus  $H_{A8}$ :  $\mu_{\text{remibrutinib}} > \mu_{\text{Placebo}}$

where  $\mu$  is the mean cumulative number of weeks that participants achieve AAS7=0 response between baseline and Week 12,

A graphical representation of the testing strategy is presented in [Figure 12-2](#)

**Figure 12-2 Testing strategy with ISS7/HSS7 as the co-primary endpoints**



The value inside the circle represents the significance level. The arrow and value inside the square represent the "alpha-propagation".

The first two hypotheses are tested: both  $H_{1a}$  and  $H_{1b}$  are tested with full level alpha (0.025 one-sided) and only if both are rejected, then  $H_2$  hypothesis is tested with full-level alpha; otherwise, the testing procedure stops. The testing is strictly hierarchical, so that null hypotheses can be tested along the pre-defined order at the level assigned until a null hypothesis cannot be rejected, at which point the testing stops. Furthermore, the testing strategy reflects the separation of primary and secondary endpoints, so that hypotheses related to secondary endpoints will only be tested if both null hypotheses related to the co-primary endpoints are rejected.

### 12.5.2 Safety endpoints

For all safety analyses, the safety set will be used. All listings and tables will be presented by treatment group.

Safety summaries (tables, figures) include only data from the on-treatment period with the exception of baseline data which will also be summarized where appropriate (e.g., change from baseline summaries). In addition, a separate summary for death including on treatment and post treatment deaths will be provided. In particular, summary tables for adverse events (AEs) will summarize only on-treatment events, with a start date during the on-treatment period (treatment-emergent AEs).

The on-treatment period lasts from the date of first administration of study treatment to 28 days after the date of the last actual administration.


Due to the open-label period after the double-blind period, the on-treatment double-blind period will stop at the earliest on:

- the date of the last actual dose intake of remibrutinib double-blind
- the date of first dose intake of open-label treatment

### Adverse events

All information obtained on adverse events will be displayed by treatment group and participant.

The number (and percentage) of participants with treatment emergent adverse events (events started after the first dose of study medication or events present prior to start of double-blind treatment but increased in severity based on preferred term) will be summarized in the following ways:



- by treatment, primary system organ class and preferred term.
- by treatment, primary system organ class, preferred term and maximum severity.
- by treatment, Standardized MedDRA Query (SMQ) and preferred term.

Separate summaries will be provided for study medication related adverse events, death, serious adverse events, other significant adverse events leading to discontinuation by treatment group and study period.

The number (and proportion) of participants with adverse events of special interest for remibrutinib (related to identified and potential risks) will be summarized by treatment group and study period.

A participant with multiple adverse events within a primary system organ class is only counted once towards the total of the primary system organ class.

### **Vital signs**

All vital signs data will be listed by treatment group, participant, and visit/time and if ranges are available, abnormalities (and relevant changes) will be flagged. Summary statistics will be provided by treatment and visit.

### **12-lead ECG**

PR, QRS, QT, QTcF, and RR intervals will be obtained from 12-lead ECGs for each participant during the study. ECG data will be read and interpreted centrally.

All ECG data will be listed by treatment group, participant and visit/time, abnormalities will be flagged. Summary statistics will be provided by treatment and visit/time.

### **Clinical laboratory evaluations**

All laboratory data will be listed by treatment group, participant, and visit and if normal ranges are available abnormalities will be flagged. Summary statistics for the change from baseline will be provided by treatment and visit. Shift tables using the low/normal/high/ (low and high) classification will be used to compare baseline to the worst on-treatment value.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

**Dermatology Life Quality Index (DLQI)**

For DLQI total score, summary statistics will be provided for absolute change from baseline as well as for percent change from baseline by treatment group and visit.

The proportion of participants achieving DLQI = 0-1 will be provided by treatment group and visit.

**Angioedema Activity Score (AAS)**

For AAS7 score, summary statistics will be provided for absolute change from baseline as well as for percent change from baseline over time by treatment group, in participants with angioedema at baseline (AAS7 >0) and in all participants.

[REDACTED]

The proportion of participants achieving AAS7 = 0 will be provided over time by treatment group.

For angioedema burdened days, summary statistics will be provided for absolute change from baseline as well as for percent change from baseline over time by treatment group.

[REDACTED]

[REDACTED]

[REDACTED]



## 12.7 Interim analyses

A primary analysis may be conducted when all participants have completed their Week 24 visit or discontinued early and when a minimum of 150 participants across both Phase 3 pivotal studies have completed the treatment period (a second, nearly identical Phase 3 study will be conducted in parallel). The minimum of 150 participants reaching week 52 should enable analysis on a minimum of 100 participants exposed to remibrutinib for 52 weeks, considering the initial randomization to either the remibrutinib or the placebo arm (2:1). The results of the primary analysis will further inform decision-making for the remibrutinib development program. Formal testing of the primary endpoint and key secondary endpoints will only be performed at the primary analysis time point; thus, no adjustment for multiplicity is required.

After the primary analysis and/or after all participants entered the open-label treatment period, additional optional interim analyses may be conducted at the discretion of the Sponsor to support potential Health Authority requests and interactions (these interim analyses are not expected to have any impact on the conduct or scientific integrity of the study). The decision to conduct optional interim analyses and the timing of these analyses will be documented in the Statistical Analysis Plan prior to the conduct of any interim analysis. These interim analyses will be performed and interpreted by members of the Novartis clinical team.

## 12.8 Sample size calculation

### 12.8.1 Primary endpoint(s)

In order to fulfill registration and ICH E1 requirements on the number of participants treated for 6 months and 12 months in the development program, a sample size of 300 participants in the active arm and 150 in the placebo arm is targeted. Hence, the total sample size is 450 randomized participants.

From an efficacy point of view, the sample size justification is based on UAS7 change from baseline (for scenario with one primary endpoint), ISS7 and HSS7 change from baseline (for scenario with co-primary endpoints) and achievement of  $UAS7 \leq 6$  and  $UAS7 = 0$  at Week 12. To avoid assigning an unnecessary large number of participants to placebo, participants will be randomized in a 2:1 ratio to remibrutinib 25 mg b.i.d. and placebo arms, respectively.

All calculations were performed with nQuery Advisor 8.4.1.0 and Ri386 4.0.2 softwares.


#### **For scenario with UAS7 as the primary efficacy endpoint**

##### **UAS7 change from baseline at Week 12**

Approximately 10% drop-out is expected at week 12, thus with 270 participants in the active arm and 135 participants in the placebo arm, this gives a nominal power of more than >99% to detect a difference between remibrutinib and placebo if the mean change of UAS7 from baseline to Week 12 is at least 10 in favor of remibrutinib, with common standard deviation of approximately 12 (based on the primary endpoint analysis of Phase 2b study (CLOU064A2201)), based on a t-test, assuming type I error 0.025 (one-sided).

#### **For scenario with ISS7/HSS7 as the co-primary efficacy endpoints**

##### **ISS7 change from baseline at Week 12**



Approximately 10% drop-out is expected at week 12, thus with 270 participants in the active arm and 135 participants in the placebo arm, this gives a nominal power of more than >99% to detect a difference between remibrutinib and placebo if the mean change of ISS7 from baseline to Week 12 is at least 4 in favor of remibrutinib, with common standard deviation of approximately 6 (based on the primary endpoint analysis of Phase 2b study (CLOU064A2201)), based on a t-test, assuming type I error 0.025 (one-sided).

#### **HSS7 change from baseline at Week 12**

Approximately 10% drop-out is expected at week 12, thus with 270 participants in the active arm and 135 participants in the placebo arm, this gives a nominal power of more than >99% to detect a difference between remibrutinib and placebo if the mean change of HSS7 from baseline to Week 12 is at least 4 in favor of remibrutinib, with common standard deviation of approximately 6 (based on the primary endpoint analysis of Phase 2b study (CLOU064A2201)), based on a t-test, assuming type I error 0.025 (one-sided).

With 300 participants in the active arm and 150 participants in the placebo arm randomized in this study, this gives a power of more than >90% to detect a difference between remibrutinib and placebo in both mean change of ISS7 and HSS7 from baseline to Week 12 when correlation between endpoints is 0 (conservative assumption, as higher the correlation is, higher the power is).

#### **12.8.2 Secondary endpoint(s)**

##### **Achievement of UAS7 = 0 at Week 12**

Similarly, with approximately 10% drop-out at week 12, then with 270 participants in the active arm and 135 participants in the placebo arm, this gives a nominal power of more than >99% to detect a difference between remibrutinib and placebo arm assuming a proportion of complete response (UAS7=0) of 0.35 in the remibrutinib arm and of 0.10 in the placebo arm, based upon a 2-group continuity corrected  $\chi^2$  test with a 0.025 one-sided significance level.

##### **Achievement of UAS7 $\leq$ 6 at Week 12**

Similarly, with approximately 10% drop-out at week 12, then with 270 participants in the active arm and 135 participants in the placebo arm, this gives a nominal power of more than >99% to detect a difference between remibrutinib and placebo arm assuming a proportion of disease activity control response (UAS7 $\leq$ 6) of 0.53 in the remibrutinib arm and of 0.15 in the placebo arm, based upon a 2-group continuity corrected  $\chi^2$  test with a 0.025 one-sided significance level.

The primary and secondary endpoints analyses are planned to use the multiple testing strategy to control the family-wise error at  $\alpha=0.025$  (one-sided). It is considered, however, this hierarchical approach could impact the sample size compared to the separate endpoint approach, which depends on how the recycled alpha will be used. In both scenarios, the “family-wise” power (power to reject all null hypotheses) is >90% when correlation between endpoints is 0 (Higher the correlation is, higher the power is).



## **13 Ethical considerations and administrative procedures**

### **13.1 Regulatory and ethical compliance**

This clinical study was designed and shall be implemented, executed and reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical principles laid down in the Declaration of Helsinki.

### **13.2 Responsibilities of the investigator and IRB/IEC**

Before initiating a trial, the investigator/institution must obtain approval/favorable opinion from the Institutional Review Board/Independent Ethics Committee (IRB/IEC) for the trial protocol, written informed consent form, consent form updates, participant recruitment procedures (e.g., advertisements) and any other written information to be provided to participants. Prior to study start, the investigator is required to sign a protocol signature page confirming his/her agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to Novartis monitors, auditors, Novartis Quality Assurance representatives, designated agents of Novartis, IRBs/IECs, and regulatory authorities as required. If an inspection of the clinical site is requested by a regulatory authority, the investigator must inform Novartis immediately that this request has been made.

### **13.3 Publication of study protocol and results**

The protocol will be registered in a publicly accessible database such as [clinicaltrials.gov](http://clinicaltrials.gov) and as required in EudraCT. In addition, after study completion (defined as last patient last visit) and finalization of the study report the results of this trial will be submitted for publication and posted in a publicly accessible database of clinical trial results, such as the Novartis clinical trial results website and all required Health Authority websites (e.g., [Clinicaltrials.gov](http://Clinicaltrials.gov), EudraCT etc.).

For details on the Novartis publication policy including authorship criteria, please refer to the Novartis publication policy training materials that were provided at the trial investigator meetings.

### **13.4 Quality Control and Quality Assurance**

Novartis maintains a robust Quality Management System (QMS) that includes all activities involved in quality assurance and quality control, to ensure compliance with written Standard Operating Procedures as well as applicable global/local GCP regulations and ICH Guidelines.

Audits of investigator sites, vendors, and Novartis systems are performed by auditors, independent from those involved in conducting, monitoring or performing quality control of the clinical trial. The clinical audit process uses a knowledge/risk-based approach.

Audits are conducted to assess GCP compliance with global and local regulatory requirements, protocols and internal SOPs, and are performed according to written Novartis processes.



### **13.5 Participant Engagement**

The following participant engagement initiatives are included in this study and will be provided, as available, for distribution to study participants at the timepoints indicated. If compliance is impacted by cultural norms or local laws and regulations, sites may discuss modifications to these requirements with Novartis.

- Thank You letter
- Plain language trial summary - after CSR publication
- Individual study results - after CSR publication
- Trial Feedback Questionnaires - 3 timepoints: at the start, during and at the end of the trial.

## **14 Protocol adherence**

This protocol defines the study objectives, the study procedures and the data to be collected on study participants. Additional assessments required to ensure safety of participants should be administered as deemed necessary on a case by case basis. Under no circumstances including incidental collection is an investigator allowed to collect additional data or conduct any additional procedures for any purpose involving any investigational drugs under the protocol, other than the purpose of the study. If despite this interdiction prohibition, data, information, observation would be incidentally collected, the investigator shall immediately disclose it to Novartis and not use it for any purpose other than the study, except for the appropriate monitoring on study participants.


Investigators ascertain they will apply due diligence to avoid protocol deviations. If an investigator feels a protocol deviation would improve the conduct of the study this must be considered a protocol amendment, and unless such an amendment is agreed upon by Novartis and approved by the IRB/IEC and Health Authorities, where required, it cannot be implemented.

### **14.1 Protocol amendments**

Any change or addition to the protocol can only be made in a written protocol amendment that must be approved by Novartis, health authorities where required, and the IRB/IEC prior to implementation.

Only amendments that are required for participant safety may be implemented immediately provided the health authorities are subsequently notified by protocol amendment and the reviewing IRB/IEC is notified.

Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate action required for the safety of any participant included in this study, even if this action represents a deviation from the protocol. In such cases, Novartis should be notified of this action and the IRB/IEC at the study site should be informed according to local regulations.



## 15 References

References are available upon request

Angst D, Gessier F, Janser P, et al (2020) Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase. *J Med Chem* p. 5102-5118.

Bernstein JA, Lang DM, Khan DA, et al (2014) The diagnosis and management of acute and chronic urticaria: 2014 update. *J Allergy Clin Immunol* p. 1270-7.

[REDACTED]

Bretz F, Maurer W, Brannath W, et al (2009) A graphical approach to sequentially rejective multiple test procedures. *Stat Med* p. 586-604.

Brukinsa® Prescribing Information (2021) BeiGene, Brukinsa (zanubrutinib) 80 mg capsule (Internet). Available from: <<https://www.brukinsa.com/prescribing-information.pdf>> (Accessed 22-Mar-2022).

Brukinsa® SmPC (2022) BeiGene, Brukinsa (zanubrutinib) 80 mg capsule (Internet). Available from: <[https://www.ema.europa.eu/en/documents/product-information/brukinsa-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/brukinsa-epar-product-information_en.pdf)> (Accessed 22-Mar-2022).

Bye AP, Unsworth AJ, Vaiyapuri S, et al (2015) Ibrutinib inhibits platelet integrin  $\alpha$ IIb $\beta$ 3 outside-in signaling and thrombus stability but not adhesion to collagen. *Arterioscler Thromb Vasc Biol*; 35(11):2326-35.

Calquence® Prescribing Information (2019) AstraZeneca, Calquence (acalabrutinib) 100 mg capsules (Internet). Available from: <<https://www.azpicentral.com>> (Accessed 26-Apr-2022).

Calquence® SMPC (2021) AstraZeneca, Calquence (ascalabrutinib) 100 mg capsules (Internet). Available from: <[https://www.ema.europa.eu/en/documents/product-information/calquence-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/calquence-epar-product-information_en.pdf)> (Accessed 26-Apr-2022).

Dispenza MC, Pongracic JA, Singh AM, et al (2018) Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy. *J. Allergy Clin. Immunol.* p. 1914-1916.e7.

Dispenza MC, Regan JA, Bochner BS (2017) Potential applications of Bruton's tyrosine kinase inhibitors for the prevention of allergic reactions. *Expert Rev Clin Immunol* p. 921-923.

Ferrer M (2015) Immunological events in chronic spontaneous urticaria. *Clin Transl Allergy* p. 30.

Farez et al (2019) Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2019 Sep 24;93(13):584-594

Finlay AY (2005) Current severe psoriasis and the rule of tens. *Br. J. Dermatol.* p. 861-7.

[REDACTED]

Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. *Clin. Exp. Dermatol.* p. 210-6.

Futatani T, Watanabe C, Baba Y, et al (2001) Bruton's tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females. *Br J Haematol* p. 141-9.

Gabizon R, London N (2020) A Fast and Clean BTK Inhibitor. *J Med Chem* p. 5100-5101.

Gonçalo M, Giménez-Arnau A, Al-Ahmad M, et al (2021) The global burden of chronic urticaria for the patient and society. *Br J Dermatol* p. 226-236.

Greaves MW (2003) Chronic idiopathic urticaria. *Curr Opin Allergy Clin Immunol* p. 363-8.

Guillén-Aguinaga S, Jáuregui Presa I, Aguinaga-Ontoso E, et al (2016) Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. *Br J Dermatol* p. 1153-1165.

Hawro T, Ohanyan T, Schoepke N, et al (2018) The Urticaria Activity Score-Validity, Reliability, and Responsiveness. *J Allergy Clin Immunol Pract* p. 1185-1190.e1.

Hendriks RW, Yuvaraj S, Kil LP (2014) Targeting Bruton's tyrosine kinase in B cell malignancies. *Nat Rev Cancer* p. 219-32.

Hongbo Y, Thomas CL, Harrison MA, et al (2005) Translating the science of quality of life into practice: What do dermatology life quality index scores mean? *J. Invest. Dermatol.* p. 659-64.

Imbruvica<sup>®</sup> Prescribing Information (2020) JanssenCilag International NV, Imbruvica (ibrutinib) 70 and 140 mg hard capsules (Internet). Available from: <<https://www.imbruvica.com/files/prescribing-information.pdf>> (Accessed on 26-Apr-2022).

Imbruvica<sup>®</sup> SmPC (2022) Janssen-Cilag International NV, Imbruvica (ibrutinib) 140 mg hard capsules. Summary of Product Characteristics. Available from <[https://www.ema.europa.eu/en/documents/product-information/imbruvica-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/imbruvica-epar-product-information_en.pdf)> (Accessed on 26-Apr-2022).

Kaplan A, Ferrer M, Bernstein JA, et al (2016) Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. *J Allergy Clin Immunol* p. 474-81.

Kaplan AP, Horáková Z, Katz SI (1978) Assessment of tissue fluid histamine levels in patients with urticaria. *J Allergy Clin Immunol* p. 350-4.

Kaul M, Storim J, End P, et al (2019) LOU064: A highly selective and potent covalent oral BTK inhibitor with promising pharmacodynamic effects in skin p. 333-376.

Kaul M, End P, Cabanski M, et al (2021) Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial p. 1-13.

[REDACTED]

Maurer M, Abuzakouk M, Bérard F, et al (2017) The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. *Allergy* p. 2005-2016.

Maurer M, Rosén K, Hsieh HJ, et al (2013) Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. *N Engl J Med* p. 924-35.

[REDACTED]

Mlynek A, Zalewska-Janowska A, Martus P, et al (2008) How to assess disease activity in patients with chronic urticaria? *Allergy* p. 777-80.

O'Donnell BF, Lawlor F, Simpson J, et al (1997) The impact of chronic urticaria on the quality of life. *Br J Dermatol* p. 197-201.

[REDACTED]

Pleyer et al (2021) Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. *Blood*. 2021 Jan 14;137(2):185-189

Powell RJ, Du Toit GL, Siddique N, et al (2007) BSACI guidelines for the management of chronic urticaria and angio-oedema. *Clin Exp Allergy* p. 631-50.

Regan JA, Cao Y, Dispenza MC, et al (2017) Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity. *J. Allergy Clin. Immunol.* p. 875-879.e1.

[REDACTED]

Rip J, Van Der Ploeg EK, Hendriks RW, et al (2018) The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity. *Crit Rev Immunol* p. 17-62.

Saini SS, Kaplan AP Chronic Spontaneous Urticaria: The Devil's Itch. *J Allergy Clin Immunol Pract* p. 1097-1106.

Smiljkovic D, Blatt K, Stefanzi G, et al (2017) BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils. *Allergy* p. 1666-1676.

Weber et al (2021) Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic. *Neurol Neuroimmunol Neuroinflamm* 2021;8:e1067.

[REDACTED]

[REDACTED]

Weller K, Groffik A, Magerl M, et al (2013) Development, validation, and initial results of the Angioedema Activity Score. *Allergy* p. 1185-92.

Zuberbier T, Aberer W, Asero R, et al (2014) The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. *Allergy* p. 868-87.

Zuberbier T, Aberer W, Asero R, et al (2018) The EAACI/GA<sup>2</sup>LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. *Allergy* p. 1393-1414.

Zuberbier T, Asero R, Bindslev-Jensen C, et al (2009) EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. *Allergy* p. 1427-43.

[REDACTED]



## 16 Appendices

### 16.1 Appendix 1: Clinically notable laboratory values and vital signs

The following specific criteria have been identified for this study. Should these criteria be met, a re-test must be done within 5 days after the first assessment. Discontinuation of the study treatment should be considered if the abnormal hematology parameter is confirmed:

- Hemoglobin: < 10 g/dl
- Platelets: < 75 000/mm<sup>3</sup>
- Leukocytes: < 3 000/mm<sup>3</sup>
- Neutrophils: < 1 500/mm<sup>3</sup>

For all other laboratory assessments, the central laboratory will flag laboratory values falling outside of the normal ranges on the central laboratory report (which the investigator should review and sign-off) and the investigator will report any values considered clinically significant in the eCRF.

Refer to [Section 16.2](#) for clinically notable laboratory values for hepatotoxicity.

Refer to [Section 16.3](#) for clinically notable laboratory values for nephrotoxicity.

Notable values for vital signs and change from baseline will be summarized.

Notable values are defined as follows:

- heart rate of < 50 or > 100 bpm
- systolic blood pressure of < 90 and  $\geq$  140 mmHg
- diastolic blood pressure of < 60 and  $\geq$  90 mmHg

For ECGs, a notable QTc value is defined as an absolute QTc (Fridericia's) interval of greater than 450 msec for males or greater than 460 msec for females or QTcF increase of  $\geq$ 60 msec compared to baseline QTcF value – all such ECGs will be flagged by the central CRO's cardiologist and require assessment for clinical relevance by the investigator.

## 16.2 Appendix 2: Liver event and laboratory trigger definitions & follow-up requirements

**Table 16-1 Liver event and laboratory trigger definitions**

|  | Definition/ threshold  |
|--|--|
| Liver laboratory triggers<br>If ALT, AST and total bilirubin normal at baseline: | <ul style="list-style-type: none"> <li>• ALT or AST &gt; 5 × ULN</li> <li>• ALP &gt; 2 × ULN (in the absence of known bone pathology)</li> <li>• Total bilirubin &gt; 3 × ULN (in the absence of known Gilbert syndrome)</li> <li>• ALT or AST &gt; 3 × ULN and INR &gt; 1.5</li> <li>• Potential Hy's Law cases (defined as ALT or AST &gt; 3 × ULN and Total bilirubin &gt; 2 × ULN [mainly conjugated fraction] without notable increase in ALP to &gt; 2 × ULN)</li> <li>• Any clinical event of jaundice (or equivalent term)</li> <li>• ALT or AST &gt; 3 × ULN accompanied by (general) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia</li> <li>• Any adverse event potentially indicative of a liver toxicity</li> </ul> |

ALP: Alkaline phosphatase, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, ULN: upper limit of normal

**Table 16-2 Follow up requirements for liver laboratory triggers: ALT, AST and TBL**

| Trigger  | Liver Symptoms | Action Taken   |   |  |
|--|----------------|--|---|--|
|  |                | Monitoring   | Follow-up Monitoring  | Study Medication   |
| <b>ALT</b>   |                |  |   |  |
| ALT > 3 ULN<br>TBL normal, or no change for participants with Gilbert's syndrome                           | None           | Measure ALT, AST, ALP, GGT, TBL, INR, albumin, CK, and GLDH in 48-72 hours | Follow up for symptoms  | Continue dosing  |
| ALT > 5 x ULN for more than two weeks<br>TBL normal, or no change for participants with Gilbert's syndrome | None           | Measure ALT, AST, ALP, GGT, TBL, INR, albumin, CK, and GLDH in 48-72 hours | Follow-up for symptoms<br>Initiate close monitoring and workup for competing etiologies | Interrupt<br>Study drug can be restarted only if another etiology is identified and liver enzymes return to baseline |

| Trigger  | Liver Symptoms  | Action Taken  |   |  |
|--|---|---|---|--|
|  |   | Monitoring  | Follow-up Monitoring  | Study Medication   |
| ALT > 8 x ULN<br>TBL normal, or no change for participants with Gilbert's syndrome                                     | None  | Measure ALT, AST, ALP, GGT, TBL, INR, albumin, CK, and GLDH in 48-72 hours  | Follow-up for symptoms<br>Initiate close monitoring and workup for competing etiologies   | Interrupt<br>Study drug can be restarted only if another etiology is identified and liver enzymes return to baseline |
| ALT > 3 x ULN<br>TBL > 2 x ULN (or INR > 1.5)<br>For patients with Gilbert's syndrome:<br>Doubling of direct bilirubin | None  | Measure ALT, AST, ALP, GGT, TBL, INR, albumin, CK, and GLDH in 48-72 hours  | Follow-up for symptoms<br>Initiate close monitoring and workup for competing etiologies   | Interrupt<br>Study drug can be restarted only if another etiology is identified and liver enzymes return to baseline |
| ALT > 3 x ULN<br>TBL normal or elevated  | Severe fatigue, nausea, vomiting, right upper quadrant pain | Measure ALT, AST, ALP, GGT, TBL, INR, albumin, CK, and GLDH in 48-72 hours  | Follow-up for symptoms<br>Initiate close monitoring and workup for competing etiologies   | Interrupt<br>Study drug can be restarted only if another etiology is identified and liver enzymes return to baseline |
| <b>Total Bilirubin (isolated)</b>  |   |   |   |  |
| >1.5 – 3.0 ULN   |   | Repeat LFTs within 48-72 hours  | Monitor LFTs weekly until resolution <sup>1</sup> to ≤ Grade 1 or to baseline   | Continue dosing  |
| > 3 - 10 × ULN (in the absence of known Gilbert syndrome)  |   | Repeat LFT within 48-72 hours<br>Hospitalize if clinically appropriate<br>Establish causality<br>Record the AE and contributing factors (e.g., conmeds, med hx, lab) in the appropriate CRF | Monitor LFTs weekly until resolution <sup>1</sup> to ≤ Grade 1 or to baseline (ALT, AST, total bilirubin, Alb, PT/INR, ALP and GGT)<br>Test for hemolysis (e.g., reticulocytes, haptoglobin, unconjugated [indirect] bilirubin) | Interrupt  |
| > 10 x ULN   |   | Hospitalize the participant<br>Establish causality  | ALT, AST, total bilirubin, Alb, PT/INR, ALP and GGT until resolution <sup>1</sup> (frequ  | Discontinue treatment immediately  |

| Trigger                          | Liver Symptoms  | Action Taken   |                                  |  |
|----------------------------------|---|--|----------------------------------|--|
|                                  |   | Monitoring   | Follow-up Monitoring             | Study Medication   |
|                                  |   | Record the AE and contributing factors(e.g., conmeds, med hx, lab) in the appropriate CRF                        | ency at investigator discretion) |  |
| <b>General Clinical Symptoms</b> |   |  |                                  |  |
|                                  | Any AE potentially indicative of a liver toxicity including: (General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia | Establish causality<br>Record the AE and contributing factors(e.g., conmeds, med hx, lab) in the appropriate CRF | Investigator discretion          | Consider study treatment interruption or discontinuation |

<sup>1</sup> Resolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level after a maximum of 6 months, (4) liver transplantation, and (5) death


Alb: Albumin, ALP: Alkaline phosphatase, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, CK: Creatinine kinase, CRF: Case report form, GGT: Gamma-glutamyl transferase, GLDH: glutamate dehydrogenase, INR: International Normalized Ratio, LFTs: Liver function tests, Med Hx: medical history, PT: Prothrombin time, TBL: Total bilirubin, ULN: upper limit of normal

**Table 16-3 Follow up requirements for liver laboratory triggers - Isolated Hyperbilirubinemia**

| Criteria  | Actions required   | Follow-up monitoring   |
|---|--|--|
| <b>Total Bilirubin (isolated)</b>                         |  |  |
| >1.5 – 3.0 ULN  | - Maintain treatment- Repeat LFTs within 48-72 hours   | Monitor LFTs weekly until resolution to ≤ Grade 1 (≤ 1.5 ULN) or to baseline   |
| > 3 - 10 × ULN (in the absence of known Gilbert syndrome) | - Interrupt treatment<br>- Repeat LFT within 48-72 hours<br>- Hospitalize if clinically appropriate<br>- Establish causality<br>- Record the AE and contributing factors (e.g., conmeds, med hx, lab) in the appropriate CRF | - Monitor LFTs weekly until resolution to ≤ Grade 1 (≤ 1.5 ULN) or to baseline (ALT, AST, total bilirubin, Alb, PT/INR, ALP and GGT)<br>- Test for hemolysis (e.g., reticulocytes, haptoglobin, unconjugated [indirect] bilirubin) |
| > 10 x ULN  | - Discontinue the study treatment immediately<br>- Hospitalize the participant<br>- Establish causality  | ALT, AST, total bilirubin, Alb, PT/INR, ALP and GGT until resolution (frequency at investigator discretion)  |

| Criteria  | Actions required   | Follow-up monitoring    |
|---|--|-------------------------|
| <b>Total Bilirubin (isolated)</b>                 |  |                         |
|   | <ul style="list-style-type: none"><li>- Record the AE and contributing factors (e.g., conmeds, med hx, lab) in the appropriate CRF</li></ul>   |                         |
| Any AE potentially indicative of a liver toxicity | <ul style="list-style-type: none"><li>- Consider study treatment interruption or discontinuation</li><li>- Hospitalization if clinically appropriate</li><li>- Establish causality- Record the AE and contributing factors (e.g., conmeds, med hx, lab) in the appropriate CRF</li></ul> | Investigator discretion |

Based on investigator's discretion investigation(s) for contributing factors for the liver event can include: Serology tests, imaging and pathology assessments, hepatologist's consultancy; obtaining more detailed history of symptoms and prior or concurrent diseases, history of concomitant drug use, exclusion of underlying liver disease.



### 16.3 Appendix 3: Specific Renal Alert Criteria and Actions and Event Follow-up


**Table 16-4 Specific renal alert criteria and actions**

| Renal Event  | Actions   |
|--|---|
| Confirmed serum creatinine increase 25 – 49%   | <ul style="list-style-type: none"> <li>Consider causes and possible interventions</li> <li>Follow -up within 2-5 days; increase fluid intake before assessment if appropriate</li> <li>Repeat follow-up (every 2-5 days) until creatinine is &lt;125% of baseline value</li> </ul>  |
| Serum creatinine increase 50 % <sup>1</sup>  | <ul style="list-style-type: none"> <li>Consider causes and possible interventions and initiate renal investigation</li> <li>Repeat assessment within 24-48 h if possible</li> <li>Interruption of study drug</li> <li>Close follow-up (every 24-48 h), consider participant hospitalization and specialized treatment until creatinine is &lt;125% of baseline value</li> </ul> |
| New onset dipstick proteinuria ≥ 3 <sup>1</sup><br>When urine proteins are measured as a follow-up of positive urine dipstick measurements:<br>Protein-creatinine ratio (PCR) ≥ 1g/g Cr (or mg/mmol equivalent as converted by the measuring laboratory) | <ul style="list-style-type: none"> <li>Consider causes and possible interventions</li> <li>Assess serum albumin &amp; serum total protein</li> <li>Repeat assessment to confirm</li> <li>Consider drug interruption or discontinuation unless other causes are diagnosed and corrected</li> </ul>   |
| New onset hematuria ≥ 3 <sup>1</sup> on urine dipstick   | <p>Assess and document:</p> <ul style="list-style-type: none"> <li>Repeat assessment to confirm</li> <li>Distinguish hemoglobinuria from hematuria</li> <li>Urine sediment microscopy</li> <li>Assess sCr</li> <li>Exclude infection, trauma, bleeding from the distal urinary tract/bladder, menstruation</li> <li>Consider bleeding disorder</li> </ul>                       |

<sup>1</sup> Corresponds to KDIGO criteria for Acute Kidney Injury

Whenever a renal event is identified, a detailed participant history and examination are indicated to identify and potentially eliminate risk factors that may have initiated or contributed to the event:

- Blood pressure assessment (after 5-minute rest, with an appropriate cuff size)
- Signs and symptoms like fever, headache, shortness of breath, back or abdominal pain, dysuria or hematuria, dependent or periorbital edema
- Changes in blood pressure, body weight, fluid intake, voiding pattern, or urine output



- Concomitant events or procedures such as trauma, surgical procedures, cardiac or hepatic failure, contrast media or other known nephrotoxin administration, or other diseases or causes, eg, dehydration due to delirium, tumor lysis

**Table 16-5 Renal event follow-up**

---

**FOLLOW-UP OF RENAL EVENTS**

---

Assess, document and record in the CRF:

- Urine dipstick and sediment microscopy evidence of Drug-Induced Nephrotoxicity (DIN): crystals, red blood cells (dysmorphic/glomerular vs. non-dysmorphic/non-glomerular), white blood cells, tubular epithelial cells
- Blood pressure and body weight
- Serum creatinine, BUN, electrolytes (sodium, potassium, phosphate, calcium), bicarbonate and uric acid
- Urine output

---

Review and record possible contributing factors to the renal event (co-medications, other co-morbid conditions) and additional diagnostic procedures (MRI etc.) in the CRF

---

Monitor participant regularly (frequency at investigator's discretion) until:

- Event resolution: (sCr within 10% of baseline or PCR < 1 g/g Cr, or ACR <300 mg/g Cr) or
- Event stabilization: sCr level with  $\pm 10\%$  variability over last 6 months or protein-creatinine ratio stabilization at a new level with  $\pm 50\%$  variability over last 6 months.

---

Analysis of urine markers in samples collected over the course of the DIN event

---

## 16.4 Appendix 4: PRO Tools

Samples of questionnaires provided here are for illustrative purpose only. The text format and wording might slightly vary.

### Patient Diary: Urticaria Patient Daily Diary (UPDD)

#### General Instructions

Please answer each question to the best of your ability.

There are no right or wrong answers.

For each question, please choose the response that describes your experience.

Please pay close attention to the timeframe of interest. Some questions ask about the past 12 hours, while others ask about the past 24 hours.

#### Instructions for Counting the Number of Hives

Count each hive separately even if you have more than one hive grouped together with other hives.



Today's Date

|     |  |  |       |  |  |  |      |  |  |
|-----|--|--|-------|--|--|--|------|--|--|
|     |  |  |       |  |  |  |      |  |  |
| day |  |  | month |  |  |  | year |  |  |

Please complete this section every morning throughout the duration of the study.  
(Please circle only one response.)

1. Thinking about the past 12 hours, please record the severity of itch and the number of hives you may have had associated with your skin condition. Please count each hive separately even if you have more than one hive grouped together with other hives.

Itch (severity)

- 0 = none
- 1 = mild
- 2 = moderate
- 3 = severe

Hives (number)

- 0 = none
- 1 = between 1 and 6 hives
- 2 = between 7 and 12 hives
- 3 = greater than 12 hives

Today's Date

|     |  |  |       |  |  |  |      |  |  |
|-----|--|--|-------|--|--|--|------|--|--|
|     |  |  |       |  |  |  |      |  |  |
| day |  |  | month |  |  |  | year |  |  |

Please complete this section every evening throughout the duration of the study.  
(Please circle only one response.)

2. Thinking about the past 12 hours, please record the severity of itch and the number of hives you may have had associated with your skin condition. Please count each hive separately even if you have more than one hive grouped together with other hives.

Itch (severity)

- 0 = none
- 1 = mild
- 2 = moderate
- 3 = severe

Hives (number)

- 0 = none
- 1 = between 1 and 6 hives
- 2 = between 7 and 12 hives
- 3 = greater than 12 hives

Today's Date

|     |  |  |       |  |  |  |      |  |  |
|-----|--|--|-------|--|--|--|------|--|--|
|     |  |  |       |  |  |  |      |  |  |
| day |  |  | month |  |  |  | year |  |  |

*Please complete this section once each day throughout the duration of the study (preferably at the same time each day).*

*(Please circle only one response.)*

3. Please rate how much your hives or itch interfered with your sleep during the past 24 hours.

0 = No interference

1 = Mild, little interference with sleep

2 = Moderate, awoke occasionally, some interference with sleep

3 = Substantial, woke up often, severe interference with sleep

4. Please rate how much your hives or itch interfered with your daily activities during the past 24 hours. This could include work, school, sports, hobbies, and activities with friends and family.

0 = No interference

1 = Mild, little interference with daily activities

2 = Moderate, some interference with daily activities

3 = Substantial, severe interference with daily activities

*These next questions are about your symptoms and how you managed them during the past 24 hours.*

5. During the past 24 hours, how many tablets of rescue medication did you use in order to control symptoms of your skin condition such as itch or hives?

The maximum number of tablets per day should be according to your doctor's recommendation.

- 6a. During the past 24 hours, did you have any rapid swelling on your face, (especially your eyelids or lips), inside your mouth (including your throat or tongue), or elsewhere on your body? This rapid swelling, also called angioedema, is at a deeper level under your skin than hives.

0 = No (GO TO Question 7)

1 = Yes

- 6b. If Yes, how did you treat this rapid swelling? (Circle all that apply.)

0 = Did nothing (GO TO Question 7)

1 = Took some prescription or non-prescription medication

2 = Called my doctor, nurse or nurse practitioner

3 = Went to see my doctor, nurse or nurse practitioner

4 = Went to the emergency room at the hospital

5 = Was hospitalized


7. During the past 24 hours, did you or someone else call your doctor, nurse or nurse practitioner because of your skin condition?

0 = No

1 = Yes

### Patient Diary: Angioedema Activity Score (AAS)

**Instructions:** Please document your symptoms retrospectively once a day. Refer to the last 24 hours in each case. Please answer all questions as fully as possible

|  |                        | Day |   |   |   |   |   |   |
|--|------------------------|-----|---|---|---|---|---|---|
|  |                        | 1   | 2 | 3 | 4 | 5 | 6 | 7 |
| Have you had a swelling episode in the last 24 hours?  | no                     |     |   |   |   |   |   |   |
|  | yes                    |     |   |   |   |   |   |   |
| <br>Please answer the questions below about this swelling episode during the last 24 hours. If you did not have a swelling episode, leave them blank. |                        |     |   |   |   |   |   |   |
| At what time(s) of day was this swelling episode(s) present?<br>(please select all applicable times)   | midnight – 8 a.m.      |     |   |   |   |   |   |   |
|  | 8 a.m. – 4 p.m.        |     |   |   |   |   |   |   |
|  | 4 p.m. - midnight      |     |   |   |   |   |   |   |
| How severe is / was the physical discomfort caused by this swelling episode(s) (e.g., pain, burning, itching?)   | no discomfort          |     |   |   |   |   |   |   |
|  | slight discomfort      |     |   |   |   |   |   |   |
|  | moderate discomfort    |     |   |   |   |   |   |   |
|  | severe discomfort      |     |   |   |   |   |   |   |
| Are / were you able to perform your daily activities during this swelling episode(s)?  | no restriction         |     |   |   |   |   |   |   |
|  | slight restriction     |     |   |   |   |   |   |   |
|  | severe restriction     |     |   |   |   |   |   |   |
|  | no activities possible |     |   |   |   |   |   |   |
| Do / did you feel your appearance is / was adversely affected by this swelling episode(s)?   | no                     |     |   |   |   |   |   |   |
|  | slightly               |     |   |   |   |   |   |   |
|  | moderately             |     |   |   |   |   |   |   |
|  | severely               |     |   |   |   |   |   |   |
| How would you rate the overall severity of this swelling episode?  | negligible             |     |   |   |   |   |   |   |
|  | mild                   |     |   |   |   |   |   |   |
|  | moderate               |     |   |   |   |   |   |   |
|  | severe                 |     |   |   |   |   |   |   |



## Dermatology Life Quality Index (DLQI):

### DERMATOLOGY LIFE QUALITY INDEX

Hospital No:  
Name:  
Address:

Date:  
Diagnosis:

Score:

DLQI

The aim of this questionnaire is to measure how much your skin problem has affected your life OVER THE LAST WEEK. Please tick  one box for each question.

- |     |  |  |                                       |
|-----|--|--|---------------------------------------|
| 1.  | Over the last week, how itchy, sore, painful or stinging has your skin been?   | Very much <input type="checkbox"/><br>A lot <input type="checkbox"/><br>A little <input type="checkbox"/><br>Not at all <input type="checkbox"/> |                                       |
| 2.  | Over the last week, how embarrassed or self conscious have you been because of your skin?  | Very much <input type="checkbox"/><br>A lot <input type="checkbox"/><br>A little <input type="checkbox"/><br>Not at all <input type="checkbox"/> |                                       |
| 3.  | Over the last week, how much has your skin interfered with you going shopping or looking after your home or garden?                          | Very much <input type="checkbox"/><br>A lot <input type="checkbox"/><br>A little <input type="checkbox"/><br>Not at all <input type="checkbox"/> | Not relevant <input type="checkbox"/> |
| 4.  | Over the last week, how much has your skin influenced the clothes you wear?  | Very much <input type="checkbox"/><br>A lot <input type="checkbox"/><br>A little <input type="checkbox"/><br>Not at all <input type="checkbox"/> | Not relevant <input type="checkbox"/> |
| 5.  | Over the last week, how much has your skin affected any social or leisure activities?  | Very much <input type="checkbox"/><br>A lot <input type="checkbox"/><br>A little <input type="checkbox"/><br>Not at all <input type="checkbox"/> | Not relevant <input type="checkbox"/> |
| 6.  | Over the last week, how much has your skin made it difficult for you to do any sport?  | Very much <input type="checkbox"/><br>A lot <input type="checkbox"/><br>A little <input type="checkbox"/><br>Not at all <input type="checkbox"/> | Not relevant <input type="checkbox"/> |
| 7.  | Over the last week, has your skin prevented you from working or studying?  | Yes <input type="checkbox"/><br>No <input type="checkbox"/>  | Not relevant <input type="checkbox"/> |
|     | If "No", over the last week how much has your skin been a problem at work or studying?   | A lot <input type="checkbox"/><br>A little <input type="checkbox"/><br>Not at all <input type="checkbox"/>                                       |                                       |
| 8.  | Over the last week, how much has your skin created problems with your partner or any of your close friends or relatives?                     | Very much <input type="checkbox"/><br>A lot <input type="checkbox"/><br>A little <input type="checkbox"/><br>Not at all <input type="checkbox"/> | Not relevant <input type="checkbox"/> |
| 9.  | Over the last week, how much has your skin caused any sexual difficulties?   | Very much <input type="checkbox"/><br>A lot <input type="checkbox"/><br>A little <input type="checkbox"/><br>Not at all <input type="checkbox"/> | Not relevant <input type="checkbox"/> |
| 10. | Over the last week, how much of a problem has the treatment for your skin been, for example by making your home messy, or by taking up time? | Very much <input type="checkbox"/><br>A lot <input type="checkbox"/><br>A little <input type="checkbox"/><br>Not at all <input type="checkbox"/> | Not relevant <input type="checkbox"/> |

Please check you have answered EVERY question. Thank you.

